CXCR2 engineered immune cells
Engineering CXCR2 expression in CAR-T cells addresses suboptimal T cell function and low antigen expression challenges, enhancing proliferation and cytotoxicity for improved cancer treatment efficacy.
Patent Information
- Application Number
- PCT/AU2026/050443
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-05
- Filing Date
- 2026-05-04
- Publication Date
- 2026-11-12
AI Technical Summary
Chimeric Antigen Receptor (CAR)-T cell therapy is compromised by suboptimal T cell function and diminished efficacy against cancers with low target antigen expression, particularly in patients who have undergone cancer treatment.
Engineering immune effector cells, such as CAR-T cells, to express or overexpress CXCR2, which enhances proliferation and cytotoxicity independently of CXCR2 ligands, particularly effective for suboptimal T cells and low antigen-expressing tumors.
Improves the proliferation and cytotoxicity of CAR-T cells, enabling effective cancer treatment, including solid tumors, even in the absence of CXCR2 ligands, and allows for reduced cell doses due to enhanced in vivo efficacy.
Smart Images

Figure IMGF000051_0001_TABLE 
Figure IMGF000052_0001_TABLE 
Figure IMGF000058_0001_TABLE
Abstract
Description
Title of InventionCXCR2 ENGINEERED IMMUNE CELLSPriority Claim
[0001] This application claims priority from Australian provisional patent application number 2025901676 filed on 5 May 2025, the contents of which are to be taken as incorporated herein by this reference.Technical Field
[0002] The present invention relates to genetic modification of Chimeric Antigen Receptor (CAR) immune cells to improve their proliferative and cytotoxic capacity, and the use of such modified CAR cells.Background of Invention
[0003] Chimeric Antigen Receptor T (CAR T) cell therapy has emerged as a transformative approach for the treatment of various malignancies. Typical CAR-T cell therapy utilizes the patient's own T cells, which are genetically engineered to express CARs targeting specific cancer antigens. Despite the promising outcomes observed in clinical settings, the efficacy of CAR-T cell therapy can be significantly compromised in certain patient populations.
[0004] The responsiveness, viability and number of T cells varies significantly between individuals. Further, patients who have cancer treatment such as chemotherapy or radiotherapy often exhibit T cells that are suboptimal for CAR T therapy, while some patient populations have T cells with a significant portion of senescent or exhausted T cells. This results in the production of CAR-T cells with suboptimal function. Similarly, CAR-T cells derived from some individuals may demonstrate diminished proliferative capacity and cytolytic activity relative to other individuals. These challenges pose significant barriers to the broader application and success of CAR-T cell therapies.
[0005] Moreover, while CAR-T cells can effectively treat cancers (particularly haematological cancers) which have high levels of surface expression of the targetantigen for the CAR, they have diminished ability to treat cancers that express low levels of target antigen.
[0006] The present invention may assist CAR-T cell function, particularly when the T cells are suboptimal or when the target cancer expresses low levels of the antigen recognised by the CAR. As such, the present invention may provide improved CAR-T cell treatment in suboptimal situations.Summary of Invention
[0007] The present invention is predicated by the surprising discovery that exogenous expression of CXCR2 in immune effector cells, particularly CAR-T cells, increased their proliferation and increased the ability of the CAR-expressing cells to kill cancer cells. Surprisingly, this effect was independent of CXCR2 -mediated chemotaxis and occurred even in the presence of CXCR2 antagonists. The ability of CXCR2 expression to improve the function of CAR-T cells was particularly prominent for CAR T-cells that otherwise lysed tumour cells in a suboptimal manner, or when the target tumour cells expressed low levels of the CAR’s target antigen.
[0008] Accordingly, the present invention provides a method of increasing the proliferation and / or cytotoxicity of immune effector cells comprising a CAR, the method comprising engineering the expression, or overexpression, of CXCR2 in the immune effector cells expressing the CAR and stimulating the cells.
[0009] Further, the present invention can be used to improve the proliferation and / or cytotoxicity of immune effector cells comprising a CAR in the absence of a ligand for CXCR2 (such as CXCL1 , CXCL2 and CXCL8). Therefore, the expression of a CXCR2 ligand by the tumour is not a requirement for the performance of the present invention. In some embodiments, the tumour does not express, or expresses substantially none or minimal, ligand for CXCR2, which may be one or more of CXCL1, CXCL2 and CXCL8.
[0010] In preferred embodiments, the method comprises engineering isolated immune effector cells to express a CAR and engineering them to express, or overexpress, CXCR2. Alternatively, the method may comprise engineering CXCR2 expression in cells already expressing a CAR.
[0011] The immune effector cells can be any suitable immune effector cells including lymphocytes such as T cells and natural killer (NK) cells, or monocytes, such as macrophages. In some embodiments, the cells comprising the CAR are NK cells or are T cells. In some specific embodiments, the immune effector cells comprising the CAR are T cells. Suitable T cells for use in the method include CD4+ T cells, CD8+ T cells and invariant natural killer T (iNKT) cells.
[0012] The cells can be stimulated by any known means. However, in preferred embodiments of the method, the immune effector cells are T cells, and the CAR-T cells are stimulated with at least one T cell mitogen or T cell antigen. Suitable means of T cell stimulation include stimulation with a CD3 agonist, alone or together with a CD28 agonist. Such CD3 and CD28 agonists include antibodies, which can be solubilised or immobilised on a substrate such as the surface of a culture plate or on a micro-bead. Alternative, or additional, means of stimulating the CAR-expressing immune effector cells include stimulating the cells with the CAR’s cognate antigen.
[0013] Further, in some embodiments, the method includes exposing the CAR-expressing immune effector cells to a cytokine, which may include one or more of interleukin 2, interleukin 15, interleukin 7, or interleukin 21. Indeed, stimulation of the cells may be performed in the presence of a cytokine (including those listed above).
[0014] In some embodiments of the invention, the CAR is configured to bind to LGR5. In such embodiments, stimulating the cells with LGR5 may comprise exposing the CAR-expressing immune effector cells to target cells expressing LGR5, or exposing the cells to recombinant forms of LGR5 which can be solubilised or immobilised.
[0015] In some embodiments of the invention, the CAR is configured to bind to nonfunctional P2X7 (nfP2X7). In such embodiments, stimulating the cells with nfP2X7 may comprise exposing the CAR-expressing immune effector cells to target cells expressing nfP2X7, or exposing the cells to recombinant forms of nfP2X7 that can be solubilised or immobilised.
[0016] As indicated herein, engineering expression of CXCR2 in immune effector cells is particularly effective in improving the efficacy of suboptimal immune effector cells. Such suboptimal immune effector cells, particularly T cells, may be identified by assessing markers of exhaustion or cell differentiation. Accordingly, in someembodiments, the immune effector cells are T cells, and the cells are assessed for characteristics of T cell exhaustion or T cell differentiation prior to engineering expression or overexpression of CXCR2. In such embodiments, the method may be performed only when the T cells have characteristics of T cell exhaustion, or differentiation.
[0017] In some embodiments, the characteristics of T cell exhaustion or T cell differentiation comprise an increased frequency of cells in a cell population expressing one or more of: PD-1, CTLA-4, LAG-3, TIGIT, CD160 (BY55), CD38, CD39, CD272 (BTLA), CD244 (2B4) and VISTA, or an increased expression of one or more of: PD-1 , CTLA-4, LAG-3, TIGIT, CD160 (BY55), CD38, CD39, CD272 (BTLA), CD244 (2B4) and VISTA.
[0018] In some embodiments, the method includes determining the expression of one or more of CD45RO or CD62L. Preferably, the method includes determining the frequency of T cells in a population having a profile of CD45RO+CD62L- or CD45RO-CD62L-. In preferred embodiments, the method is performed on CAR-T cell populations comprising an increased frequency of T cells with a profile of CD45RO+CD62L- or CD45RO-CD62L-. What constitutes an increased frequency can be determined by a person skilled in the art, for example an increase may be assessed relative to T cells populations shown to be efficacious or, alternatively, inefficacious. However, in some embodiments, the method is performed on a CAR-T cell population comprising 26% or more T cells with the profile CD45RO+CD62L-. In some embodiments, the method is performed on a CAR-T cell population comprising 13% or more T cells with the profile CD45RO-CD62L-.
[0019] Immune effector cells engineered to express CARs are particularly useful in treating neoplastic diseases such as cancer. However, many cancer patients have suboptimal immune effector cells, or T cells with profiles typical of T cell exhaustion, or differentiation into less efficacious T cell phenotypes. Furthermore, typical treatments for cancer such as chemotherapy and radiotherapy result in T cell senescence, or suboptimal T cells. Accordingly, the present invention is particularly useful when the immune effector cells, which were engineered to comprise the CARs, were isolated from a patient that has undergone cancer treatment comprising one or more of radiotherapy or chemotherapy prior to isolation of the cells.
[0020] The present invention also provides a method of treating or preventing cancer, the method comprising administering to a subject having cancer, or having a likelihood of cancer, immune effector cells comprising a CAR and engineered to express, or overexpress, CXCR2. Such cells can be prepared by the method described herein.
[0021] The type of cancer can be any cancer amenable to treatment with antibodies, or CAR-expressing cells, directed against cancer-associated or cancerspecific antigens. However, in some preferred embodiments, the cancer is selected from the group consisting of: ovarian cancer, melanoma, non-small cell lung cancer, head and neck carcinoma, B-cell lymphoma, prostate cancer, breast cancer, neuroblastoma, pancreatic cancer, liver cancer, gastric cancer or colorectal cancer.
[0022] Chimeric antigen receptor expressing T cells have been demonstrated to be particularly useful against haematological cancers but have had limited success in treating solid cancers. Therefore, improving the cytotoxicity and / or proliferative capacity of immune effector cells expressing CARs may be particularly beneficial in treating solid tumour cancers. Accordingly, in some embodiments of the method of treating cancer, the cancer is a solid tumour. In some embodiments, the cancer is a primary cancer. However, the method can also be used to treat secondary cancers.
[0023] Embodiments of the method may be particularly beneficial in treating cancers expressing a moderate or low level of the cognate antigen for the CAR. What constitutes a moderate or low level of the CAR’s cognate antigen can be empirically determined by a user, or may be based on analysis of the tumour tissue. However, in some embodiments, a moderate or low level of the cognate antigen comprises approximately 60% or less, approximately 50% or less, approximately 40% or less, approximately 30% or less, approximately 20% or less, approximately 15% or less, approximately 10% or less, or approximately 5% or less of the cancer cells expressing the cognate antigen of the CAR. Accordingly, the method of treating cancer may include a step of identifying the expression of the cognate antigen of the CAR on the cancer and treating patients determined to have a cancer with a low to moderate level of the cognate antigen.
[0024] Engineering CAR-expressing immune effector cells to express CXCR2 may be particularly beneficial when the immune effector cells have been shown to be suboptimal in treating cancer. What constitutes a suboptimal population of immune effector cells can be empirically determined by a user.
[0025] In some embodiments, empirical determination of a suboptimal CAR cell response may be based on in vitro assays such as target cell lysis assays against control target cells (e.g., cells expressing or engineered to express a target antigen) or against primary tumour cells (such as the patient’s tumour). Alternatively, determination of a suboptimal CAR immune effector cell response may be based on the patient having demonstrated a low or suboptimal response to previous treatment with CAR-expressing immune effector cells.
[0026] In some embodiments, the immune effector cells used in the previous treatment are T cells and these cells express markers of T cell exhaustion and / or T cell differentiation, preferably markers indicating T effector memory or T effector cell types.
[0027] As demonstrated herein, the inventors have exemplified that the present method improves the efficacy of suboptimal immune effector cells comprising a CAR which targets LGR5 or comprising a CAR which targets non-functional P2X7 (nfP2X7).
[0028] The method of treating cancer can be performed alone or can be performed together with other complimentary treatments, or adjuvant treatments. In some embodiments, the method of treatment comprises a combination therapy including the administration of an immune checkpoint inhibitor. Specifically envisaged immune checkpoint inhibitors are those that inhibit signalling of one or more of PD-1 , CTLA-4 or LAG-3 signalling.
[0029] The production of CAR-expressing immune effector cells, such as CAR-T cells, typically requires the isolation of cells from a patient followed by transduction and expansion of the autologous ex vivo cell sample. Because engineering the immune effector cells to express, or overexpress, CXCR2 results in improved efficacy in vivo as well as improved in vivo proliferation, the method of treating a subject having cancer (or preventing cancer in a subject) may comprise the administration of a reduced dose of immune effector cells comprising a CAR, while still maintaining efficacy. This is particularly advantageous where only a limited number of immune effector cells can beisolated from the patient, as is common in patients having cancer or undergoing cancer treatment.
[0030] While what constitutes a reduced dose can be determined by a person skilled in the art and may be relative to effective doses determined in clinical environments, or in clinical trials. In some embodiments, a reduced dose comprises approximately 90% or less, approximately 80% or less, approximately 70% or less, approximately 60% or less, approximately 50% or less, approximately 40% or less, approximately 30% or less, approximately 20 % or less, approximately 15% or less, or approximately 10% or less of the standard dose of the immune effector cells comprising the CAR.
[0031] In some embodiments, the method of preventing cancer, comprises preventing cancer recurrence in a patient previously having cancer or in remission from cancer.
[0032] In some embodiments, the immune effector cells comprising a CAR used in the method of treating or preventing cancer are natural killer (NK) cells or T cells. In some embodiments the T cells are CD8+ T cells. In some embodiments the T cells are CD4+ T cells. In some embodiments the T cells are iNKT cells.
[0033] The present invention also provides an immune effector cell comprising a CAR, wherein the immune effector cell comprising the CAR is engineered to express or overexpress CXCR2. Preferably, the CAR includes an antigen-binding domain which binds to LGR5 or nfP2X7.
[0034] In some embodiments, wherein the CAR includes a binding domain which binds to LGR5, the antigen-binding domain includes: a heavy chain CDR1 having an amino acid sequence as set forth in SEQ ID NO: 3, or having an amino acid sequence as set forth in SEQ ID NO: 3 with up to 2 amino acid modifications; a heavy chain CDR2 having an amino acid sequence as set forth in SEQ ID NO: 4, or having an amino acid sequence as set forth in SEQ ID NO: 4 with up to 2 amino acid modifications; and a heavy chain CDR3 having an amino acid sequence as set forth in SEQ ID NO: 5, or having an amino acid sequence as set forth in SEQ ID NO: 5 with up to 2 amino acid modifications.
[0035] In some embodiments, wherein the CAR includes a binding domain which binds to LGR5, the antigen-binding domain includes: a light chain CDR1 having an amino acid sequence set forth in SEQ ID NO: 6, or having an amino acid sequence as set forth in SEQ ID NO: 6 with up to 2 amino acid modifications; a light chain CDR2 having an amino acid sequence LTS, or having an amino acid sequence LTS with one amino acid modifications; and a light chain CDR3 having an amino acid sequence set forth in SEQ ID NO: 8, or having an amino acid sequence as set forth in SEQ ID NO: 8 with up to 2 amino acid modifications.
[0036] In some embodiments, wherein the CAR includes a binding domain which binds to nfP2X7, the antigen-binding domain includes: a heavy chain CDR1 having an amino acid sequence as set forth in SEQ ID NO: 27, or having an amino acid sequence as set forth in SEQ ID NO: 27 with up to 2 amino acid modifications; a heavy chain CDR2 having an amino acid sequence as set forth in SEQ ID NO: 28, or having an amino acid sequence as set forth in SEQ ID NO: 28 with up to 2 amino acid modifications; and a heavy chain CDR3 having an amino acid sequence as set forth in SEQ ID NO: 29, or having an amino acid sequence as set forth in SEQ ID NO: 29 with up to 2 amino acid modifications.
[0037] In some embodiments of the above CARs, the binding domain comprises a single-chain variable fragment comprising the C-terminus of a variable heavy (VH) chain linked to the N-terminus of a variable light (VL) chain.
[0038] In alternative embodiments, the binding domain comprises a single-chain variable fragment comprising the C-terminus of the variable light (VL) chain linked to the N-terminus of the variable light (VH) chain.
[0039] In addition to comprising a CAR and CXCR2 the immune effector cells may be engineered to express a cytokine. In some embodiments, the cell is engineered to express one or more of interleukin 2 (IL-2) or interleukin 15 (IL-15). This expression may be conditional on T-cell expression
[0040] The construct encoding the CAR may be the same as the construct encoding CXCR2, or CXCR2 and the CAR may be encoded on different constructs. Furthermore, in embodiments engineered to express a cytokine, the cytokine may be encoded on its own construct, or on the same construct encoding the CAR and / or CXCR2.
[0041] Typically, CARs comprise an antigen-binding domain which is linked via a linker domain to a transmembrane domain. The linker domain gives flexibility to the antigen-recognising domain as well as optimizing the size of the immune cell / target cell synapse. Accordingly, the length of the linker domain may, in some instances, influence the efficacy of the CAR. In some embodiments, the linker domain is at least 12 amino acids in length, or is at least about 12 amino acids in length. In some embodiments, the linker domain is at least 119 amino acids in length, or is at least about 119 amino acids in length. In some embodiments, the linker domain is at least 229 amino acids in length, or is at least about 229 amino acids in length. In some embodiments, the linker domain is up to 119 amino acids in length, or up to about 119 amino acids in length. In some embodiments, the linker domain is up to 229 amino acids in length, or up to about 229 amino acids in length. In preferred embodiments, wherein the CAR comprises an antigen-binding domain which binds to LGR5, the linker domain is about 119 amino acids, or is 119 amino acids in length.
[0042] The linker domain can comprise any suitable amino acid sequence. However, in some embodiments, the linker domain includes an amino acid sequence identical to the sequence of the lgG4 hinge or includes a sequence identical to a modified version of the lgG4 hinge, having up to 2 amino acid modifications. In some embodiments, the linker domain comprises the CH2 region of the lgG4 molecule. In some embodiments, the linker domain comprises the CH3 region of the lgG4 molecule. In some particular embodiments, the linker domain includes, or consists of, a sequence selected from SEQ ID NO: 56, SEQ ID NO: 57 or SEQ ID NO: 58, or functional variants thereof.
[0043] Particularly preferred immune effector cells comprise NK cells or T cells. As indicated above, the T cell may be a CD4+ T cell, a CD8+ T cell or an iNKT cell.
[0044] Methods for engineering the immune effector cells comprising a CAR and / or CXCR2 include transducing the cell to express an exogenous nucleic acid or expression encoding CXCR2 and / or the CAR, or transducing the cell to comprise a genomically integrated form of the nucleic acid. The nucleic acid is preferably DNA, and in some embodiments comprises a DNA vector. In some embodiments, the same nucleic acid encodes for both CXCR2 and the CAR.Brief Description of Drawings
[0045] Figure 1 - CAR constructs
[0046] Schematic of the anti-nfP2X7-CAR-CXCR2 (CAR-CXCR2) construct (a) and the anti-nfP2X7-CAR (control CAR) construct (b).
[0047] Figure 2 - Schematic of CAR-T cell manufacturing process.
[0048] CD3+T cells were purified from human peripheral blood or buffy coats by density separation and stimulated with a-CD3 and a-CD28 beads. The following day, cells were transduced with lentivirus encoding for the CXCR2 -modified or unmodified nfP2X7-specific CAR construct before the virus was removed by partial media changes. On d7 post-isolation, beads were removed and on d8 post-isolation, cells were rapidly expanded via stimulation with irradiated PBMC and an a-CD3 monoclonal antibody (OKT3). T cell phenotype was assessed on d7 and d8 post-isolation and on d7 and d14 following peripheral blood mononuclear cell (PBMC) stimulation (post-PBMC).
[0049] Figure 3 - T cells are successfully transduced to express CXCR2 and / or an anti-nfP2X7 CAR.
[0050] Freguency of CXCR2 and EGFR reporter expression on cells pre-gated on CD3+ at d8 post-isolation (n = 10-15) demonstrating expression of CXCR2 together with anti-nfP2X7 CAR or expression of anti-nfP2X7 CAR alone (indicated by EGFR expression) in CD3 T cells.
[0051] Figure 4 - CXCR2-expressing CAR-T and control CAR-T cells express an anti-nfP2X7 CAR.
[0052] Freguency of nfP2X7 biotinylated peptide mimetic (PM) binding on cells relative to EGFR or CXCR2 expression pre-gated on CD3+, as assessed by simultaneous staining after 3 days recovery post-thaw. Statistical significance was determined by a paired f-test (EGFR-PM: n = 4, CXCR2-PM: n = 6)
[0053] Figure 5 - Anti-nfP2X7 CAR-T cells co-expressing CXCR2 express functional CXCR2.
[0054] Chemotaxis to CXCL8 after 3 days recovery post-thaw in culture media containing IL-2 and IL-15. Columns left to right are untransduced (UT) T cells, CAR-T cells (i.e., anti-nfP2X7 CAR-T cells), and CXCR2 -expressing anti-nfP2X7 CAR-T cells. Statistical significance was determined by Ordinary one-way ANOVA with Bonferroni’s post-test.
[0055] Figure 6 - CXCR2-expressing CAR-T and control CAR-T cells display similar T cell phenotypes.
[0056] a-d At d14 post-PBMC stimulation, CXCR2-modified and control nfP2X7-targeting CAR-T cells were assessed for frequency of CD45RO and CD62L expression (a), TH1 cytokine and cytotoxic molecule expression after PMA stimulation (b), activation marker expression (c) and co-inhibitory molecule expression (d) of CD4+and CD8+cells (n = 10-15). Columns left to right are untransduced (UT) T cells, CAR-T cells (i.e., anti-nfP2X7 CAR-T cells), and CXCR2-expressing anti-nfP2X7 CAR-T cells. Data in a-d was pooled from 7 independent CAR-T cell preparations derived from 5 healthy donors and statistical significance was determined by Ordinary one-way ANOVA with Bonferroni’s post-test. Data represented as mean ± SEM; ** p<0.01.
[0057] Figure 7 - Engineering CXCR2 expression onto CAR-T cells enhances their anti-tumour efficacy against human prostate and breast cancer models.
[0058] a-c NSG mice were subcutaneously injected with 1x106PC3 human prostate cancer cells into the lower abdomen and intravenously injected with 5x106CXCR2-transduced nfP2X7 -targeting CAR-T cells, control nfP2X7 -targeting CAR-T cells or untransduced T cells on d7 post-tumour injection. Tumours were harvested for flow cytometric analysis on d27-30 post-tumour injection. Tumour growth curves (as pooled and individual mice) and tumour weights (n = 13-14 mice / group). Statistical significance between tumour sizes was determined by separate two-way ANOVA analyses between CXCR2 CAR-T and CAR-T, and CXCR2 CAR-T and UT. Statistical significance between CXCR2 CAR-T and CAR-T tumour weights was determined by an unpaired t-test (a). Frequency of human CD3+T cells of total viable cells in tumours, number of CD3+per mg of tumour and CD8+ / CD4+ratio of CD3+(n = 12-13 mice / group) (b).Frequency of PD-1, CTLA-4, LAG-3 and TIM-3 expression by intratumoural CD4+and CD8+T cells (n = 12-13 mice / group) (c). Lines from top to bottom (at right hand side)in Figure 7Aare untransduced (UT) T cells, CAR-T cells ( / .e., anti-nfP2X7 CAR-T cells), and CXCR2-expressing anti-nfP2X7 CAR-T cells. Columns in Figure 7C from left to right are untransduced (UT) T cells, CAR-T cells (i.e., anti-nfP2X7 CAR-T cells), and CXCR2-expressing anti-nfP2X7 CAR-T cells. Data in a-c are pooled from two similar in vivo experiments following delivery of two independent CAR-T cell preparations derived from two healthy donors, d-f NSG mice were subcutaneously injected with 2x106MDA-MB-231 human breast cancer cells into the fourth mammary fat pad and intravenously injected with 2x107CXCR2-transduced nfP2X7 -targeting CAR-T cells, control nfP2X7-targeting CAR-T cells or untransduced T cells on d7 post-tumour injection. Tumours were harvested for flow cytometric analysis on d40 post-tumour injection. Tumour growth curves (as pooled and individual mice) and tumour weights (n = 11-18 mice / group). Statistical significance was determined by two-way ANOVA with Bonferroni’s post-test (d). Frequency of human CD3+T cells of total viable cells in tumours, number of CD3+per mg of tumour and CD8+ / CD4+ratio of CD3+(n = 11-18 mice / group). Statistical significance was determined by an unpaired f-test (e).Frequency of PD-1, CTLA-4, LAG-3 and TIM-3 expression by intratumoural CD4+and CD8+T cells (n = 10-14 mice / group). Lines from top to bottom (at right hand side) in Figure 7D are untransduced (UT) T cells, CAR-T cells (i.e., anti-nfP2X7 CAR-T cells), and CXCR2-expressing anti-nfP2X7 CAR-T cells. Columns in Figure 7F from left to right are untransduced (UT) T cells, CAR-T cells (i.e., anti-nfP2X7 CAR-T cells), and CXCR2-expressing anti-nfP2X7 CAR-T cells. Statistical significance was determined by an unpaired t-test (f). Data in d-f are pooled from two independent in vivo experiments. Data represented as mean ± SEM; *p<0.05, *** p<0.001 , **** p<0.0001.
[0059] Figure 8 - Ex vivo analysis of endpoint MDA-MB-231 tumours indicates CAR-T cells differentiate in the TME and have cytotoxic potential.
[0060] NSG mice were subcutaneously injected with 2x106MDA-MB-231 human breast cancer cells into the fourth mammary fat pad and intravenously injected with 2x107CXCR2-transduced nfP2X7 -targeting CAR-T cells, control nfP2X7 -targeting CAR-T cells or untransduced T cells on d7 post -tumour injection. Tumours were harvested for flow cytometric analysis on d40 post-tumour injection. Frequency of T cell subsets as defined by CD45RO and CD62L expression by intratumoural CD4+and CD8+T cells (n = 5-16 mice / group). Columns from left to right are untransduced (UT) T cells, CAR-T cells (i.e., anti-nfP2X7 CAR-T cells), and CXCR2-expressing anti-nfP2X7 CAR-T cells. Statistical significance was determined by two-way ANOVA with Bonferroni’s post-test (a). Frequency of TH1 cytokine and cytotoxic molecule expression by intratumoural CD4+and CD8+T cells (n = 3-8 mice / group) (b). Data is pooled from two independent in vivo experiments and represented as mean ± SEM; * p<0.05.
[0061] Figure 9 - Engineering CXCR2 expression onto CAR-T cells does not enhance trafficking into solid tumours at different disease stages.
[0062] a Experimental schematic: NSG mice were subcutaneously injected with 1x106PC3 human prostate cancer cells into the lower abdomen and intravenously injected with 10x106CXCR2-transduced nfP2X7 -targeting CAR-T cells, control nfP2X7 -targeting CAR-T cells or untransduced T cells on days 14, 20, or 27 posttumour injection. Tumours were harvested for flow cytometric analysis 48 hrs post-T cell transfer, b Concatenated flow cytometric plots showing CD3+cell infiltration into PC3 tumours 48 hrs post-T cell transfer, c Frequency and d number of live CD3+cells within PC3 tumours 48 hrs post-T cell transfer, e-g Frequency of divided CD3+cells (as measured by eF670) (left), number of divided CD3+cells (middle), and division index of CD3+cells (right) within the tumour on day 14 (e), 20 (f), and 27 (g) post-tumour injection. Threshold for division was defined as 0.5 divisions and is represented as a dashed line, c-g Statistical significance was determined by Ordinary one-way ANOVA with Bonferroni’s post-test. Columns in Figure 9C and 9D from left to right are untransduced (UT) T cells, CAR-T cells ( / .e., anti-nfP2X7 CAR-T cells), and CXCR2-expressing anti-nfP2X7 CAR-T cells. Data in b is concatenated from one of two independent experiments and data in c-g are pooled from two independent experiments per timepoint (n = 6-9 (UT), 9-10 (CAR-T), 8-9 (CXCR2 CAR-T) mice / group). Data represented as mean ± SEM; *p<0.05. p.t.i., post-tumour injection.
[0063] Figure 10 - Engineered CXCR2 expression enhances the cytotoxic potential of nfP2X7 -targeting CAR-T cells in vitro.
[0064] NfP2X7-targeting CAR-T cells were co-cultured with luciferase-expressing cancer cell lines at the indicated ratios. At 16h, luciferin was added and tumour cell lysis was quantified based on loss of luminescence relative to target cell only controls. Statistical significance was determined by two-way ANOVA with Bonferroni’s post-test (statistical analysis shown is between CXCR2-expressing CAR-T cells and controlCAR-T cells) Data is pooled from 2-7 independent CAR-T cell preparations derived from up to 5 healthy donors (for each individual cancer cell line). Data represented as mean ± SEM; *p<0.05, ** p<0.01 , *** p<0.001 , **** p<0.0001.
[0065] Figure 11 - Engineered CXCR2 expression enhances the ligandindependent cytotoxic potential of nfP2X7 -targeting CAR-T cells in vitro.
[0066] Tumour cell lysis was guantified as per Figure 10 after treatment with CXCR2 small molecule antagonists, SB265610 (100nM) and SB225002 (5pM). Data pooled from two independent experiments from two CAR-T cell preparations for each individual cancer cell line. Data represented as mean ± SEM; *p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001.
[0067] Figure 12 - CXCR6 or CCR10 overexpression on CAR-T cells has no impact on in vitro cytotoxicity.
[0068] a CCR10-modified or b CXCR6-modified nfP2X7 -targeting CAR-T cells (directly from culture or after 3 days recovery post-thaw) were co-cultured with luciferase-expressing cancer cell lines at the indicated ratios. At 16 hours, luciferin was added and tumour cell lysis was guantified based on loss of luminescence relative to target cell only controls. Data in a is pooled from 2-4 independent experiments across 3 independent CAR-T cell preparations for each individual cancer cell line. Data in b is pooled from 2-5 independent experiments across 3 independent CAR-T cell preparations for each individual cancer cell line. Statistical significance was determined by two-way ANOVA with Bonferroni’s post-test (statistical analysis in a is between CCR10-transduced CAR-T cells and untransduced cells; statistical analysis in b is between CXCR6-transduced CAR-T cells and untransduced cells). Data represented as mean ± SEM; * p<0.05, ** p<0.01 , *** p<0.001 , **** p<0.0001.
[0069] Figure 13 - Engineered CXCR2 expression enhances the antigenindependent proliferation of nfP2X7 -targeting CAR-T cells in vitro.
[0070] a CAR-T cells were cultured for 3 days post-thaw and co-cultured with ffluc+GFP+Namalwa B-cell lymphoma cells at the indicated ratios. At 16h, luciferin was added and tumour cell lysis was guantified based on loss of luminescence relative to target cell only controls. Data is pooled from 4 independent experiments, b CAR-T cellswere cultured for 3 days post-thaw, labelled with CellTrace Violet and co-cultured with ffluc+GFP+Namalwa cells at the indicated ratios. Cells were co-cultured for the indicated timepoints and assessed for frequency of cell division. Data is represented in two ways, by separated by timepoint (Figure 13B) and by effector: target ratio (Figure 13C). Groups in Figure 13C (in order from top to bottom at 72 hrs) are CD3+ T cells transduced with both the nfP2X7 CAR construct and CXCR2 (CXCR2-CAR-T CD3+), CD3+ T cell transduced with the nfP2X7 CAR construct (CAR-T CD3+) and untransduced CD3+ T cells. Data is pooled from 2 independent experiments. Statistical significance was determined by two-way ANOVA with Bonferroni’s post-test (statistical analysis shown is between CXCR2 -expressing CAR-T cells and control CAR-T cells). Data represented as mean ± SEM; * p<0.05, ** p<0.01 , *** p<0.001 , **** p<0.0001.
[0071] Figure 14 - Expression of CXCR2 confers enhanced proliferative potential for CAR-T cells in vivo.
[0072] a Experimental schematic: NSG mice were subcutaneously injected with 1x106PC3 human prostate cancer cells into the lower abdomen and intravenously injected with 10x106CXCR2-transduced nfP2X7 -targeting CAR-T cells, control nfP2X7 -targeting CAR-T cells or untransduced T cells on day 20 post-tumour injection. Tumours were harvested for flow cytometric analysis 96 hrs and 7 days post-T cell transfer, b Concatenated flow cytometric plots showing CD3+cell infiltration into PC3 tumours, c Frequency and number of live CD3+cells within PC3 tumours at 96 hours (top panels) and 7 days (bottom panels) post-T cell transfer, d, e Division index of CD3+cells within tumours at 96 hrs (d) and 7 days (e) post-T cell transfer, f-i, Division index of T cells within the tumour (left panels) and number of T cells per mg of tumour (right panels) of CD8+cells at (f) 96 hrs and (g) 7 days post-T cell transfer and CD4+cells at 96 hrs (h) and (i) 7 days post-T cell transfer. Threshold for division was defined as 0.5 divisions and is represented as a dashed line. Data in c-i are pooled from two independent experiments per timepoint (n = 4-9 (UT), 7-8 (CAR-T), 7-8 (CXCR2 CAR-T) mice / group). Statistical significance was determined by Ordinary one-way ANOVA with Bonferroni’s post-test. Data represented as mean ± SEM; *p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001.
[0073] Figure 15 - Variable expression of LGR5 on cancer cell lines.
[0074] Various cancer cell lines (Figure 15A) had significant variation in LGR5 expression. LGR5 was highly expressed on CHO cell lines engineered to express exogenous LGR5 (positive control) and was absent on wild-type CHO cells (negative control). The cell lines LIM1215, LoVo and Hct116 were chosen for use in subsequent assays as they express (relatively) high, medium and low levels (respectively) of LGR5 (Figure 15B).
[0075] Figure 16 - CXCR2-expressinq LGR5-tarqetinq CAR-T (CNA310201) cells elicit enhanced in vitro cytotoxicity against low antigen colorectal cancer cells.
[0076] T cells were co-cultured with luciferase-transduced human colorectal cancer cell lines at the indicated ratios. Following 16h of co-culture, luciferin was added and tumour cell lysis was quantified based on loss of luminescence relative to target only controls (spontaneous lysis). Data is pooled from experiments testing 7 independent CAR-T cell preparations derived from 6 donors. Each condition was tested at least 5 times. Data represented as mean ± SEM; two-way ANOVA with Bonferroni’s post-test. Control LGR5-targeting CAR-T cells (CNA3102) and CXCR2-modified LGR5-targeting CAR-T cells (CNA310201). For all plots, columns left to right sequentially depict untransduced (UT) T cells, CNA3102 and CNA310201 cells.
[0077] Figure 17 - LGR5-tarqetinq primary CAR-T cells kill tumour cells in vivo.
[0078] NSG mice were subcutaneously injected with 2x106LoVo human colorectal cancer cells into the lower abdomen and intravenously injected with 5x106CXCR2-transduced LGR5-targeting CAR-T cells (CNA310201), control LGR5-targeting CAR-T cells (CNA3102) or untransduced T cells derived from a first donor on d14 post-tumour injection. (Left) Tumour growth curves and (right) Kaplan-Meier survival curves of pooled mice (n = 4-7 mice / group). Data in tumour growth curves represented as mean ± SEM. Statistical significance was determined by Mantel-Cox test; ** p<0.01, *** p<0.001.
[0079] Figure 18 - CXCR5 expression improves killing by sub-optimal LGR5-tarqetinq primary CAR-T cells in vivo.
[0080] NSG mice were subcutaneously injected with 2x106LoVo human colorectal cancer cells into the lower abdomen and intravenously injected with 5x106CXCR2-transduced LGR5-targeting CAR-T cells (CNA310201), control LGR5-targeting CAR-T cells (CNA3102) or untransduced T cells derived from a second donor on d14 posttumour injection. (Left) Tumour growth curves and (right) Kaplan-Meier survival curves of pooled mice (n = 7 mice / group). Data in tumour growth curves represented as mean ± SEM. Statistical significance was determined by Mantel-Cox test; **p<0.01.
[0081] Figure 19 - CXCR5 expression improves killing by sub-optimal LGR5-targeting primary CAR-T cells in vivo.
[0082] NSG mice were subcutaneously injected with 2x106LoVo human colorectal cancer cells into the lower abdomen and intravenously injected with 5x106CXCR2-transduced LGR5-targeting CAR-T cells (CNA310201), control LGR5-targeting CAR-T cells (CNA3102) or untransduced T cells derived from a third donor on d14 post-tumour injection. (Top) Tumour growth curves of pooled mice and (bottom) tumour weights of individual mice (n = 7-14 mice / group). Data represented as mean ± SEM. Statistical significance was determined by unpaired / -tests; **p<0.01.
[0083] Figure 20 - CXCR5 expression improves killing by sub-optimal LGR5-targeting primary CAR-T cells in vivo.
[0084] NSG mice were subcutaneously injected with 2x106LoVo human colorectal cancer cells into the lower abdomen and intravenously injected with 10x106CXCR2-transduced LGR5-targeting CAR-T cells (CNA310201), control LGR5-targeting CAR-T cells (CNA3102) or untransduced T cells derived from the first donor on d14 posttumour injection, (a) Tumour growth curves of pooled mice (n = 6-8 mice / group), prior to time point of first euthanasia event due to tumour size, (b) Tumour growth curves and Kaplan-Meier survival curves of pooled mice up to experimental endpoint. Statistical significance was determined by two-way ANOVA with Bonferroni’s post-test in a and Mantel-Cox test in b. Growth curve data represented as mean ± SEM. * p<0.05, ** p<0.01, **** p<0.0001.
[0085] Figure 21 - CXCR5 expression improves killing by sub-optimal LGR5-targeting primary CAR-T cells in vivo.
[0086] NSG mice were subcutaneously injected with 2x106LoVo human colorectal cancer cells into the lower abdomen and intravenously injected with 10x106CXCR2-transduced LGR5-targeting CAR-T cells (CNA310201), control LGR5-targeting CAR-T cells (CNA3102) or untransduced T cells derived from the first donor on d21 posttumour injection, (a) Tumour growth curves of pooled mice (n = 5-8 mice / group), prior to time point of first euthanasia event due to tumour size, (b) Tumour growth curves and Kaplan-Meier survival curves of pooled mice up to experimental endpoint. Statistical significance was determined by two-way ANOVA with Bonferroni’s post-test in (a) and Mantel-Cox test in (b). Growth curve data represented as mean ± SEM. * p<0.05, *** p<0.001 , **** p<0.0001.
[0087] Figure 22 - CXCR5 expression improves killing by moderately effective LGR5-targeting primary CAR-T cells in vivo.
[0088] NSG mice were subcutaneously injected with 2x106LoVo human colorectal cancer cells into the lower abdomen and intravenously injected with 10x106CXCR2-transduced LGR5-targeting CAR-T cells (CNA310201), control LGR5-targeting CAR-T cells (CNA3102) or untransduced T cells. Each figure represents data from two independent in vivo experiments, testing CAR-T cells generated from independent preparations from two different healthy donors. T cells were administered on day 7. (a) Tumour growth curves of pooled mice (n = 10-13 mice / group) administered CAR-T cells either expressing CXCR2 or not, and untransduced cells, (b) individual tumour growth curves of mice administered CAR-T cells either expressing CXCR2 or not, and untransduced cells. Statistical significance was determined by two-way ANOVA with Bonferroni’s post-test in a. Growth curve data represented as mean ± SEM. * p<0.05, *** p<0.001 , **** p<0.0001.Detailed Description
[0089] Chemokines are signalling proteins that guide the movement of immune cells along concentration gradients towards desired locations such as sites of inflammation or infection. As such, selecting cells that express desired chemokine receptors, or inducing expression of specific chemokine receptors, can be used to deliberately direct the migration of immune cells, particularly effector immune cells such as lymphocytes (including T cells, NK cells and iNK-T cells). By incorporating specificchemokine receptors into such cells, it may be possible to improve the ability of these cells to migrate to and infiltrate tumours. This may be particularly useful for solid tumours, which have a complex and often immune-suppressive microenvironment.
[0090] C-X-C motif chemokine receptor 2 (CXCR2) (UniProt number P25025, NCBI Gene ID 3579; SEQ ID NO: 1) is a G-protein coupled receptor and a promiscuous receptor for a range of several CXCL chemokines. Also known as Interleukin 8 receptor, beta, CD182, CDw128b, CMKAR2, IL8R2, IL8RA, IL8RB and WHIMS2, CXCR2 is agonised by seven human chemokines (namely, CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL7, and CXCL8 (also known as interleukin 8) - see Lazennec G, Rajarathnam K, Richmond A. CXCR2 chemokine receptor - a master regulator in cancer and physiology. Trends Mol Med. 2024;30(1):37-55). CXCR2 is expressed in various cell types, predominantly in neutrophils, and to a lesser extent in endothelial cells, macrophages, oligodendrocytes, neurons, neural crest-derived cells, and some cancer cells. CXCR2 plays diverse roles in pathophysiology, including combating bacterial and viral infections, contributing to development, blood vessel narrowing, and diseases of several organs such as the heart, lungs, liver, and brain, as well as in various cancer etiologies. However, studies have primarily focused on its function in immune cell (e.g., neutrophil) chemotaxis. As such, its expression is primarily considered to drive migration of cells along a concentration gradient of its cognate ligands.
[0091] Contrary to the demonstrated role of CXCR2 and its ligands in immune cell migration, the present inventors showed that exogenous expression of CXCR2 in immune effector cells, specifically in CAR-T cells, did not lead to increased cell infiltration into tumours, even when the tumours expressed the CXCR2 ligands. However, exogenous expression of CXCR2 in immune effector cells, particularly CAR-T cells, did increase their proliferation and increased the ability of the CAR-T cells to kill cancer cells expressing the target antigen of the CAR, even in the absence of CXCR2 ligands. The latter effect was particularly prominent for CAR-T cells that lysed tumour cells in a suboptimal manner, or when the target tumour cells expressed low levels of the CAR target antigen.
[0092] Methods of Improving the Performance of Immune Effector Cells
[0093] Accordingly, the present invention provides a method of increasing the proliferation of a chimeric antigen receptor (CAR) expressing cell or increasing the cytotoxicity of a CAR-expressing cell, the method comprising engineering the expression, or overexpression, of C-X-C motif chemokine receptor 2 (CXCR2) in the cell and stimulating the cell. In some embodiments, the cell is an immune effector cells, preferably a lymphocyte. In some embodiments, the cell is a T cell, or an NK cell. In some embodiments, T cell is an invariant natural killer T (iNKT) cells. In some embodiments, the immune effector cell is a macrophage.
[0094] Increased proliferation of immune effector cells expressing CXCR2 can be assessed by comparing the proliferation of cells expressing the CAR and CXCR2 relative to cells expressing the CAR, but without exogenous CXCR2, or cells which express the CAR and do not express exogenous or endogenous CXCR2 (i.e. cells which are CXCR2-negative). The compared populations of cells can be from the same sample, or from different samples isolated from the same individual or from a different individual.
[0095] Methods for assessing cell proliferation are provided herein and are known in the art (see for example Ganesan N, et al. Methods to Assess Proliferation of Stimulated Human Lymphocytes In Vitro: A Narrative Review. Cells. 2023;12(3):386. Published 2023 Jan 20; Jin L, Tao H, Karachi A, et al. CXCR1- or CXCR2-modified CAR-T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors. Nat Commun.2019; 10:4016; Abbott CA, Freimayer EL, Tyllis TS, et al. Determination of Tr1 cell populations correlating with distinct activation states in acute IAV infection. Mucosal Immunol. 2023;16(5):606-623; and Roederer M. Interpretation of cellular proliferation data: Avoid the panglossian. Cytometry A. 2011 ;79(1 ):95-101 ). These methods include incorporation of radiolabelled DNA precursor (such as tritiated thymidine incorporation) or nucleotide analogues such as Bromodeoxyuridine, proliferation markers such as Ki67 expression or Proliferating Cell Nuclear Antigen (PCNA), or dye dilution assays (for example serial dilution of Carboxyfluorescein Succinimidyl Ester).
[0096] Methods for assessing the cytotoxicity of T cells are provided herein and are known in the art (see for example Piccinini C, Carloni S, Arienti C, et al. In vitro CAR-Tcell killing: validation of the potency assay. Cancer Immunol Immunother.2024;73(9):168; Zurowski D, Patel S, Hui D, et al. High-throughput method to analyze the cytotoxicity of CAR-T cells in a 3D tumor spheroid model using image cytometry. SLAS Discov. 2023;28(3):65-72; and Foulke JG, Chen L, Chang H, McManus CE, Tian F, Gu Z. Optimizing Ex Vivo CAR-T Cell-Mediated Cytotoxicity Assay through Multimodality Imaging. Cancers. 2024; 16(14):2497). These methods include various co-culture killing assays, which may include labelled target cells (see for example Jin L, Tao H, Karachi A, et al. CXCR1- or CXCR2-modified CAR-T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors. Nat Commun. 2019;10:4016). Additionally, cytotoxicity of CAR-T cells can be measured by way of their secretion of effector proteins such as cytokines and toxins. Accordingly, some embodiments of the present invention provide a method of increasing the secretion by CAR-T cells of one or more effector proteins, such as cytokines or toxins, by engineering the expression, or overexpression, of CXCR2 in the CAR-T cell and stimulating the CAR-T cell. Cytotoxic effector proteins are known in the art and include perforin, granzymes, IFNgamma, TNFalpha and TNFbeta (see Janeway CA Jr, Travers P, Walport M, et al. Immunobiology: The Immune System in Health and Disease. 5th edition. New York: Garland Science; 2001. T cell-mediated cytotoxicity. Available from: https: / / www.ncbi.nlm.nih.gov / books / NBK27101 / ),
[0097] Chimeric antigen receptor expressing NK cells (CAR-NK cells) have demonstrated the potential to be an effective means to target cancers in patients (see Wang W, Liu Y, He Z, et al. Breakthrough of solid tumor treatment: CAR-NK immunotherapy. Cell Death Discov. 2024; 10:40. doi:10.1038 / s41420-024-01815-9; and Moscarelli J, Zahavi D, Maynard R, Weiner LM. The Next Generation of Cellular Immunotherapy: Chimeric Antigen Receptor-Natural Killer Cells. Transplant Cell The 2022;28(10):650-656). Methods for producing CAR-NK cells are known in the art as are methods for assessing the efficacy of CAR-NK cells both in in vivo tumour models and in in vitro co-culture assays (see Kailayangiri S, Altvater B, Spumy C, et al. Targeting Ewing sarcoma with activated and GD2-specific chimeric antigen receptor-engineered human NK cells induces upregulation of immune-inhibitory HLA-G. Oncoimmunology. 2016;6(1 ):e1250050).
[0098] Chimeric antigen receptors have also been transduced into invariant natural killer (iNKT) cells. These cells are categorised as expressing a semi-invariant a|3 T-cellreceptor (TCR) which recognises a range of glycolipid antigens presented by the non-polymorphic MHC class 1 -like antigen-presenting molecule, CD1d (Gapin L. iNKT cell autoreactivity: what is 'self' and how is it recognized?. Nat Rev Immunol.2010; 10(4):272-277). Further, these cells express markers typically associated with NK cells including CD161 and CD56. Accordingly, these cells can be identified by way of a combination of these markers and the presence of the invariant TCR (see Montoya CJ, Pollard D, Martinson J, et al. Characterization of human invariant natural killer T subsets in health and disease using a novel invariant natural killer T cell-clonotypic monoclonal antibody, 6B11. Immunology. 2007; 122(1): 1-14).
[0099] The present invention also provides a method of producing a chimeric antigen receptor (CAR) T cell, the method comprising engineering an isolated T cell to express a CAR and express, or overexpress, CXCR2 and stimulating the CAR-T cell.
[0100] In embodiments, the term “engineered to express” means utilisation of genetic engineering techniques to increase surface expression of CXCR2 in T cells.
[0101] Techniques for increasing surface expression of CXCR2 in cells include (i) introduction of exogenous genetic material (ii) gene editing with suitable programmable endonucleases such as CRISPR / Cas systems (see for example Gao L, Yang L, Zhang S, et al. Engineering NK-92 Cell by Upregulating CXCR2 and IL-2 Via CRISPR-Cas9 Improves Its Antitumor Effects as Cellular Immunotherapy for Human Colon Cancer. J Interferon Cytokine Res. 2021;41(12):450-460) or (iii) mRNA transfection (see for example Ryser MF, llgarte F, Thieme S, et al. mRNA transfection of CXCR4-GFP fusion--simply generated by PCR--results in efficient migration of primary human mesenchymal stem cells. Tissue Eng Part C Methods. 2008; 14(3): 179-184).
[0102] Methods are known in the art for the deliberate introduction (transfection / transduction) of exogenous genetic material, such as nucleic acid constructs, into eukaryotic cells. As will be understood, the method best suited for introducing a nucleic acid construct into a desired host cell is dependent on many factors, such as the size of the nucleic acid construct, the type of host cell, the desired rate of efficiency of the transfection / transduction and the final desired, or required, viability of the transfected / transduced cells. Non-limiting examples of such methods include; chemical transfection with chemicals such as cationic polymers, calciumphosphate, or structures such as liposomes and dendrimers; non-chemical methods such as electroporation (see for example Potter H, Heller R. Transfection by Electroporation. In: Ausubel FM, ed. Current Protocols in Molecular Biology. 2003: Unit-9.3.), sonoporations (see for example Wang D, Liu S, Warrell J, et al. Comprehensive functional genomic resource and integrative model for the human brain. Sci Rep.2018;8:3885), heat-shock or optical transfection; particle-based methods such as ‘gene gun’ delivery, magnetofection, or impalefection, lipid nanoparticles or viral transduction (see Peng W, Ye Y, Rabinovich BA, et al. Transduction of Tumor-Specific T Cells with CXCR2 Chemokine Receptor Improves Migration to Tumor and Antitumor Immune Responses. Clin Cancer Res. 2010;16(22):5458-5468).
[0103] Preferably, the expression, or overexpression, of CXCR2 is engineered via transduction of the cells with a nucleic acid encoding CXCR2, preferably viral transduction. A variety of viral transduction techniques for mammalian cells are known in the art. Common viral vectors include lentivirus and retrovirus (see for example Elegheert J, Behiels E, Bishop B, et al. Lentiviral transduction of mammalian cells for fast, scalable and high-level production of soluble and membrane proteins. Nat Protoc.2018;13(12):2991-3017; and Eremenko E, Taylor ZV, Khand B, Zaccai S, PorgadorA, Monsonego A. An optimized protocol for the retroviral transduction of mouse CD4 T cells. STAR Protoc. 2021 ;2(3): 100719). Alternative viral vectors include, HSV, Adenovirus and AAV (Howarth JL, Lee YB, Uney JB. Using viral vectors as gene transfer tools (Cell Biology and Toxicology Special Issue: ETCS-UK 1 day meeting on genetic manipulation of cells). Cell Biol Toxicol. 2010;26(1): 1-20).
[0104] In some embodiments, the present invention provides a lentivirus comprising a nucleic acid encoding CXCR2 as described herein. The lentivirus can comprise a nucleic acid encoding CXCR2 or can encode both CXCR2 and a CAR. Further, the present invention provides a use of a viral vector as described herein, preferably a retrovirus such as a lentivirus or a gamma retrovirus, in the preparation of an immune effector cell, such as an NK cell or T cell (including iNKT cells).
[0105] In accordance with the invention, a cell is engineered to express CXCR2 when an exogenous CXCR2 is expressed on the surface of the cell. In some embodiments, the cells engineered to express CXCR2 are isolated lymphocytes, including NK cells or T cells that were negative for CXCR2 before engineering. In someembodiments, the cells engineered to express CXCR2 were positive for CXCR2 and are engineered to overexpress CXCR2 (i.e. , express CXCR2 above their former level).
[0106] Methods for producing CAR-expressing cells, particularly CAR-T cells, are provided herein and are known in the art, (see for example Ayala Ceja M, Khericha M, Harris CM, Puig-Saus C, Chen YY. CAR-T cell manufacturing: Major process parameters and next-generation strategies. J Exp Med. 2024;221(2):e20230903; Blache U, Popp G, Dunkel A, et al. Potential solutions for manufacture of CAR-T cells in cancer immunotherapy. Nat Commun. 2022; 13:5225; and Wang X, Riviere I. Clinical manufacturing of CAR-T cells: foundation of a promising therapy. Mol Ther Oncolytics.2016;3:16015. Published 2016 Jun 15).
[0107] In some embodiments of the methods, wherein exogenous nucleic acids are introduced, the CAR and CXCR2 are introduced into one or more cells simultaneously, preferably on the same nucleic acid molecule. In some embodiments, the CAR and CXCR2 are introduced into one or more cells simultaneously by way of separate nucleic acid molecules. In some embodiments, the CAR and CXCR2 are introduced separately. For example, CXCR2 can be introduced into cells which have already been transduced (or otherwise induced) to express a CAR.
[0108] In some embodiments of the methods, the CAR-expressing cell comprising the exogenous CXCR2 is cultured in the presence of exogenous cytokines or stimulants. Preferably, the method further comprises exposing the CAR-expressing cell to an interleukin, preferably one or more of interleukin 2, interleukin 15, interleukin 7, or interleukin 21. In some embodiments, the dose of IL-2 is at least 30 units (U) / ml, at least 40 ll / rnl, at least 50 ll / rnl, or at least 60 ll / rnl. In a preferred embodiment, the dose of IL-2 is approximately 50 U / ml. In some embodiments, the dose of IL-7 is at least 4 ng / ml, at least 4.5 ng / ml, at least 5 ng / ml, or at least 5.5 ng / ml. In a preferred embodiment, the dose of IL-7 is approximately 5 ng / ml. In some embodiments, the dose of IL-15 is at least 0.4 ng / ml, at least 0.45 ng / ml, at least 0.5 ng / ml, or at least 0.55 ng / ml. In a preferred embodiment, the dose of IL-15 is approximately 0.5 ng / ml. In some embodiments, the dose of IL-21 is at least 8 ng / ml, at least 9 ng / ml, at least 10 ng / ml, or at least 11 ng / ml. In a preferred embodiment, the dose of IL-15 is approximately 10 ng / ml.
[0109] In some embodiments of the method relating to CAR-T cells, the T cells are stimulated with at least one T cell antigen. The T cell antigen will typically be the tumour-associated antigen (TAA) that the CAR is designed against (such as those described herein). T cells can also be stimulated in an antigen-independent manner using T cell mitogens. Accordingly, in some embodiments, of the method the CAR-T cell is stimulated with at least one T cell mitogen. T cell mitogens may include Phytohemagglutinin (PHA), wheat germ agglutinin (WGA), and Concanavalin A (Con A), pokeweed mitogen (PWM), protein kinase C (PKC), which activates most antibodybased CARs (see for example Isakov N, Maliy Ml, Altman A. Mitogen-induced human T cell proliferation is associated with increased expression of selected PKC genes. Mol Immunol. 1992;29(7-8):927-933; a Mak TW, Saunders ME. 14 - T Cell Activation. In: Mak TW, Saunders ME, eds. The Immune Response. Academic Press; 2006:373-401 ).
[0110] CAR-T cells can also be stimulated by non-specific stimulation of the CAR receptor (for example using protein L) or by stimulation of co-receptors such as CD3 / CD28 (see for example Si X, Xiao L, Brown CE, Wang D. Preclinical Evaluation of CAR-T cell Function: In Vitro and In Vivo Models. Int J Mol Sci. 2022;23(6):3154; and Trickett A, Kwan YL. T cell stimulation and expansion using anti-CD3 / CD28 beads. J Immunol Methods. 2003;275(1-2):251-255). Accordingly, in some embodiments the method comprises stimulating the CAR with a CD3 agonist and / or a CD28 agonist. Suitable CD3 / CD28 agonists include antibodies which can be soluble or immobilised to a culture plate or microbeads.
[0111] Like CAR-T cells, NKT cell can be stimulated by way of the cognate antigen for their engineered CAR. However, these cells can also be stimulated by way of their invariant T cell receptor, for example by exposing the cell to a-GalCer, generally in the presence of a cytokine such as IL-2 (see for example Hadiloo K, Tahmasebi S, Esmaeilzadeh A. CAR-NKT cell therapy: a new promising paradigm of cancer immunotherapy. Cancer Cell Int. 2023;23:86).
[0112] As discussed above, the methods of the present invention are particularly useful in CAR-T cells that are suboptimal, or when there is low expression of the target antigen for the CAR on the cancer cells. Typically, CAR-T cells are derived from a patient being treated for cancer (i.e. , autologous to a treated patient). In such situations, the T cells are often not ideal for adoptive T cell therapy, either because they areinherently suboptimal, or because the patient has been undergoing treatment for cancer, such as chemotherapy or radiotherapy. Accordingly, T cells isolated from such patients often display characteristics of exhaustion or apoptosis. Accordingly, in some embodiments, the method is performed on CAR-T cells which have characteristics of exhaustion prior to engineering expression or overexpression of CXCR2. Accordingly, In some embodiments, the method includes assessing markers of exhaustion on the T cells. In some embodiments, the method includes assessing markers of the differentiation status on the T cells.
[0113] T cell exhaustion may be empirically assessed by way of cytotoxic function either in vitro or in vivo. T cell exhaustion, and differentiation, can also be determined by way of phenotypic markers. Markers of T cell differentiation and exhaustion are known in the art and include inhibitory receptors such as PD-1, CTLA-4, LAG3, TIGIT, CD160 (BY55), CD38, CD39, CD272 (BTLA), CD244 (2B4) and VISTA (Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev.2015;15(8):486-499; Miggelbrink AM, Jackson JD, Lorrey SJ, et al. CD4 T-Cell Exhaustion: Does It Exist and What Are Its Roles in Cancer? Clin Cancer Res.2021 ;27(21 ):5742-5752; and Tang D, Zhao L, Yan F, et al. Expression of VISTA regulated via IFN-y governs endogenous T-cell function and exhibits correlation with the efficacy of CD19 CAR-T cell treated B-malignant mice. Journal for ImmunoTherapy of Cancer. 2024;12:e008364.). Accordingly, in some embodiments, the method is performed on T cells which have differential expression of, or an increased frequency of cells having a phenotype indicative of exhaustion. This may be indicated by assessing the expression of one or more of the above markers. Preferably at least two of the above markers are used to identify a population prior to CXCR2 engineering the cells to express CXCR2 and / or a CAR. Envisaged combinations include, PD-1 and CTLA-4; PD-1 and LAG3; PD-1 and TIGIT; PD-1 and CD160; PD-1 and CD38; PD-1 and CD39; PD-1 and CD272; PD-1 and CD244; PD-1 and VISTA; CTLA-4 and LAG3; CTLA-4 and TIGIT; CTLA-4 and CD160; CTLA-4 and CD38; CTLA-4 and CD39; CTLA-4 and CD272; CTLA-4 and CD244; CTLA-4 and VISTA; LAG3 and TIGIT; LAG3 and CD160; LAG3 and CD38; LAG3 and CD39; LAG3 and CD272; LAG3 and CD244; LAG3 and VISTA; TIGIT and CD160; TIGIT and CD38; TIGIT and CD39; TIGIT and CD272; TIGIT and CD244; TIGIT and VISTA; CD160 and CD38; CD160 and CD39; CD160 and CD272; CD160 and CD244; CD160 and VISTA; CD38 and CD39; CD38 and CD272;CD38 and CD244; CD38 and VISTA; CD39 and CD272; CD39 and CD244; CD39 and VISTA; CD272 and CD244; CD272 and VISTA; CD244 and VISTA.
[0114] The characteristics of the CAR-T cell population can be evaluated relative to control populations including (but not limited to) healthy subjects, subjects who have not undergone cancer treatments, subjects responsive to CAR-T cell therapy, or subjects unresponsive or sub-responsive to CAR-T cell therapy. Further, the characteristics of the CAR-T cell population can be evaluated relative to a predetermined control standard, which may be reflective of a control population. Suitable control populations may be healthy subjects, subjects who have not undergone cancer treatments, one or more populations of CAR-T cells previously demonstrated to be effective, or one or more populations of CAR-T cells previously demonstrated to be ineffective or sub-optimally effect. In some embodiments, the method is performed on cells which have an elevated level of one or more of the markers listed above (including the combinations listed above), or on a population of cells having an elevated frequency of cells positive for one or more of the markers listed above (including the combinations listed above). In some embodiments, the methods of the invention include determining the level of one or more of the listed markers (or listed combinations of markers) prior to engineering the cells to express CXCR2. This determination may be performed before the cells are engineered to express a CAR. Alternatively, this determination may be performed after the cells are engineered to express a CAR.
[0115] Expression of CXCR2 in CAR-T cells may result in altered expression of, or a change in the frequency of cells expressing, one or more markers of exhaustion or T cell differentiation status. Envisaged markers include those listed above, including the combinations listed above. Such an alteration may be relative to cells prior to being engineered to express CXCR2, or may be relative to a control population or control standard (including those described above). Further, an increase in expression may be determined by comparing cells with the transduced population that are expressing CXCR2 (and the CAR) with those not expressing the CXCR2 in the same population. The level of these markers may be assessed after the cells are engineered to express CXCR2, or after the engineered cells are stimulated with cytokine, mitogen or antigen either in vitro, or in vivo. In some embodiments, the expression or frequency of cellsexpressing these markers are decreased after the cells are engineered to express CXCR2.
[0116] In some embodiments, the method is performed on T cells which have one or more markers of T effector memory or T effector function, or have an elevated frequency of T cells with a T effector memory phenotype or a T effector phenotype. Such an elevation may be evaluated relative to control populations or relative to a predetermined control standard, such as those described above. Markers for determining T cell differentiation include CCR7, CD27, CD28, CD39, CD45RA, CD45RO, CD62L, CD69, CD95, IL7Ra (see Ren H, Cao K, Wang M. A Correlation Between Differentiation Phenotypes of Infused T Cells and Anti-Cancer Immunotherapy. Front Immunol. 2021 ; 12:745109. Published 2021 Sep 15). Accordingly, in some embodiments, the method comprises assessing the expression of, or assessing the frequency of cells in a population expressing, one or more of CCR7, CD27, CD28, CD39, CD45RA, CD45RO, CD62L, CD69, CD95, IL7Ra. Preferably, the method involves assessing the expression of CD45RO and CD62L, preferably wherein the expression of CD62L is decreased. Additionally, the T cells can be assessed for their expression of CD45RO, alone or in combination with CD62L. In preferred embodiments, the method comprises assessing the number or frequency of cells in a population having the phenotype CD45RO+CD62L- (T effector memory) or CD45RO-CD62L- (T effector). Preferably, the method is performed on T cell populations with an increased frequency of cells which are CD45RO+CD62L- (T effector memory) or CD45RO-CD62L- (T effector), prior to engineering the cells to express CXCR2.
[0117] In some embodiments, the method is performed on cell populations having 26% or more of CD3+ cells which are CD45RO+CD62L-. In some embodiments, the percentage of CD3+ cells which are CD45RO+CD62L- is 24% or more, 25% or more, 26% or more, 27% or more, 28% or more, 29% or more, 30% or more, 31% or more, 32% or more, 33% or more, 34% or more, 35% or more, 36% or more, 37% or more, 38% or more, 39% or more, 40% or more, 42% or more, 44% or more, 46% or more, 48% or more, 50% or more, 55% or more, 60% or more, 65% or more, or 70% or more. Preferably, the percentage of CD3+ cells which are CD45RO+CD62L- is 26% or greater
[0118] In some embodiments, the method is performed on cell populations having 26% or more of CD3+ cells which are CD45RO-CD62L-. In some embodiments, thepercentage of CD3+ cells which are CD45RO-CD62L- is 10% or more, 11% or more, 12% or more, 13% or more, 14% or more, 15% or more, 16% or more, 17% or more, 18% or more, 19% or more, 20% or more, 21% or more, 22% or more, 23% or more, 24% or more, 25% or more, 26% or more, 27% or more, 28% or more, 29% or more, 30% or more, 32% or more, 34% or more, 36% or more, 38% or more, 40% or more, 45% or more, 50% or more, 55% or more, or 60% or more. Preferably, the percentage of CD3+ cells which are CD45RO-CD62L- is 13% or greater.
[0119] T cell exhaustion may be the result of poor metabolic fitness of the T cells, which may result from poor mitochondrial function. Accordingly, in some embodiments, T cell exhaustion is assessed by mitochondrial function and the method is performed on T cells having poor mitochondrial function, or T cell populations having an elevated frequency of cells with poor mitochondrial function.
[0120] Indicators of poor mitochondrial function include: decreased mitochondrial biogenesis, smaller mitochondrial size, decreased levels of PGC1 alpha, and reduced levels of GLUT1. On the other hand, indicators of good mitochondrial function include increased mitochondrial biogenesis, larger mitochondria size, increased levels of PGC1 alpha, and increased levels of GLUT1 (see Rostamian H, Khakpoor-Koosheh M, Fallah-Mehrjardi K, Mirzaei HR, Brown CE. Mitochondria as Playmakers of CAR T-cell Fate and Longevity. Cancer Immunol Res. 2021;9(8):856-861).
[0121] Mitochondrial function can also be assessed using assays such as MitoTracker™ Dyes, and other lipophilic cationic dyes. These dyes are taken up by the mitochondria and subsequently fluoresce. This allows for visualisation of the mass and morphology of the mitochondria, which can be assessed by fluorescence microscopy or flow cytometry (see Agnello M, Morici G, Rinaldi AM. A method for measuring mitochondrial mass and activity. Cytotechnology. 2008;56:145-149; Monteiro LB, Davanzo GG, de Aguiar CF, Moraes-Vieira PMM. Using flow cytometry for mitochondrial assays. MethodsX. 2020;7: 100938; and Baldwin JG, Heuser-Loy C, Saha T, et al. Intercellular nanotube-mediated mitochondrial transfer enhances T cell metabolic fitness and antitumor efficacy. Cell. 2024;187(23):6614-6630.e21). In some embodiments, Mitotracker™ Deep Red (MDR) is used to assess mitochondrial function, with cells having mitochondrial poor mitochondrial function demonstrating lowor mid (i,e., MDR|OWor MDRmid) fluorescence, while cells with functional mitochondria show high (i.e. , MDRhi) fluorescence.
[0122] In some embodiments, the method is performed on T cells populations with 6% or more, 7% or more, 8% or more, 9% or more, 10% or more, 11% or more, 12% or more, 13% or more, 14% or more, 15% or more, 16% or more, 17% or more, 18% or more, 19% or more, 20% or more, 22% or more, 24% or more, 26% or more, 28% or more, 30% or more, 35% or more, or 40% or more of the T cells in the population having poor mitochondrial function, preferably assessed by MitoTracker™ Deep Red (Invitrogen™). In a preferred embodiment, the method is performed on T cell populations with 10% or more cells having poor mitochondrial function.
[0123] The characteristics of the CAR-T cell population can be evaluated relative to control populations (such as healthy subjects, or subjects responsive to CAR-T cell therapy), or relative to a predetermined control standard which may be reflective of a control population (such as healthy subjects, subjects who have not undergone cancer treatments, or one or more populations of CAR-T cells previously demonstrated to be effective).
[0124] As shown in the examples, the present inventors have demonstrated the ability of CXCR2 expression to improve the proliferation and / or cytotoxicity of immune effector cells, particularly T cells, expressing a CAR targeting LGR5 or non-functional P2X7 (nfP2X7). Therefore, in some preferred embodiments of the present invention, the CAR-expressing cell comprises a CAR having an antigen- recognising domain which binds to LGR5 or nfP2X7. Therefore, in some embodiments, the cells expressing a CAR targeting nfP2X7 are analysed for the above markers, or the markers are analysed prior to transducing the cells with a CAR targeting nfP2X7. In some preferred embodiments, cells expressing a CAR targeting LGR5 are analysed for the above markers, or the markers are analysed prior to transducing the cells with a CAR targeting LGR5.
[0125] In some embodiments of the invention, the expression of markers for T cell population characteristics are assessed before or after performing the method. In some embodiments the method comprises assessing a combination of PD-1, CD27, CD28, CD45RO and / or CD62L.
[0126] In some embodiments, the cells which express the CAR and are engineered to express or over express CXCR2 have a low response to their cognate antigen prior to engineering the cell with CXCR2. This can be determined by assessing cell proliferation in an in vitro assay in the presence of the CARs cognate antigen. Accordingly, in some embodiments, engineering the CAR-expressing cells to express CXCR2 improves their response to the CAR’s cognate antigen. Such an increase in response may be an increase in proliferation, an increase in cytotoxicity or an increase in secretion of one or more effector proteins, such as cytokines or toxins.
[0127] Preferably, the T cells (including iNKT cells) comprising the CAR, and engineered to express CXCR2, are CD8+ T cells. Alternatively, the T cells comprising the CAR, and engineered to express CXCR2, are CD4+ T cells, or both CD8+ and CD4+ T cells.
[0128] Because the present invention improves proliferation of suboptimal CAR-T cells, it may be particularly useful in the generation of CAR-expressing cells from patients undergoing therapies that impair immune effector cell function, such as some cancer therapies. Typically, both radiotherapy and chemotherapy can result in damage to immune cells and impairment of immune cell function. This can result in poor CAR-T cell performance when cells from patients undergoing such therapies are used in the manufacture of CAR T-cells (see Das RK, O'Connor RS, Grupp SA, Barrett DM. Lingering effects of chemotherapy on mature T cells impair proliferation. Blood Adv.2020;4(19):4653-4664; and Gough MJ, Crittenden MR. The paradox of radiation and T cells in tumors. Neoplasia. 2022;31 : 100808). Therefore, in some embodiments, the cells used in the methods of the invention are derived from a patient who has cancer, or is undergoing cancer treatment. In some embodiments, cells comprising the CARs were isolated from a patient that has undergone cancer treatment comprising one or more of radiotherapy or chemotherapy prior to isolation of immune effector cells, such as T cells, NK cells or iNKT cells.
[0129] Typical CAR cell production is performed by transducing and expanding autologous ex vivo cell samples from a patient in need of treatment. Accordingly, in some embodiments, the methods described herein are performed in vitro. However, aspects of the methods, such as stimulation, may be performed in vitro or in vivo (for example by administering the cells to a subject comprising a cancer having the targetfor the CAR). Further, the increased level of proliferation or cytotoxicity may only occur after administration to a patient.
[0130] In some embodiments, the method comprises stimulating the CAR-expressing cell with its cognate antigen (7.e. , the antigenic target of the binding domain of the CAR). In some specific embodiments, the target antigen is LGR5 or nfP2X7. Alternatively, the method can be performed in vitro without stimulation with the cognate antigen of the CAR.
[0131] Nucleic Acids and Vectors
[0132] In some embodiments, the present invention provides nucleic acids and vectors that encode for a CAR and CXCR2. In preferred embodiments, the CAR includes an antigen-recognising domain which binds to LGR5 or nfP2X7. Examples of CARs that bind to LGR5 and nfP2X7 are described herein. As such, the nucleic acids and vectors of the present invention encode for any of the relevant amino acid sequences or CAR domains described herein, either alone or in combination. Specifically, the nucleic acids or vectors encode for one or more of the following components: an antigen-recognising domain that binds to LGR5 or nfP2X7, a linker domain, a transmembrane domain, a signalling domain, and / or a co-stimulatory domain (in addition to CXCR2).
[0133] In some embodiments, the nucleic acids or vectors comprise the DNA sequence according to any one of SEQ ID NOs: 71 , 72, 73 or 74, or a functional variant comprising at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity to any one of SEQ ID NOs: 71, 72, 73 or 74.
[0134] In some embodiments, the nucleic acid or vector comprises DNA. In some embodiments, the nucleic acid comprises RNA and the RNA sequence is the RNA equivalent of the DNA nucleic acid sequences provided herein.
[0135] As used herein vectors include (but are not limited to) nucleic acids vectors and viral vectors, such as those described herein.
[0136] In some embodiments, the CAR and CXCR2 are encoded by the same nucleic acid or vector. In some embodiments, the CAR and CXCR2 are encoded by separate nucleic acids or vectors.
[0137] Methods of Treatment
[0138] Also provided by the present invention is a method of treating cancer, the method comprising administering to a subject having cancer, CAR immune effector cells which are engineered to express or overexpress CXCR2. Preferably, these immune effector cells are NK cells or T cells (including iNKT cells). Accordingly, in some embodiments, these cells are T cells, or NK cells. In some embodiments, the T cells are iNKT cells.
[0139] Methods for preparing a CAR, or a cells expressing a CAR, for use in the method of treating cancer include the methods described above, and exemplified herein.
[0140] The cells engineered to express CXCR2 and a CAR can be any CAR-expressing cell known in the art, including those listed or described herein, particularly known CAR-T cells. As of 2022, over 1000 clinical trials of CAR-T cells had commenced, or been completed globally. These trials include (but are not limited to) CAR-T cells directed against haematological cancers including: lymphoma, lymphoblastic leukemia, multiple myeloma, acute myeloid leukemia, myelodysplastic syndrome, BPDCN, plasma cell and myeloma, and solid tumour cancers including: liver, glioblastoma, pancreas, stomach, lungs, colorectal, neuroblastoma, breast, ovarian, sarcoma, prostate, renal, malignant pleural mesothelium, melanoma, esophagus, medulloblastoma, nasopharynx, bladder, cholangiocarcinoma, cervical, head and neck, endometrial, ependymoma, rhabdoid tumour, thyroid, and testicular. Accordingly, embodiments of the method of treating cancer of the present invention can be used to treat any of the above listed cancers.
[0141] In preferred embodiments, the cancer is selected from the group consisting of: ovarian cancer, melanoma, non-small cell lung cancer, head and neck carcinoma, B-cell lymphoma, prostate cancer, breast cancer, neuroblastoma, pancreatic cancer, liver cancer, gastric cancer or colorectal cancer. In some embodiments, the cancer is a solid tumour. In some embodiments, the cancer is a primary cancer or is a secondary cancer.
[0142] Further, clinical trials of CAR-NK cells in the treatment of the following cancers were listed as of 2022: Acute Lymphoblastic Leukemia, B LymphoidMalignancies, Glioblastoma, Metastatic Solid Tumors, Non-small Cell Lung Carcinoma, Castration-resistant Prostate Cancer, Relapsed or Refractory B Cell Lymphoma, Epithelial Ovarian Cancer, B-Cell Lymphoma, Chronic Lymphocytic Leukemia, Adults With AML or MDS, Acute Myeloid Leukemia, Relapsed or Refractory B Cell NonHodgkin Lymphoma, B Cell Malignancies, Refractory or Relapsed B-cell Non Hodgkin Lymphoma, Adults With B-cell Cancers, Locally Advanced or Metastatic Solid Tumors, Relapsed or Refractory Multiple Myeloma, Refractory Metastatic Colorectal Cancer, Recurrent or Metastatic Gastric or Head and Neck Cancer, Relapsed or Refractory Acute Myeloid Leukemia, Advanced Solid Tumors, Relapse or Refractory Hematological Malignances, and Relapsed or Refractory CD19-Positive B-Cell Malignancies (see Li H, Song W, Li Z, Zhang M. Preclinical and clinical studies of CAR-NK-cell therapies for malignancies. Front Immunol. 2022; 13:992232. Published 2022 Oct 24).
[0143] In some embodiments, the cancer to be treated does not express a ligand for CXCR2, or does not express an elevated level of a ligand for CXCR2.
[0144] As the present invention results in immune effector cells (particularly CAR-T cells) with an approved ability to proliferate and kill cells, it is particularly useful in treating cancers which express moderate or low levels of the cognate (target) antigen of the CAR. Accordingly, in some embodiments of the method of treating cancer, the cancer expresses a moderate or low level of the cognate antigen of the CAR.
[0145] What constitutes a moderate or low level of expression of the cognate antigen can be determined by a person skilled in the art and may be compared to similar cancers which also express the cognate antigens, or may be inferred from the response of the CAR-expressing cells. In some embodiments, a cancer expresses a moderate or low level of the cognate antigen if its expression is at or below the 10thpercentile, at or below the 20thpercentile, at or below the 30thpercentile, at or below the 40thpercentile, at or below the 50thpercentile, or at or below the 60thpercentile. In some embodiments, a cancer expresses a moderate or low level of the cognate antigen if approximately 80% or less, approximately 70% or less, approximately 60% or less, approximately 50% or less, approximately 40% or less, approximately 30% or less, approximately 20% or less, approximately 15% or less, approximately 10% or less, or approximately 5% or less of the cancer cells express the cognate antigen of the CAR.
[0146] To determine if the cancer expresses a moderate or low level of the cognate antigen for the CAR, embodiments of the method of treating cancer may include a step of identifying the expression of the cognate antigen of the CAR on the cancer. Such identification can be performed by way of known assays such as immunohistochemistry, flow cytometry, western blot analysis, ELISA or any other assay known in the art. Typically, these assays use antibodies directed to the same antigen as the CAR.
[0147] In some embodiments, the patient being treated had a low response to previous treatment with CAR-expressing cells, such as CAR-T cells. What constitutes a low response can be determined by a person skilled in the art, but may comprise continuous cancer progression, a minor pause in cancer progression, or a minor decrease in cancer progression. In some embodiments a low response to previous treatment means an incomplete response. The degree of response can be determined from appropriate clinical data including clinical trial data. In some embodiments, the CAR-expressing cells from a patient whom has been previously treated have a low response to their cognate antigen in vivo or in vitro. This can be determined by assessing T cell proliferation in an in vitro assays in the presence of the CARs cognate antigen. In some embodiments, a low response means a response (in vitro or in vivo) in the bottom 10thpercentile of responders, or the bottom 20thpercentile of responders, or the bottom 30thpercentile of responders, or the bottom 40thpercentile of responders, or the bottom 50thpercentile of responders, or the bottom 60thpercentile of responders, or the bottom 70thpercentile of responders.
[0148] In some embodiments, the CAR-T cells used in the previous treatment expresses markers of exhaustion and / or T cell differentiation.
[0149] In some embodiments, the method of treatment comprises a combination therapy including the administration of one or more of an immune checkpoint inhibitor in combination with CAR-expressing immune effector cells, preferably T cells. This is particularly beneficial when CAR-T cells demonstrate upregulation of immune checkpoint inhibitors such as PD-1 , CTLA-4, LAG-3 or TIM-3 either after expansion or after activation (either in vitro of in vivo). Accordingly, in some embodiments, the immune checkpoint inhibitor inhibits the signalling of one or more of the following molecules, PD-1, CTLA-4, LAG-3 or TIM-3, preferably PD-1, CTLA-4 or LAG-3.
[0150] The term “combination therapy” includes the administration of the two or more components of the therapy with such timing that the components interact in vivo. Accordingly, combination therapy includes simultaneous, sequential and separate administration, as long as the timing of the separate administration results in interaction of the active components within a subject.
[0151] Because the engineering of CAR-expressing immune effector cells to express or overexpress CXCR2 improves their proliferation and cytotoxicity, in embodiments of the method of treatment described herein the subject is administered a reduced dose of CAR-expressing cells. The reduced dose may be determined relative to a specified “normal” does of immune effector cells not engineered to express or overexpress CXCR2. Such a normal dose may be determined by clinical trials, or previous use of the CAR-expressing cells. In some embodiments, a reduced dose of CAR-expressing cells comprises approximately 90% or less, approximately 80% or less, approximately 70% or less, approximately 60% or less, approximately 50% or less, approximately 40% or less, approximately 30% or less, approximately 20 % or less, approximately 15%, or less or approximately 10% or less of the standard dose of CAR-T cells normally administered to a subject.
[0152] In some embodiments of the methods disclosed herein, the CAR-expressing cell is a T cell as described herein.
[0153] CAR Targets
[0154] The methods of the present invention should not be restricted to any specific CAR target or cancer type - unless explicitly specified. As of 2022 CAR-T cells are in clinical trials targeting the following haematological markers: CD19, BCMA, CD19 / CD22, CD22, CD7, CD19 / CD20, CD123, CD20, CD30, BCMA / CD19, CD33, CD5, CLL-1, CD139, NKG2D, CD4, BCMA / TACI, CD19 / CD20 / CD22, BAFF, BCMA / CPRC5D, GPRC5D, SLAMF7, CD44v6, TRBC1, FLT3, CD19 / CD70, CD19 / CD79b, CD20 / CD22, CD38, Siglec-6, CD33+CLL1, IgBeta, and CD20 / CD79b; and solid tumour markers: Mesothelin, GPC3, MIIC1, GD2, HER-2, NKG2D, EGFR, B7-H3, Claudin, CEA, PSMA, CD70, ROR1, FAP, T4, GD2 / CD70, GD2 / CD56, GD2 / PSMA, CD70 / PSMA, CD207, MMP2, BT-001, GUCY2C, TAG72. Further, clinical trials are underway (as of 2022) for CAR NK cells directed against: CD19, CD20, HER2,NKG2D, PD-1, PSMA, CD19 / CD22, CD22, Mesothelin, CD33 / CLL1, 5T4, BCMA, PD-L1, CD5, and CD70.Therefore, the present invention should include (but not be limited to) CARs directed to any of the above markers, or others known in the art.
[0155] As shown in the examples, the present inventors have demonstrated the ability of CXCR2 expression to improve the proliferation and cytotoxicity of T cells expressing a CAR targeting LGR5 and non-functional P2X7. Therefore, in some preferred embodiments of the present invention, the CAR of the immune effector cell is LGR5. In some other preferred embodiments, the CAR target is non-functional P2X7 (nfP2X7).
[0156] CAR-Expressing Cells Engineered to Co-Express CXCR2
[0157] The present invention provides a T cell, NK cell or iNKT cell comprising a chimeric antigen receptor (CAR), wherein the cell comprising the CAR is engineered to express or overexpress CXCR2.
[0158] In some embodiments, the cell is engineered with a construct encoding both the CAR and CXCR2 (such as the same nucleic acid vector or molecule). In such embodiments, the construct may include a cleavage site between the CAR and CXCR2 so that the two components can be cleaved from each other during or after transcription or translation. One such suitable cleavage site is the T2A self-cleavage site. When using the T2A self-cleavage site, and upon expression of the CAR / CXCR2 construct, CXCR2 is cleaved from the mature chimeric antigen receptor polypeptide and is separately expressed on the cell surface. Alternatively, the CAR and CXCR2 can be expressed on different constructs (such as different nucleic acid vectors or molecules).
[0159] T cells expressing CARs engineered to express cytokines are typically referred to as TRUCK-T cells (T cells redirected for natural cytokine-mediated killing) and are also referred to as fourth generation CAR-T cells. Such CAR-T cells can be engineered to express or overexpress a cytokine. Specifically, TRUCK-T cells can be engineered to express one or more of interleukin (IL)-2, IL-7, IL-12, IL-15, IL-18, IL-21, IL-23, IL-36 or Flt3L. Accordingly, to improve the efficacy of the CAR-T cell further, in some embodiments, the cell is engineered to express one or more of IL-2, IL-7, IL-12, IL-15, IL-18, IL-21, IL-23, IL-36, or Flt3L. Preferably, in some embodiments, the cell is engineered to express one or more of IL-2, IL-7, IL-15, IL-21, or IL-23. In some morepreferred embodiments, the cell is engineered to express a combination of IL-2 and IL-15, or IL-7 and IL-21. Similarly, immune effector cells other than T cells, such as NK cells can also be engineered to express cytokines. Accordingly, the aforementioned cytokines can be engineered into other immune effector cells.
[0160] As shown in the examples, and as mentioned above, the present inventors have demonstrated the ability of CXCR2 expression to improve the proliferation and / or cytotoxicity of immune effector cells, particularly T cells, expressing a CAR targeting LGR5 or targeting non-functional P2X7. Therefore, in some preferred embodiments of the present invention, the CAR-expressing cell comprises a CAR having an antigenbinding domain which binds to LGR5. In some other embodiments, the CAR-expressing cell comprises a CAR having an antigen-binding domain which binds to nfP2X7.
[0161] In some embodiments, the CAR-expressing cell is engineered to express an exogenous nucleic acid encoding CXCR2, or a genomically integrated form thereof. Preferably, the nucleic acid is a DNA vector. In some embodiments, the exogenous nucleic acid encodes CXCR2 and the CAR.
[0162] Antigen-binding domain
[0163] Chimeric Antigen Receptors typically comprise an antigen-binding domain (which is specific for the target antigen), a linker domain (also known as a spacer or hinge region) which links the antigen-binding domain to a transmembrane region which spans the cell membrane, and an intracellular domain which comprises one or more signalling domains that, when the CAR encounters its cognate antigen, induces activation of the immune effector cell (see constructs of Figure 1 ).
[0164] As used throughout the specification the term “targets” (in relation to a CAR-expressing cells) refers to the ability of the CAR-expressing cell to recognise and respond to, or lyse, a target cell (such as a cancer) expressing a desired target antigen. As used herein the term “binds” or “binding” (in relation to the CAR) refers to the ability of the binding domain of the CAR to associate with a desired protein. Preferably this recognition is selective, in that the binding domain binds exclusively, or predominantly, to the specified target. The binding domain may directly bind to the target, or may bind to a processed form of the target (such as forms of the target which have been truncatedor digested, typically, as a result of intracellular processing, including forms or epitope portions of the target that are presented on major histocompatibility complexes).
[0165] The CAR binding domain can be any suitable domain that can recognise the CAR target, or an epitope thereof. As used throughout the specification the term “binding domain” refers to the portion of the CAR that provides the specificity of the CAR for the target. The binding domain, in the context of the present invention, comprises a portion of the extracellular region of the CAR.
[0166] The binding domain of the CAR can comprise a range of binding molecules. These include antibodies (including non-conventional antibodies, such as heavy chain antibodies), antibody fragments, fusion proteins and protein binding scaffolds.
[0167] In some embodiments, the antigen-binding domain includes a binding portion of an antibody that binds to the target. In some embodiments, the binding domain includes the variable heavy chain of an antibody that binds to the target. In some embodiments, the binding domain includes the variable light chain of an antibody that binds to the target.
[0168] Predominantly, CARs have been generated using antigen-binding domains that are derived from, or based upon, antibodies. As is known in the art, antibodies consist of four chains (two heavy and two light chains) and can be separated into the Fc (fraction crystallisable) and the Fab (fraction antigen binding) domains. The Fab portion contains the antigen binding regions of the antibody and is critical for the specificity of an antibody for the desired epitope.
[0169] Accordingly, in some embodiments, the binding domain of the CAR is an Fab fragment of an antibody. Fab fragments can be individual Fab fragments (i.e. , the antibody fragment is generated in the absence of linking disulphide bridges) or an F(ab’)2 fragment which comprises the two Fab fragments of an antibody linked via disulphide bridges. These fragments are typically generated by fragmenting an antibody using digestion enzymes, such as pepsin. Methods are known in the art for generating Fabs (see for example Sjogren J, Andersson L, Mejare M, Olsson F. Generating and Purifying Fab Fragments from Human and Mouse IgG Using the Bacterial Enzymes IdeS, SpeB and Kgp. Methods Mol Biol. 2017;1535:319-329).
[0170] Each Fab fragment of an antibody has six CDRs in total with the VH and VL chains comprising three CDRs each (within a framework consisting of 4 framework regions). The constant regions of the Fab fragment can be removed to leave only the VH and VL regions of an antibody. Individual VH and VL chains (each only comprising three CDRs) have been shown to bind specifically with high affinity. Typically, individual binding regions are known as single domain antibody (sdAbs). Alternatively, the VH and VL chains can be linked via a linker to form a fusion protein known as a singlechain variable fragment (scFv - also known as a diabody). Unlike Fabs, scFvs are not fragmented from an antibody, but rather are typically recombinantly formed based on the CDR and framework regions of an antibody. Further, sdAbs can also be recombinantly produced and form the binding component of a larger fusion protein which may also include additional portions. Consequently, in some embodiments, the binding domain is, or includes, an scFv or an sdAb. The scFv may include multiple VH and VL chains linked together to form a multivalent scFv, such as a di-scFv or a tri-scFv.
[0171] In some embodiments, the binding domain is a single-domain antibody (sdAb) including a sequence identical to a variable heavy or variable light chain of an antibody that binds to a desired target, or a sequence identical to a fragment antigen binding (Fab) fragment of an antibody that binds to a desired target, or a sequence identical to a single-chain variable fragment (scFv) comprising the variable heavy and variable light regions of an antibody that binds to a desired target. In preferred embodiments, the binding domain comprises an scFv.
[0172] Anti-LGR5 CAR
[0173] Leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5 - SEQ ID NO: 2. - Uniprot accession number 075473, NCBI Accession number NP_003658.1 and NM_003667.2 - also known by the synonyms GPR49, GPR67, FEX and GPR HG38) is a seven-transmembrane protein of the class A Rhodopsin-like family of GPCRs. LGR5, when bound by its ligand R-Spondin, interacts with Wnt receptors Frizzled and LPR5 / 6 to potentiate Wnt / [3-catenin signalling (Carmon, K. S. et al., PNAS., 2011; 108, 11452-7). The protein comprises 907 amino acids and consists of an extracellular domain of 561 amino acids including a 21 amino acid signalling domain and up to 17 leucine-rich repeats from amino acid 67-446. The leucine-rich repeatsform an arcuate structure with a convex surface in the extracellular domain and a concave surface which interacts with RSPO1 and RNF43 (Kumar K. etal., Protein Sci.2014; 23(5): 551-65 Chen P. et al. Genes Dev., 2013; 27(12): 1345-50). LGR5 further includes 7 transmembrane helical domains of 21 amino acids and an 84 amino acid cytoplasmic tail. The most C-terminal region of extracellular domain contains a hinge domain spanning resides 481-552.
[0174] Notably, LGR5 has been identified as being upregulated in a various cancer types including adenocarcinoma, basal cell carcinomas, glioblastoma, hepatocellular carcinomas, colorectal cancer, pancreatic cancer, B cell malignancies, non-small cell lung carcinoma (NSCLC) and ovarian cancer (Tanese K, et al., Am J Pathol.2008;173(3): 835-43; Carmon, K. S. et al., Proc Natl Acad Sci USA., 2011; 108, 11452-7; Jiang XM, etal. Proc Natl Acad Sci USA. 2013; 110(31): 12649-54; Gao etal. Transl Cancer Res., 2019; 8(1): 203-211 and McClanahan T, et al., Cancer Biol Then 2006;5(4): 419-26).
[0175] Primarily LGR5 upregulation in cancer has been demonstrated to stimulate cancer stem cell proliferation and renewal as well as promoting cancer mobility and tumour formation. LGR5 has also been shown to promote epithelial to mesenchymal transition in breast cancer (Yang L, etal., Stem Cells. 2015;33(10): 2913-24.). As such, LGR5 has an important role in cancer metastasis and secondary tumour formation and is expressed on cancer stem cells (CSC).
[0176] CARs targeting LGR5 have been disclosed in the international patent publication WO2022 / 104424 A1, the entire disclosure of which is incorporated by way of this reference.
[0177] In some embodiments, the CAR that binds to LGR5 includes variable heavy and / or variable light chains from an antibody that binds to LGR5, or CDRs from such variable heavy and variable light chains.
[0178] Antibodies that recognise LGR5 are known in the art and include anti-LGR5 antibodies available from: Huabio (ET1608-18), LifeSpan BioSciences (LS-A1236), mybiosource (MBS856950, MBS7113118 and MBS9604330), Novus Biologicals (NLS1236), Biorbyt (orb137136 and orb137177), ProSci (23-394), BioVision (A1007-100), Cusabio (CSB-PA012906LA01 HU), StressMarq Biosciences Inc (SPC-764),Biolegend (373803 and 373804), R&D systems (MAB8240), Bioss (bsm-52412R), Biorad (AHP2742), GOBiosciences (ITA3755), RayBiotech (144-10545-50), Atlas Antibodies (HPA012530), OriGene Technologies (TA890013), Elabscience (E-AB-63432), GeneTex (GTX71143), St John’s Laboratory (STJ112563), ThermoFisher (MA5-32978 and MA5-32979), NS J Bioreagents (F48166), Acam (ab219107), Abnova (PAB30456 and PAB2591), Miltenyi Biotec (130-111-390), Sino Biological (100687-T04), Abbexa Ltd (abx019126), MBL International (MC-1236 and MC-1235), BosterBio (M00239), Signalway Antibody (21659 and C44974), Wuhan Fine Biotech (FNabO4765), Merck (HPA012530), Leading Biology (AMM03069G), Neuromics (RA25071), Antibody Research Corporation (111302), Bon Opus Biosciences (BA111499), Creative Diagnostics (L640) and Creative Biolabs (NAB-1650-VHH). Further, anti-LGR5 antibodies are disclosed in US20190248889A1 (antibodies GEN89.LGR5.1-12 and antibodies GEN89.LGR5.26-1), BD Pharmingen™ (4D11F8 and 8F2).
[0179] In some embodiments, the antibody is a humanised antibody. In preferred embodiments, the antibody which recognises LGR5 is 18G7H6A3 or 18G7H6A1 (BNC101) as described in WO2015153916 (entitled: Humanized antibodies that bind LGR5 - the entire disclosure of which is incorporated herein) and WO2018232164A1 (entitled: Antibody drug conjugates that bind LGR5 - the entire disclosure of which is incorporated herein). Accordingly, in some embodiments the binding domain of the CAR that binds to LGR5 includes a binding portion of the antibody 18G7H6A1 or 18G7H6A3.
[0180] Epitope mapping of the interaction of antibodies 18G7H6A1 and 18G7H6A3 with LGR5 has identified the critical epitope residues as T175, E176, Q180, R183, S186, A187, Q189, D247, E248, T251, R254, S257, N258, and K260 of LGR5 (SEQ ID NO: 2). In some embodiments, the CAR that binds to LGR5 binds to one or more of the epitope residues T175, E176, Q180, R183, S186, A187, Q189, D247, E248, T251, R254, S257, N258, and K260 of LGR5.
[0181] In some preferred embodiments, the binding domain of the CAR that binds to LGR5 binds to an epitope between residue 22-561 of the LGR5 protein. In some embodiments, the binding domain binds to an epitope of LGR5 on the convex surfaceof LGR5. In some embodiments, the binding domain binds to an epitope between residues 67-446.
[0182] In some embodiments, the CAR that binds to LGR5 comprises an antigenbinding domain comprising: a heavy chain CDR1 having an amino acid sequence as set forth in SEQ ID NO: 3 or having an amino acid sequence as set forth in SEQ ID NO: 3 with up to 2 amino acid modifications; a heavy chain CDR2 having an amino acid sequence as set forth in SEQ ID NO: 4, or having an amino acid sequence as set forth in SEQ ID NO: 4 with up to 2 amino acid modifications; and a heavy chain CDR3 having an amino acid sequence as set forth in SEQ ID NO: 5, or having an amino acid sequence as set forth in SEQ ID NO: 5 with up to 2 amino acid modifications.
[0183] In some embodiments, the CAR that binds to LGR5 comprises an antigenbinding domain comprising: a light chain CDR1 having an amino acid sequence set forth in SEQ ID NO: 6 or having an amino acid sequence as set forth in SEQ ID NO: 6 with up to 2 amino acid modifications; a light chain CDR2 having an amino acid sequence LTS, or having an amino acid sequence LTS with one amino acid modifications; and a light chain CDR3 having an amino acid sequence set forth in SEQ ID NO: 8 or having an amino acid sequence as set forth in SEQ ID NO: 8 with up to 2 amino acid modifications.
[0184] In some embodiments, the antigen-binding domain of the CAR that binds to LGR5 comprises an scFv, comprising a heavy chain CDR1 having an amino acid sequence as set forth in SEQ ID NO: 3 or having an amino acid sequence as set forth in SEQ ID NO: 3 with up to 2 amino acid modifications; a heavy chain CDR2 having an amino acid sequence as set forth in SEQ ID NO: 4, or having an amino acid sequence as set forth in SEQ ID NO: 4 with up to 2 amino acid modifications; and a heavy chain CDR3 having an amino acid sequence as set forth in SEQ ID NO: 5, or having an amino acid sequence as set forth in SEQ ID NO: 5 with up to 2 amino acid modifications; and comprising a light chain CDR1 having an amino acid sequence set forth in SEQ ID NO: 6, or having an amino acid sequence as set forth in SEQ ID NO: 6 with up to 2 amino acid modifications; a light chain CDR2 having an amino acid sequence LTS, or having an amino acid sequence LTS with one amino acid modifications; and a light chain CDR3 having an amino acid sequence set forth in SEQ ID NO: 8, or having an amino acid sequence as set forth in SEQ ID NO: 8 with up to 2 amino acid modifications.
[0185] In some embodiments, the heavy chain CDRs are from the heavy chain variable region of SEQ ID NO: 9. In some embodiments, the light chain CDRs are from the light chain variable region of SEQ ID NO: 10. CDRs can be determined from the disclosed variable heavy and variable light chain sequences using various numbering protocols such as Kabat, Chothia, IMGT, Martin (Enhanced Chothia or AbM) and Honneger’s (Aho) Numbering (see Zhu Z, Olson KS, Magliery TJ. 50 Years of Antibody Numbering Schemes: A Statistical and Structural Evaluation Reveals Key Differences and limitations Antibodies. 2024; 13(4):99).
[0186] In some embodiments, the binding domain that binds to LGR5 comprises a single-chain variable fragment comprising the C-terminus of a variable heavy (VH) chain linked (by way of a fusion protein) to the N-terminus of a variable light (VL) chain.
[0187] In some embodiments, the binding domain that binds to LGR5 comprises a single-chain variable fragment comprising the C-terminus of the variable light (VL) chain linked (by way of a fusion protein) to the N-terminus of the variable heavy (VH) chain.
[0188] In embodiments, wherein the biding domain is an scFv, the variable heavy and variable light chains can be linked by a fusion protein domain which includes, or consist of, the sequence of SEQ ID NO. 11 (scFv fusion protein). In some embodiments, the antigen-binding domain comprises one of the binding domains disclosed in SEQ ID NO: 12 (CNA30XX binding domain) or SEQ ID NO: 13 (CNA31XX binding domain), or variants thereof having at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity.
[0189] In some embodiments, the anti-LGR5 CAR has the sequence set for in SEQ ID NO: 14 (CNA3103 - VH-VL-lgG4 medium hinge (short hinge - 119 a. a.)), or is a functional variant of SEQ ID NO: 14 having at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity. Preferably, the functional variant includes the six CDRs for the anti-LGR5 CAR as described above (i.e. , SEQ ID Nos: 3 to 8).
[0190] Alternative embodiments of the LGR5 CAR are provided below:• CNA3002 - VL-VH-lgG4 hinge (short hinge - 12 a. a.): amino acid sequence - SEQ ID NO: 15.• CNA3003 - VL-VH-lgG4 hinge-CH3 (medium hinge - 119 a. a.): amino acid sequence - SEQ ID NO: 16.• CNA3004- VL-VH-lgG4 hinge-CH2-CH3 (long hinge -229 a. a.): amino acid sequence - SEQ ID NO: 17.• CNA3103 - VH-VL-lgG4hinge-CH3 (medium hinge - 12 a. a.): amino acid sequence - SEQ ID NO: 18.• CNA3104 - VH-VL-lgG4hinge-CH2-CH3 (long hinge -229 a. a.): amino acid sequence - SEQ ID NO: 19.
[0191] In some embodiments of the LGR5 CAR, the amino acid sequence is a functional variant of one or the above sequences, having at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity. Preferably, the functional variant includes the six CDRs for the anti-LGR5 CAR as described above (i.e. , SEQ ID Nos: 3 to 8).
[0192] Each of the above CAR constructs can be combined with the CXCR2 sequence provided in SEQ ID NO: 20.
[0193] The amino acid sequence of an exemplary LGR5 CAR with CXCR2 (CNA310201) is provided in SEQ ID NO: 21.
[0194] Non-functional (nf) P2X7
[0195] P2rx7 receptor Purinergic receptor P2X, ligand-gated ion channel, 7 (P2X7 - SEQ ID NO: 22, - Uniprot accession number Q99572, NCBI Accession number NP_002553.3 and NM_002562.5 - also known by the synonyms P2X purinoceptor 7, ATP receptor, P2Z receptor, P2X7 receptor, and purinergic receptor, and purinergic receptor P2X7 variant A.) is an ATP-gated ion channel that is expressed in a number of species including humans.
[0196] The P2X7 receptor is formed from three protein subunits (monomers), wherein in the native receptor in humans at least one of the monomers has an amino acid sequence set forth in SEQ ID NO: 22 . It is to be understood that reference to P2X7 as referred to herein includes reference to the receptor including naturally occurring variations of the receptor including splice variants, naturally occurring truncated forms and allelic variants of the receptor. A P2X7 receptor may also include subunits that have a modified amino acid sequence, for example those including truncations, aminoacid deletions or modifications of the complete amino acid sequence set forth in SEQ ID NO: 22.
[0197] The P2X7 receptor is activated by the binding of ATP to the ATP-binding site of the receptor. This leads to the rapid opening (within milliseconds) of a channel that selectively allows for movement of small cations across the membrane. After a short period of time (within seconds) a large pore forms in the membrane of the cell resulting in permeation of the cell membrane by molecules up to 900 Da in size. This pore formation ultimately leads to depolarization of the cell and in many cases cytotoxicity and cell death. This role indicates that the P2X7 receptor is involved in apoptosis in a variety of cell types.
[0198] Like other molecules involved in apoptosis, such a Bcl2 and Bax, a decrease or loss in function of the P2X7 receptor can lead to a cell that is comparatively resistant to induced apoptosis. In many cases this resistance to apoptosis is critical in the transition of a normal ‘healthy’ cell to a mutated pre-cancerous or cancerous cell. Consequently, the ability to target cells that have a decreased function, or a loss of function, of the P2X7 receptor provides a promising target for cancer therapy.
[0199] As used throughout the specification the term “non-functional” (“nf”) with reference to the P2X7 receptor includes any decrease in function of the receptor with respect to its comparative function in normal conditions (e.g., in non-tumour cells), or in a non-mutated of conformationally normal form. In some embodiments, the function of non-functional P2X7 receptor may be decreased by at least 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 100%. A completely non-functional P2X7 receptor is unable to be induced to permit permeability of cations and other molecules across the cell membrane.
[0200] Any change in the wild-type or native form of the P2X7 receptor that leads to a decreased functional receptor is encompassed herein. For example, the dysfunctional receptor may be the result of a mutation or alteration in one or more amino acids of the receptor that are associated with ATP binding to the receptor. In effect, the P2X7 receptor is dysfunctional as it has a reduced capacity to, or cannot, bind ATP at the ATP-binding site. In this instance, the antigen-binding domain of the chimeric antigen receptor will recognise an epitope of the dysfunctional P2X? receptorassociated with the ATP-binding site. Consequently, in some embodiments of the invention, the antigen-binding domain of a CAR for nfP2X7 recognises an epitope of the non-functional P2X7 receptor associated with the ATP-binding site. In some embodiments, the nfP2X7 receptor has a reduced capacity to bind ATP compared to an ATP-binding capacity of a wild-type (functional) P2X7 receptor. In some embodiments the nfP2X7 receptor cannot bind ATP.
[0201] An alteration in one or more amino acids of the nfP2X7 receptor may include a conformational change in one or more amino acids of the receptor. Therefore, in some embodiments the nfP2X7, has a conformational change that renders the receptor dysfunctional. Specifically, this conformational change may be a change in one or more amino acids of the P2X7 receptor from a trans-conformation to a cis-conformation. In some embodiments, the CAR binds to a nfP2X7 wherein a proline at position 210 of the P2X7 receptor is in a trans-conformation rather than the wild-type cis-conformation. In this instance, the antigen-binding domain of the CAR may recognise and bind to an epitope that includes proline at amino acid position 210 of the P2X7 receptor. In some embodiments, the antigen-binding domain of the nfP2X7 CAR binds to an epitope that includes one or more amino acids spanning from glycine at amino acid position 200 to cysteine at amino acid position 216 (inclusive) of the nfP2X7 receptor. In some embodiments, the antigen-binding domain binds to an epitope that includes the proline at position 210 of the dysfunctional P2X? receptor, and one or more of the amino acid residues spanning from glycine at amino acid position 200 to cysteine at amino acid position 216 (inclusive) of the dysfunctional P2X? receptor.
[0202] Whilst not wanting to be bound by theory, as a result of the conformational change of the proline at position 210 of the P2X7 receptor, the three-dimensional structure of the receptor may be altered. This alteration in the three-dimensional structure may allow the antigen-binding domain of the anti-nfP2X7 CAR to bind to amino acids, or epitopes, previously inaccessible in the native three-dimensional structure of the P2X7 receptor. Therefore, in some embodiments, the anti-nfP2X7 CAR recognises one or more epitopes of the P2X7 receptor exposed to the antigen-binding domain as a result of a trans- to cis-conformational change of the proline at position 210 of SEQ ID NO: 22. These epitopes may include one or more of the amino acids at position 200 to 210, or positions 297 to 306, inclusive, of the P2X7 receptor. Accordingly, in some embodiments, the antigen-binding domain of the nfP2X7recognises an epitope that includes one or more of the amino acids at positions 200 to 210 and / or 297 to 306 of the P2X? receptor.
[0203] CARs targeting the nfP2X7 receptor have been disclosed in the international patent publication WO2017 / 041143 A1 (the entire disclosure of which is incorporated by way of this reference).
[0204] In some embodiments, the antigen-binding domain includes a binding peptide that includes amino acid sequence homology to one or more CDR regions of an antibody that binds to a dysfunctional P2X7 receptor. In some embodiments, the binding peptide includes amino acid sequence identity to the CDR1, 2 and 3 domains of the VH and / or VL chain of an antibody that binds to a dysfunctional P2X7 receptor. In some embodiments, the antigen-recognising domain includes one or more amino acid sequences which are at least 50%, 60%, 70%, 80%, 90% or 94% identical to any one of the heavy and light chain CDR1 , 2 and 3 regions of the sequences set forth in SEQ ID NOS: 23, 24, 25, or 26.
[0205] The present inventors have developed an anti-nfP2X7 CAR wherein the binding domain comprises a single variable heavy domain (i.e., a single domain antibody). Accordingly, in preferred embodiments, the antigen-binding domain comprises the CDRs of a variable heavy domain single domain antibody (i.e., the antigen-binding domain does not include a corresponding variable light domain).
[0206] Antibodies directed against dysfunctional P2X7 receptors, from which suitable amino acid sequences may be derived, and methods for producing such antibodies, have been described in the art (for example W02001 / 020155, W02003 / 020762, W02008 / 043145, W02008 / 043146, W02009 / 033233, WO2010 / 000041, WO2011 / 020155 and WO2011 / 075789 - the entire disclosures of which are incorporated herein). Methods for generating polyclonal and monoclonal antibodies for specific epitopes (such as those set forth previously) would be known to a person skilled in the art. By way of summary, a desired epitope (such as a segment of the dysfunctional P2X7 receptor including the proline at position 210) is injected into a suitable host animal in the presence of an appropriate immunogenic carrier protein and an adjuvant. Serum is then collected from the immunized animal and the antibody can be isolated based on its antibody class or its antigen specificity. Followingassessment of the suitability and specificity of the purified antibody, the antibody can be further processed to isolate antigen-binding fragments, or sequenced to identify the relevant VH and VL domains. Suitable epitopes for the production of antibodies directed against the dysfunctional P2X7 receptor are known in the art (see WQ2008 / 043146, WO2010 / 000041 and W02009 / 033233, as examples).
[0207] In some embodiments, the VH and / or VL are derived from the PEP2-2-3 antibody disclosed in WO2011 / 020155A1.
[0208] In some embodiments, the VH is the amino acid sequence set forth in SEQ ID NO: 30.
[0209] Accordingly, in some embodiments, the CAR that binds to nfP2X7 comprises an antigen-binding domain comprising: a heavy chain CDR1 having an amino acid sequence as set forth in SEQ ID NO: 27, or having an amino acid sequence as set forth in SEQ ID NO: 27 with up to 2 amino acid modifications; a heavy chain CDR2 having an amino acid sequence as set forth in SEQ ID NO: 28, or having an amino acid sequence as set forth in SEQ ID NO: 28 with up to 2 amino acid modifications; and a heavy chain CDR3 having an amino acid sequence as set forth in SEQ ID NO: 29, or having an amino acid sequence as set forth in SEQ ID NO: 29 with up to 2 amino acid modifications.
[0210] In some embodiments, the binding domain comprises the heavy chain variable region of SEQ ID NO: 30, or a functional variant of SEQ ID NO: 30 having at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity, preferably wherein any variation is in the framework region only. In some embodiments, the heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 30, or a functional variant of SEQ ID NO: 30 having at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity, preferably wherein any variation is in the framework region only.
[0211] In some embodiments, the anti-nfP2X7 CAR has the sequence set forth in any one of SEQ ID NOs: 31 , 32, 33, 34 or 35 (pep 2-2-3 short, pep2-2-3 long, pep2-2-1-1 CAR, pep2 -472-2, pep2-2-12 CAR) , or a functional variant of SEQ ID NO: 31, 32, 33, 34 or 35 having at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity (as disclosed in WQ2017 / 041143).
[0212] In a preferred embodiment, the anti-nfP2X7 CAR has the sequence set for in SEQ ID NO: 36, or is a functional variant of SEQ ID NO: 36 having at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence.
[0213] In a preferred embodiment, the amino acid sequence of the nfP2X7 CAR with CXCR2 has the sequence set for in SEQ ID NO: 37, or is a functional variant of SEQ ID NO: 37 having at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence.
[0214] Linker Domain of CAR
[0215] The linker domain (also known as the spacer or hinge domain) of the CAR links the antigen-binding domain to the transmembrane domain. This domain can provide flexibility to the antigen-binding domain, improving its ability to interact with, and bind to, its target epitope region. Therefore, for some targets the length and composition of the linker region can influence the function of the CAR.
[0216] As described in WQ2022 / 104424 A1 and WQ2017 / 041143 A1 the linker domain can have various lengths. In some embodiments, the linker domain is 12 amino acids, or is at least 12 amino acids in length, or is about 12 amino acids in length. In some embodiments, the linker domain is 119 amino acids, or is at least 119 amino acids in length, or is about 119 amino acids in length. In some embodiments, the linker domain is 229 amino acids, or is at least 229 amino acids in length, or is about 229 amino acids in length.
[0217] In some embodiments the linker is up to 119 amino acids, or up to about 119 amino acids. In some embodiments, the linker is up to 229 amino acids, or up to about 229 amino acids. For the avoidance of doubt, in embodiments, the linker length can be about 12 amino acids or greater, about 12 to about 119 amino acids, or about 12 to about 229 amino acids in length, or about 119 amino acids to about 229 amino acids.
[0218] A non-exhaustive list of sequences which may, comprise or provide the linker domain is detailed in Table 1, below. In some embodiments, the linker domain of the present invention may include any one or more of the components provided in Table 1. In some embodiments, the linker domain may consist of any one or more ofthe linkers provided in Table 1. Further, the linker domain may be an artificially synthesized sequence such poly-Glycine sequences or repeats of GGGGS (Gly4Ser) sequences (for example a (Gly4Ser)s).Table 1 - Possible linker domain componentsName length Sequence SEQ ID lgG4 GQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDI 38 common 107 AVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVD heavy (CH) 3 KSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGKlgG1 hinge 15 EPKSCDKTHTCPPCP 39ERKCCVECPPCPlgG2 hinge 12 40LKTPLGDTTHTCPRCPEPKSCDTPPPCPRCPEPKSC 41 lgG3 hinge 62DTPPPCPRCPEPKSCDTPPPCPRCPlgG4 hinge 12 ESKYGPPCPSCP 42 lgG4 hinge 4312 ESKYGPPCPPCP(modified)lgA1 hinge 21 PVPSTPPTPSPSTPPTPSPSC 44ESPKAQASSVPTAQPQAEGSLAKATTAPATTRNTGR 45 IgD hinge 58GGEEKKKEKEKEEQEERETKTP IAELPPKVSVFVPPRDGFFGNPRKSKLICQATGFSPR 46 QIQVSWLREGKQVGSGVTTDQVQAEAKESGPTTYKVIgM CH2 112TSTLTIKESDWLGQSMFTCRVDHRGLTFQQNASSMC VPD PTVKILQSSCDGGGHFPPTIQLLCLVSGYTPGTINITW 47 IgE CH2 99 LEDGQVMDVDLSTASTTQEGELASTQSELTLSQKHW LSDRTYTCQVTYQGHTFEDSTKKCA CD28 Hinge 15 KHLCPSPLFPGPSKP 48AKPTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGA CD8a Hinge 4948 VHTRGLDFACD(1)CD8a Hinge TTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHT 5045(2) RGLDFACDSVVDFLPTTAQPTKKSTLKKRVCRLPRP CD8b Hinge 51 38 ETQKGPLCSP(1)CD8b Hinge VDFLPTTAQPTKKSTLKKRVCRLPRP ETQKGPLCSP 52 36(2)APPRASALPAPPTGSALPDPQTASALPDPPAASALP CD7 36 53DSGQVLLESNIKVLPTWSTPVQP CD4 Hinge 23 54PolyG / S 5+ (GGGGS)n 55
[0219] In some embodiments of the present invention, the linker domain includes an amino acid sequence identical to the sequence of an immunoglobulin hinge such as the lgG4 hinge. In some embodiments, the linker region includes a sequence identical to a modified version of the lgG4 hinge. In some embodiments, the modified version of the lgG4 hinge includes 1, 2 or 3 amino acid modifications, preferably 1 amino acid modification.
[0220] In some embodiments, the linker domain includes a sequence identical to an immunoglobulin CH3 domain, an immunoglobulin CH2 domain or both a CH2 and CH3 domain. In some embodiments, the linker domain includes a sequence identical to an immunoglobulin hinge region and one or more of a CH3 domain or a CH2 domain. In some embodiments, the CH2 and / or CH3 regions are from the lgG4 subclass of IgG antibodies.
[0221] In some embodiments, the linker domain includes, or consists of, a sequence selected from the group consisting of: SEQ ID NO: 56 (CNA..01 hinge - short hinge), SEQ ID NO: 57 (CNA..02 hinge - medium hinge) or SEQ ID NO: 58 (CNA..03 hinge - long hinge), or a functional variant, or portion, thereof having at least 50%, 60%, 70%, 80%, 90%, 95%, 98%, 99% or 99.5% sequence identity.
[0222] Transmembrane and Intracellular Domains
[0223] The transmembrane domain of a CAR bridges the extracellular portion (ectodomain) to the intracellular portion (endodomain) with its role being primarily structural. As such, the transmembrane domain can consist of any sequence that can anchor and span the lipid bilayer of a cell. However, the nature of the transmembrane domain can influence its localisation and expression.
[0224] In a preferred embodiment, the transmembrane domain has homology to a sequence of a molecule involved in T cell synapse formation, or T cell signal induction. In some embodiments, the chimeric antigen receptor of the present invention includes a transmembrane domain which includes a sequence identical to all, or part of, the transmembrane domain of CD3, CD4, CD8 or CD28. In some embodiments, the transmembrane domain includes a sequence having identity to all, or part of, the transmembrane domain of CD8 or CD28. In some embodiments, the transmembrane domain has sequence identity to all, or part of, the transmembrane domain of CD28. In some embodiments, the transmembrane domain has sequence identity to SEQ ID NO: 59, or a functional variant thereof.
[0225] In addition to the antigen-recognising domain, the linker domain and the transmembrane domain, the chimeric antigen receptor of the present invention includes an intracellular (endo) domain which includes a signalling portion (a signalling domain).
[0226] The intracellular signalling domain of the chimeric antigen receptor can be any suitable domain that is capable of inducing, or participating in the induction of, an intracellular signalling cascade upon activation of the CAR as a result of binding to the antigen by the antigen-binding domain. The signalling domain of a CAR will be specifically chosen depending on the intended cellular outcome following activation of the CAR. Whilst there are many possible signalling domains, when used in immunotherapy and cancer therapy the signalling domains can be grouped into two general categories based on the receptor from which they are derived, namely activation receptors and co-stimulatory receptors (see further details herein). Therefore, in some embodiments, the signalling domain includes a portion having an amino acid sequence identical to a signalling portion of an activation receptor, or a functional variant thereof. In some embodiments, the signalling domain includes a portion having an amino acid sequence identical to a signalling portion of a costimulatory receptor, or a functional variant.
[0227] As used throughout the specification the term “portion”, when used with respect to an activation receptor or co-stimulatory receptor, relates to any segment of the receptor that includes a sequence responsible for, or involved in, the initiation / induction of an intracellular signalling cascade following interaction of thereceptor with its cognate antigen or ligand. An example of the initiation / induction of an intracellular signalling cascade for the T cell receptor (TCR) via CD3 is outlined below.
[0228] Whilst not wanting to be bound by theory, the extracellular portion of the TCR largely comprises heterodimers of either the clonotypic TCRalpha and TCRbeta chains (the TCRalpha / beta receptor) or the TCRgamma and TCRdelta chains (the TCRydelta receptor). These TCR heterodimers generally lack inherent signalling transduction capabilities and therefore they are non-covalently associated with multiple signal transducing subunits of CD3 (primarily CD3-zeta, -gamma, -delta, and -epsilon). Each of the gamma, delta, and epsilon chains of CD3 has an intracellular (cytoplasmic) portion that includes a single Immune-receptor-Tyrosine-based-Activation-Motif (ITAM), whilst the CD3-zeta chain includes three tandem ITAMs. Upon engagement of the TCR by its cognate antigen in the presence of MHC, and the association of a requisite co-receptor such as CD4 or CD8, signalling is initiated which results in a tyrosine kinase (namely Lek) phosphorylating the two tyrosine residues within the intracellular ITAM(s) of the CD3 chains. Subsequently, a second tyrosine kinase (ZAP-70 - itself activated by Lek phosphorylation) is recruited to biphosphorylate the ITAMs. As a result, several downstream target proteins are activated which eventually leads to intracellular conformational changes, calcium mobilisation, and actin cytoskeleton rearrangement that when combined ultimately lead to activation of transcription factors and induction of an immune cell response.
[0229] As used throughout the specification the term “activation receptor” relates to receptors, or co-receptors that form a component of, or are involved in the formation of, the T cell receptor (TCR) complex, or receptors involved in the specific activation of immune cells as a result of recognition of an antigenic or other immunogenic stimulus.
[0230] Non-limiting examples of such activation receptors include components of the T cell receptor-CD3 complex (CD3-zeta, -gamma, -delta, and -epsilon), the CD4 co-receptor, the CD8 co-receptor, Fc receptors or Natural Killer (NK) cell associated activation receptors such a LY-49 (KLRA1), natural cytotoxicity receptors (NCR, preferably NKp46, NKp44, NKp30 or NKG2 or the CD94 / NKG2 heterodimer). Consequently, in some embodiments of the CAR of the present invention the signalling domain includes a portion derived from any one or more of a member of the CD3 co-receptor complex (preferably at least a signalling portion of the CD3-Zeta ( chain), theCD4 co-receptor, the CD8 co-receptor, a signalling portion of the Fc Receptor (FcR) (preferably a signalling portion of Fc epsilon Rl or Fc gamma Rl) or NK associated receptors such a LY-49.
[0231] The specific intracellular signal transduction portion of each of the CD3 chains are known in the art. By way of example, the intracellular cytoplasmic region of the CD3zeta chain spans from amino acid 52 to amino acid 164 of the sequence set forth in SEQ ID NO: 60, with the three ITAM regions spanning amino acids 61 to 89, 100 to 128 and 131 to 159 of SEQ ID NO 60. Furthermore, the intracellular portion of the CD3 epsilon chain spans amino acids 153 to 207 of the sequence set forth in SEQ ID NO: 61, with the single ITAM region spanning amino acids 178 to 205 of SEQ ID NO: 62. The intracellular portion of CD3gamma chain spans amino acids 138 to 182 of the sequence set forth in SEQ ID NO: 62 with the single ITAM region spanning amino acids amino acids 149 to 177 of SEQ ID NO: 62. The intracellular portion of CD3delta spans amino acids 127 to 171 of the sequence set forth in SEQ ID NO: 63 with the single ITAM region spanning amino acids 138 to 166 of SEQ ID NO: 63.
[0232] In some embodiments of the present invention, the signalling domain includes a portion derived from, or having sequence homology to, CD3 (preferably the CD3zeta chain or a portion thereof). In some embodiments, the signalling domain includes a sequence identical to all, or part of, the intracellular domain of CD3zeta. In some embodiments, the portion of the CD3zeta co-receptor complex includes the amino acid sequence set forth in SEQ ID NO: 64, or a functional variant thereof.
[0233] Alternative signalling domains include intracellular portions of the Fc receptors, which are known in the art. For example, the intracellular portions of the Fc epsilon R1 span amino acids 1 to 59, 118 to 130 and 201 to 244 of the sequence set forth in SEQ ID NO: 65, or a functional variant thereof. Furthermore, the intracellular portion of FcyRI spans the amino acids 314 to 374 of the sequence set forth in SEQ ID NO: 66, or a functional variant thereof.
[0234] Various combinations of portions of activation receptors can be utilized to form the transmembrane (TM) and intracellular (IC) portions of the CAR for example the CD3delta TM and CD3zeta IC (Landmeier S, Altvater B, Pscherer S, et al. Gene-Engineered Varicella-Zoster Virus-Reactive CD4+ Cytotoxic T Cells Exert Tumor-Specific Effector Function. Cancer Res. 2007;67(17):8335-8343; Guest RD, Hawkins RE, Kirillova N, et al. The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens. J Immunother. 2005;28(3):203-211.; Hornbach AA, Schildgen V, Heuser C, et al. T Cell Activation by Antibody-Like Immunoreceptors: The Position of the Binding Epitope within the Target Molecule Determines the Efficiency of Activation of Redirected T Cells. J Immunol. 2007;178(7):4650-4657), the CD4 TM and CD3zeta IC (James SE, Greenberg PD, Jensen MC, et al. Antigen Sensitivity of CD22-Specific Chimeric TCR Is Modulated by Target Epitope Distance from the Cell Membrane. J Immunol.2008; 180(10)7028-7038), the CD8 TM and CD3zeta IC (Patel SD, et al. Adenovirus-mediated gene transfer for the treatment of glioblastoma. Gene Then 1999;6(3):412-419.), and the Fc epsilon Rl gamma TM and the Fc epsilon Rl gamma IC (Haynes NM, Snook MB, Trapani JA, et al. Redirecting Mouse CTL Against Colon Carcinoma: Superior Signaling Efficacy of Single-Chain Variable Domain Chimeras Containing TCR-^vs FcsRI-y. J Immunol. 2001; 166(1): 182-187; Annenkov AE, Moyes SP, Eshhar Z, Mageed RA, Chernajovsky Y. Loss of original antigenic specificity in T cell hybridomas transduced with a chimeric receptor containing single-chain Fv of an anticollagen antibody and Fc epsilonRI-signaling gamma subunit. J Immunol.1998;161(12):6604-6613).
[0235] As discussed above, in some embodiments of the chimeric antigen receptors, the signalling domain includes a portion having an amino acid sequence identical to a signalling portion of a co-stimulatory receptor.
[0236] The term “co-stimulatory receptor” relates to receptors or co-receptors that assist in the activation of an immune cell upon antigen specific inducement of an activation receptor. As will be understood, co-stimulatory receptors do not require the presence of antigen and are not antigen specific, but are typically one of two signals, the other being an activation signal, which is required for the induction of an immune cellular response. In the context of an immune response a co-stimulation receptor is typically activated by the presence of its expressed ligand on the surface of an antigen-presenting cell (APC) such as a dendritic cell or macrophage. With specific regard to T cells, co-stimulation is necessary to lead to cellular activation, proliferation, differentiation and survival (all of which are generally referred to under the umbrella of T cell activation), whilst presentation of an antigen to a T cell in the absence of co-stimulation can lead to anergy, clonal deletion and / or the development of antigen specific tolerance. Importantly, co-stimulatory molecules can inform the T cell response to a simultaneously encountered antigen. Generally, an antigen encountered in the context of a ‘positive’ co-stimulatory molecule will lead to activation of the T cell and a cellular immune response aimed at eliminating cells expressing that antigen. Whilst an antigen encountered in the context of a ‘negative’ co-receptor will lead to an induced state of tolerance to the co-encountered antigen.
[0237] Non-limiting examples of T cell co-stimulatory receptors include CD27, CD28, CD30, CD40, DAP10, 0X40, 4-1 BB (CD137), ICOS. Specifically, CD27, CD28, CD30, CD40, DAP10, 0X40, 4-1 BB (CD137), and ICOS all represent ‘positive’ co-stimulatory molecules that enhance activation of a T cell response. Accordingly, in some embodiments of the present invention, the signalling domain includes a portion derived from any one or more of CD27, CD28, CD30, CD40, DAP10, 0X40, 4-1 BB (CD137) and ICOS.
[0238] In some embodiments of the present invention, the signalling domain includes a portion derived from the CD28, 0X40 or 4-1 BB co-stimulatory receptors. In some embodiments, the signalling domain includes a portion of 4-1 BB. In some embodiments, the portion of the 4-1 BB co-stimulatory receptor includes the amino acid sequence set forth in SEQ ID NO: 67, or a functional variant thereof.
[0239] Various portions of co-stimulatory receptors can be utilized to form the transmembrane (TM) and intracellular (IC) portions of the CAR, alone or in combination. Examples of combinations include the CD8 TM and DAP10 IC or CD8 TM and 4-1 BB IC (Marin V, Pizzitola I, Agostoni V, et al. Cytokine-induced killer cells for cell therapy of acute myeloid leukemia: improvement of their immune activity by expression of CD33-specific chimeric receptors. Exp Hematol. 2007;35(10): 1388-1397), the CD28 TM and the CD28 IC (Wilkie S, Picco G, Foster J, et al. Retargeting of Human T Cells to Tumor-Associated MLIC1: The Evolution of a Chimeric Antigen Receptor. J Immunol.2008; 180(7):4901 -4909; Maher J, Brentjens RJ, Gunset G, Riviere I, Sadelain M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCR / 7CD28 receptor. Nat Biotechnol. 2002;20(1):70-75.), and the CD8 TM and the CD28 IC (Marin V. et al. 2007, supra).
[0240] Sequence information for the above-referenced activation and costimulatory receptors is readily accessible in a variety of databases. For example, embodiments of human amino acid, gene and mRNA sequences for these receptors are provided in Table 2.
[0241] Table 2 - Summary of Activation and Co-stimulation Receptor Sequence InformationGeneBank mRNA Receptor Name Uniprot Ref No. NCBI Gene ID No.Ref No.CD3-zeta P20963 919 Gl: 166362721CD3-gamma P09693 917 Gl: 166362738CD3-delta P04234 915 GL98985799CD3-epsilon P07766 916 Gl: 166362733CD4 P0173 920 GL303522473CD8 alpha P01732 925 GL225007534CD8 beta P01966 926 GL296010927FcyRI P12314 2209 GL31331FcsR1 Q01362 2206 GL219881Ly-49 (KLRAI) Q7Z556 10748 Gl:33114184NKp46 076036 9437 GL3647268NKp44 095944 9436 GL4493701NKp30 014931 259197 GL5823969CD94 Q13241 3824 GL1098616 CD27 P26842 939 Gl: 180084CD28 P 10747 940 GL338444CD30 P28908 943 Gl: 180095CD40 P25942 958 GL29850DAP 10 Q9UBK5 10870 GL57381980X40 P43489 7293 GL4729574-1 BB (TNR9) Q07011 3604 GL571320ICOS Q9Y6W8 29851 GL9968295CTLA-4 P16410 1493 GL291928PD-1 Q15116 5133 GL2149002
[0242] Whilst Table 2 is provided with reference to human activation and costimulatory receptors, it would be understood by a person skilled in the art that homologous and orthologous versions of each receptor are present in the majority of mammalian and vertebrate species. Therefore, the above-referenced sequences are only provided as non-limiting examples of receptor sequences that may be included in a CAR of the first aspect of the present invention and homologous and orthologous sequences from any desired species may be used to generate a CAR that is suitable for the given species.
[0243] In some embodiments of the invention, the transmembrane domain and a portion of the intracellular signalling domain share homology with the same molecule. For example, a portion of CD3 including the transmembrane domain and a signalling domain may be utilised. In some embodiments, the transmembrane domain includes, or consists of, a sequence identical to all or a portion of the transmembrane domain of CD28 and the signalling domain includes, or consists of, a sequence identical to all or a portion of the intracellular domain of CD28.
[0244] In some embodiments of the present invention, the signalling domain includes a portion derived from an activation receptor and a portion derived from a co-stimulatory receptor. Whilst not wishing to be bound by theory, in this context the binding to the antigen by the antigen-binding domain of the CAR will simultaneously induce both an intracellular activation signal and an intracellular co-stimulatory signal. Consequently, this will simulate the presentation of an antigen by an APC expressing co-stimulatory ligand. Alternatively, the CAR could have a signalling domain that includes a portion derived from either an activation receptor or a co-stimulatory receptor. In this alternative form, the CAR will only induce either an activating intracellular signalling cascade or a co-stimulatory intracellular signalling cascade.
[0245] In some embodiments of the invention, the signalling domain includes, or consists of, a sequence identical to all or a portion of the intracellular domain of 4-1 BB and CD3zeta chain. In some embodiment, the CAR of the present invention includes an intracellular domain including, or consisting of, SEQ ID NO: 68, or a functional variant thereof.
[0246] In some embodiments, the CAR will have a signalling domain that includes a portion of a single activation receptor and portions of multiple co-stimulatory receptors. In some embodiments, the CAR will have a signalling domain including a sequence identical to portions of multiple activation receptors and a portion derived from a single co-stimulatory receptor. In some embodiments, the CAR will have a signalling domain that includes a sequence identical to portions of multiple activation receptors and portions of multiple co-stimulatory receptors. In some embodiments, the CAR will have a signalling domain that includes a sequence identical to a portion of a single activation receptor and portions of two co-stimulatory receptors. In some embodiments, the CAR will have a signalling domain that includes a sequence identical to a portion of a single activation receptor and portions derived from three co-stimulatory receptors. In some embodiments, the CAR will have a signalling domain that includes a sequence identical to portions of two activation receptors, and a portion of one co-stimulatory receptor. In some embodiments, the CAR will have a signalling domain that includes a sequence identical to portions of two activation receptors and portions of two co-stimulatory receptors. As will be understood there are further variations of the number of activation receptors and co-stimulatory receptors, and the above examples are not considered to be limiting on the possible combinations included herein.
[0247] In some embodiments of the invention, the sequence of the transmembrane domain and at least a portion of the signalling domain have sequence similarity to portions of distinct molecules. In some embodiments, the transmembrane domain includes, or consists of, a sequence identical to all or a portion of the transmembrane domain of CD28 and the signalling domain includes, or consists of, a sequence identical to all or a portion of the intracellular domain of 4-1 BB and CD3zeta chain.
[0248] Examples
[0249] Example 1 - Exogenous CXCR2 expression improves non-functional (nf)P2X7 CAR-T cell proliferation and cytotoxicity.
[0250] A CAR shown to be active against the pan-cancer marker, non-functional P2X7 (nfP2X7) was utilised to assess the influence of the CXCR2 receptor on CAR-T cell homing to cancers, in vivo anti-tumour efficacy, and CAR-T cell cytotoxic and proliferative capacity.
[0251] The present inventors have previously demonstrated that nfP2X7 -targeting CAR-T cells are highly effective against a wide variety of cancers, including widely used preclinical murine models of MDA-MB-231 human breast and PC3 human prostate cancer xenografts in addition to twelve different cancer families in vitro (Bandara V, Foeng J, Gundsambuu B, et al. Pre-clinical validation of a pan-cancer CAR-T cell immunotherapy targeting nfP2X7. Nature Communications. 2023; 14:41338 -the entire disclosure of which is incorporated herein), thereby positioning these CAR-T cells as a promising pan-cancer immunotherapy.
[0252] To evaluate if engineered CXCR2 expression could drive intratumoural accumulation of nfP2X7 CAR-T cells in solid tumour treatment, anti-nfP2X7 CAR-T cells were developed that expressed an exogenous nucleic acid for the CXCR2 receptor. These engineered CAR-T cells (termed CNA100301, CXCR2 CAR-T) were assessed in a range of in vivo and in vitro assays to parse the role of the CXCR2 receptor in CAR-T cell homing, proliferation and anti-tumour cytolysis.
[0253] Preparation and characterization of CXCR2-expressing anti-nfP2X7 CAR-T cells.
[0254] To generate CXCR2-modified CAR-T cells, the nfP2X7-specific CAR previously reported (Bandara & Foeng et al., 2023, supra) was expressed in transduced T cells. This CAR construct, when expressed, comprises an extracellular domain 1 (from N- to C-terminus) comprising a leader sequence of Homo sapiens CSF2Ra molecule (SEQ ID NO: 75) 2, an antigen-binding domain for nfP2X7 3 (comprising a single variable heavy domain of SEQ ID NO: 30) linked to a transmembrane domain 5 via a linker (hinge) region 4 (SEQ ID NO: 57). The transmembrane domain 5, and a portion of the intra-cellular domain 7 of the CAR is provided by a portion of the CD28 co-stimulatory receptor 6 (SEQ ID NO: 59). The remaining portion of the intracellular domain 7 of the CAR is provided by a portion of the co-stimulatory receptor 4-1 BB 8 (SEQ ID NO:67) and a portion of the activation receptor CD3 zeta 9 (SEQ ID NO: 64). A T2A self-cleaving peptide 10 (SEQ ID NO: 70) is provided at the C-terminus of the CAR, permitting the post-translational excision of any peptide sequence attached to the C-terminus.
[0255] The construct for simultaneous expression of exogenous CXCR2 and the chimeric antigen receptor (Figure 1A, nfP2X7-CAR-CXCR2) included the CXCR2 protein 11 (SEQ ID NO: 20) attached to the T2A protein 10.
[0256] The construct for expression of the nfP2X7 CAR alone (Figure 1 B, nfP2X7-CAR) included a truncated EGFR (tEGFR) 12 (SEQ ID NO: 9) connected to the T2A protein 10, in place of the CXCR2 receptor.
[0257] The construct encoding the nfP2X7 CAR and nfP2X7 CXCR2 CAR includes long terminal repeats at the 5’ 13 and 3’ 14 ends and an EF1a promoter 15.
[0258] The nfP2X7 CAR has the amino acid sequence set forth in SEQ ID NO: 36 and is encoded by the DNA sequence set forth in SEQ ID NO: 71. The nfP2X7 CXCR2 CAR has the amino acid sequence set forth in SEQ ID NO: 37 and is encoded by the DNA sequence set forth in SEQ ID NO: 72.
[0259] Non-functional P2X7 CAR-T cells were prepared using a protocol illustrated in Figure 2, with CXCR2-expressing CAR-T cells, CAR-T cells and untransduced cells prepared in parallel.
[0260] Seven days after lentiviral transduction of activated human CD3+cells with the CXCR2 CAR construct (i.e., day 8 post-isolation), CXCR2 expression was detectable on 71.21% (± 4.45 %) of activated CD3+ human cells. As the CXCR2 receptor was linked to the nfP2X7 receptor, the expression of CXCR2 provided a proxy nfP2X7 CAR expression (Figure 3). For control CAR-T cells, the lentivirus containing the nfP2X7 CAR-EGFRt construct was titrated to produce a comparable rate of transduction as determined by tEGFR expression on activated human CD3+cells (76.66 ± 2.38 % - Figure 3). Furthermore, as a direct measure of CAR expression, CAR-T cells were stained with a previously validated biotinylated peptide mimetic (PM) of nfP2X7 (Bandara & Foeng et al., 2023, supra), which indicated comparable transduction (Figure 4).
[0261] Transduced cells were frozen until required. Prior to analysis, all transduced CAR-T cells (i.e., CXCR2-CAR-T and control CAR-T) as well as untransduced cells were cultured for three days post-thaw.
[0262] The function of the CXCR2 expression on nfP2X7 CAR-T cells was determined in vitro by migration of CXCR2-transduced CAR-T cells towards CXCL8 in transwell® assays (Figure 5). No migration was observed for control CAR-T cells or untransduced T cells.
[0263] To determine whether introduction of CXCR2 affected the phenotype of T cells, a comprehensive flow cytometric assessment of batch- and donor-matched CXCR2-modified and control CAR-T cells was performed. For all preparations of these cells, the majority were of a minimally differentiated CD45RO+CD62L+TCM subset phenotype (Figure 6A). High frequencies of CD4+CXCR2-modified and control CAR-T cells expressed IFNgamma, IL-2 and TNFalpha. In the CD8+compartment, high frequencies of CXCR2-modified and control CAR-T cells expressed IFNgamma, TNFalpha, granzyme B, while approximately 26-29% expressed CD107a, indicating that these cells possessed degranulation and cytotoxic capacity (Figure 6B). CXCR2-modified and control CAR-T cells also displayed significant levels of CD27, CD28,CD95 and CXCR3 activation marker expression (Figure 6C) and minimal frequencies of PD-1, CTLA-4 and LAG-3 co-inhibitory receptor expression (Figure 6D). A statistically significant reduction in the frequency of CD28+cells in the CD8+CXCR2-modified CAR-T cell population relative to the CD8+control CAR-T cell population was observed (Figure 6C).
[0264] CXCR2 expressing anti-nfP2X7 CAR-T cells have increased anti-tumour efficacy
[0265] To explore whether exogenous expression of CXCR2 in nfP2X7-targeting CAR-T cells enhanced in vivo anti-tumour efficacy, two mouse cancer models (namely the PC3 and MDA-MB-231 xenograft models) were used. These models were chosen as tumour-specific CXCL1 , CXCL2 and CXCL8 expression was detected at day 7 posttumour injection in these in vivo models (data not shown). CXCR2 -transduced CAR-T, control CAR-T, and untransduced cells were administered into tumour-bearing NSG mice at day 7 post-tumour injection.
[0266] Five million of each of CXCR2 CAR-T cells, CAR-T cells, or UT T cells were administered to mice having PC3 prostate cancer cell tumours, with the administration of CXCR2-expressing CAR-T cells resulting in statistically significant inhibition of tumour growth compared to control CAR-T cells based on tumour size. The endpoint tumour sizes and weights of 0.68 ± 0.27 mm2and 4.70 ± 1.79 mg in mice receiving CXCR2-modified CAR-T cells relative to 6.57 ± 2.73 mm2and 9.30 ± 25.90 mg in mice receiving control CAR-T cells (Figure 7A). While there was no statistically significant difference in the frequency or number of CD3+T cells recovered from endpoint tumours (Figure 7B), there was a trend towards a significant decrease in tumour weights of mice receiving CXCR2-expressing CAR-T cells compared to control CAR-T cells (Figure 7A). No difference in the CD8+:CD4+ratio of recovered T cells was observed between mice receiving CXCR2-expressing and control CAR-T cells (Figure 7B), indicating that exogenous CXCR2 expression did not affect CD8+or CD4+numbers by this timepoint.
[0267] Twenty million cells (CXCR2 CAR-T cells, CAR-T cells and UT T cells) were administered to mice having MDA-MB-23 breast cancer tumours, with administration of CXCR2-expressing CAR-T cells resulting in significantly enhanced tumour inhibition in mice compared to control CAR-T cells. The endpoint tumour sizes and weights in micereceiving CXCR2-expressing CAR-T cells was less that mice receiving control CAR-T cells (20.32 ± 2.93 mm2and 91.38 ± 13.36 mg compared to 30.42 ± 4.16 mm2and 118.12 ± 18.81 mg - Figure 7D). Consistent with results in the PC3 model, there were no statistically significant differences in tumour weights and in the proportion or number of intratumoural CD3+T cells (Figure 7D). In contrast to the PC3 model, there was a statistically significant increase in the ratio of CD8+to CD4+cells within CXCR2-modified CAR-T cells recovered from tumours (CD8+:CD4+, 0.60 ± 0.05) compared control CAR-T cells (CD8+:CD4+, 0.36 ± 0.02 - Figure 7E).
[0268] Furthermore, in the CD8+population, a higher frequency of CXCR2-expressing CAR-T cells were TEM compared to control CAR-T cells, which were mostly TEFF, suggesting CXCR2-expressing CD8+CAR-T cells were less terminally differentiated (Figure 8A). The expression of cytotoxic molecules and TH1 cytokines was similar between CXCR2 -modified and control CAR-T cells (Figure 8B). Ex vivo analyses in both MDA-MB-231 and PC3 tumours revealed control and CXCR2-modified CAR-T cells acquired PD-1, CTLA-4 and LAG-3 expression (Figure 7C and Figure 7F) relative to their phenotypes at pre-injection (Figure 6D), which is indicative of activation and proliferation in the TME and raises the possibility of co-immunotherapeutic approaches with checkpoint inhibitors.
[0269] To investigate if this CXCR2-mediated effect could be reproduced with other chemokine receptors, CXCR6- and CCR10-modified CAR-T cells were generated using the same manufacturing protocol with CXCR6 and CXCR10 in place of CXCR2. While CXCR6 and CCR10 ligands were expressed in PC3 tumours, CAR-T cells engineered to express CXCR6 and CCR10 expression did not enhance their antitumour activity (data not shown). Altogether, these data show CXCR2 confers a unique advantage to nfP2X7 -targeting CAR-T cells in anti-tumour efficacy against multiple human tumour models.
[0270] CXCR2 expression does not promote intratumoural trafficking of CAR-T cells
[0271] In view of the demonstrated improvement of CXCR2-expressing nfP2X7 CAR-T cells in treating tumours in vivo, the relative contributions of cellular intratumoural trafficking, proliferation and cytotoxicity were evaluated. As CXCR2 is achemokine receptor, and its cognate ligands (CXCL1, CXCL2 and CXCL8) are expressed in the utilised tumour xenograft models, it follows that cell homing to the tumours would be a mechanism leading to the demonstrated improvement in CAR-T cell efficacy.
[0272] Because tumours were analysed at the experimental endpoint (>20 days post-T cell transfer) of the in vivo efficacy studies, these data did not capture potential differences in CXCR2-mediated T cell trafficking to tumours, which would have occurred significantly earlier. To test the anticipated role of CXCR2 in the homing of CAR-T cells to tumours, untransduced, control CAR-T and CXCR2-transduced CAR-T cells were labelled with eFluor670 proliferation dye and transferred into NSG tumourbearing mice at d14, d20 or d27 post-tumour injection (Figure 9A). Flow cytometric analysis of tumours was performed at 48h post-transfer to assess T cell entry into tumours. This timepoint was chosen as it would precede significant proliferation of T cells within the tumour.
[0273] Surprisingly, there was no significant difference in the number or frequency of intratumoural cells between control and CXCR2-transduced CAR-T cells at any of the examined time points (Figure 9B to 9D). Results following d14 transfer were variable due to the low number of cells recovered from relatively small tumours (Figure 9E). While minimal division (<20% mean of CD3+) of control CAR-T and CXCR2-modified CAR-T cells was observed (Figure 9E to Figure 9G, LHS), there were no differences in the number of divided control and CXCR2-modified CAR-T cells following d14, d20ord27 transfer (Figure 9E to Figure 9G, middle). When comparing the division index (DI), or the average number of divisions in a given population, there was no significant division within tumours (determined as mean DI > 0.5 limit of detection) of any groups at 48h post-transfer (Figure 9E to Figure 9G, RHS). Altogether, this data confirmed that at 48h post-transfer, T cells had migrated into tumours but had not yet significantly expanded (Figure 9E to Figure 9G). Accordingly, and surprisingly, the results indicate that expression of exogenous CXCR2 does not improve homing of CAR-T cells into tumours.
[0274] CXCR2 expression improves cytotoxic activity of nfP2X7 CAR-T cells
[0275] As exogenous CXCR2 expression improves CAR-T cell efficacy, but not CAR-T cell homing, other mechanisms must contribute to the noted improvement in function. The cytotoxic abilities of CXCR2-modified CAR-T cells, control CAR-T cells and UT cells were tested in vitro against a variety of cancer cell lines including MDA-MB-231 breast cancer cells, PC3 prostate cancer cells, PC9 lung cancer cell, SK-MEL-28 melanoma cells, Raji B lymphoma cells, Ramos B lymphoma cells (nfP2X7 negative), OVCAR5 gastrointestinal cancer cells and UMSCC-1 head and neck cancer cells. With the exception of the Ramos cell line, CXCR2-modified CAR-T cells elicited significantly greater cytotoxicity against tumour cells compared to control CAR-T cells in vitro for all the cancer cell lines tested (Figure 10). Importantly, cytotoxic killing in these assays was not reliant on migration as they involved direct co-culture of CAR-T cells and tumour target cells. Similar to control CAR-T cells, CXCR2-expressing CAR-T cells did not induce detectable lysis of wild type Ramos cells (which were P2X7-negative and nfP2X7 -negative).
[0276] To explore whether the enhanced cytotoxicity mediated by CXCR2 -modified CAR-T cells was directly due to CXCR2 ligand binding, CAR-T cells and tumour cells were co-cultured in the presence of small molecule antagonists against CXCR2, and tumour cell lysis was assessed. These antagonists, SB265610 and SB225002 are nonpeptide allosteric inhibitors that have been widely used as CXCR2 antagonists. Treatment with SB265610 or SB225002 did not abrogate the enhanced cytolysis induced by CXCR2-modified CAR-T cells against MDA-MB-231 or PC3 cells, indicating this effect was not mediated directly by ligand binding (Figure 11).
[0277] Notably, CXCR6- or CCR10-expressing CAR-T cells did not demonstrate the enhanced cytotoxic effect seen for CXCR2-modified CAR-T cells (Figure 12A -CCR10-expressing CAR-T cells; Figure 12B - CXCR6-expressing CAR-T cells) thereby indicating that the enhance cytotoxicity was uniquely related to CXCR2 expression.
[0278] CXCR2 expression improves proliferation ofnfP2X7 CAR-T cells in vitro and in vivo
[0279] To explore whether CXCR2-expressing CAR-T cells elicited enhanced cytotoxicity due to increased proliferation, CAR-T cells were labelled with fluorescent CellTrace Violet proliferation dye and co-cultured with Namalwa B-cell lymphoma cells. Similar to previous results, CXCR2 -modified CAR-T cells exhibited a cytotoxic advantage compared to control (unmodified; non-CXCR2-expressing) CAR-T cells against Namalwa cells after 16 hours of co-culture (Figure 13A). However, following 24 hours co-culture with Namalwa cells, CXCR2-modified CAR-T, control CAR-T, and untransduced cells displayed minimal proliferation (<3%). As elevated cytotoxicity of CXCR2-modified CAR-T cells was seen at 16 hours, the low level of proliferation at 24 hours indicated that this elevated cytotoxicity was not a result of enhanced CAR-T cell numbers due to proliferation. Significant proliferation of CXCR2-expressing CAR-T cells occurred by 48 hours of co-culture (11.09 ± 2.27 % divided at the 1:1 effector: target ratio), while control CAR-T and untransduced cells did not proliferate further compared to 24h. By 72h, proliferation greatly increased in all three populations with 64.28 ±2.10 % of CXCR2 -expressing CAR-T cells, 42.38 ± 2.29 % of control CAR-T cells and 17.22 ± 1.50 % of untransduced cells having divided in the 1 : 1 effector: target condition. At all effector: target ratios, CXCR2-modified CAR-T cells exhibited the highest frequency of divided cells. Analysis of CAR-T cells cultured in IL-2 and IL-15 without target cells yielded similar results to cells cultured in IL-2 and IL-15 in the presence of target cells (Figure 13B). This suggested proliferation of CAR-T cells was largely driven by antigen-independent signalling in the presence of cytokines, although the role of the CAR was not determined. Together, these data indicate CXCR2 -modified CAR-T cells possess a robust and intrinsic proliferative advantage over unmodified CAR-T cells.
[0280] Animal xenograft tumour models were utilised to assess if the enhanced proliferation demonstrated in vitro translated to the in vivo context. Timepoints which captured post-trafficking accumulation and cell division were identified based on the previous trafficking studies. Specifically, the timepoints of 96h and 7 days post-T cell transfer were chosen.
[0281] Transfer occurred at d20 post-tumour injection (see protocol in Figure 14A) as larger tumour sizes facilitated the proliferation analysis of a sufficient number of cells. At both 96h (top panel of Figure 14C) and 7 day (bottom panel of Figure 14C) timepoints, there was a significantly higher frequency and number of intratumoural CXCR2-transduced CD3+CAR-T cells compared to untransduced cells (Figure 14B and Figure 14C). While the frequency and number of the control CD3+CAR-T cell (i.e., those not expressing CXCR2) was increased relative to untransduced cells, these differences were not statistically significant (Figure 14B and Figure 14C).
[0282] There was a statistically significant increase in the frequency of live CXCR2-modified CAR-T cells within tumours compared to control CAR-T cells at 96 hours posttransfer, but this difference was not observed by 7 days post-transfer (Figure 14B and Figure 14C). At the 96 hours timepoint (Figure 14D), CD3+CXCR2-modified CAR-T cells exhibited a proliferative advantage (DI: 1.069 ± 0.033) compared to control CAR-T or untransduced cells (Dis: ~0.5) and by day 7 post-transfer the CD3+CXCR2-modified CAR-T cells had divided to a significantly greater extent compared to control CAR-T and untransduced cells (CXCR2 CAR-T DI: 3.286 ± 0.119, control CAR-T DI: 2.190 ± 0.144, UT DI: 0.676 ± 0.245 - Figure 14E). While the frequency of divided CD3+cells was significantly greater for CXCR2-modified CAR-T cells compared to untransduced cells, there was no difference between CXCR2 -modified and control CAR-T cells at 7 days post-transfer (data not shown). However, as frequency divided is a coarse measurement of all divided cells, DI was used as a more informative measure.
[0283] By 96 hours post-transfer, CD8+CXCR2-modified CAR-T cells had accumulated significantly within the tumour compared to untransduced cells, and had divided significantly more than both untransduced and control CAR-T cell populations, as determined by the division index (Figure 14F). By day 7 post-transfer, the number of CD8+CXCR2-modified CAR-T cells was significantly greater compared to untransduced cells and the proliferative advantage was further pronounced with the DI markedly increased relative to control CAR-T and untransduced populations (Figure 14G). In the CD4+population, CXCR2-modified and control CAR-T cells exhibited significant intratumoural accumulation by 96 hours post-transfer compared to untransduced cells (Figure 14H). Further, CD4+CXCR2-modified and control CAR-T cells exhibited significantly higher division indices compared to untransduced cells at96h and 7 days post-transfer, however there were no direct differences between CXCR2-modified and control CAR-T cells observed (Figures 14H and Figure 141). The CD4+data contrast with the CD8+compartment where statistically significant differences were observed (Figure 14F and Figure 14G).
[0284] Enhanced proliferation of CXCR2-transduced CAR-T cells was also observed in the spleen. However, splenic T cells exhibited reduced division indices compared to intratumoural T cells, indicating that enhanced in vivo proliferation may be partially antigen-specific, which is in contrast to the in vitro results, and / or it may occur in response to the tumour microenvironment.
[0285] Collectively, these data from the in vivo proliferation and trafficking experiments demonstrate that CXCR2 enhances the proliferation of adoptively transferred CAR-T cells within solid tumours without increased intratumoural trafficking.
[0286] Methods
[0287] Mice
[0288] NOD-sc / c / IL2Rynul1(NSG) mice were purchased and housed in specific pathogen-free conditions with a 12 hour light / dark cycle. Experiments used gender and age-matched mice between 6-12 weeks of age. Mice were allowed to acclimatise for one week before experimental procedures were performed and were humanely euthanized by CO2 asphyxiation at the experimental endpoint. All experimental procedures were conducted under the approval of the University of Adelaide Animal Ethics Committee (S / 2018 / 007).
[0289] CD3+T cell isolation from whole peripheral blood or buffy coat
[0290] Peripheral blood was drawn from healthy volunteers. Buffy coats were obtained from a blood donation collection facility under a Material Exchange Agreement. All isolation procedures followed manufacturer’s instructions. For isolation of CD3+cells from whole peripheral blood, cells were enriched using RosetteSEP™ HLA enrichment cocktail (StemCell™) and isolated via density gradient separation using Ficoll Paque Plus™ medium (GE Healthcare Life Sciences™). Following enrichment, cells were treated with human red cell lysis buffer (HRCLB, StemCell™), washed in Dulbecco’s PBS (dPBS, Sigma-Aldrich™) supplemented with 2% FCS, andstained as described in Flow cytometric analysis (below) to confirm purity of > 95% CD3+. For isolation of CD3+cells from buffy coats, cells were first treated with HRCLB before processing using RosetteSEP™ HLA enrichment cocktail according to the manufacturer’s instructions (StemCell™).
[0291] Tissue culture of cancer cell lines
[0292] See Table 3 for specific culture media and trypsin incubation duration for each cancer cell line. All cell lines were maintained in culture medium supplemented with 10% FCS (Sigma-Aldrich) and were cultured at 37°C in 5% CO2. Adherent cell lines were passaged every 2-3 days by rinsing the flasks with sterile PBS and dissociating cells with trypsin-EDTA solution (Gibco) at 37°C. The non-adherent cell lines, RPMI-8226, Ramos, Raji and Namalwa were sub-cultured at the following densities; 5x105- 2x106, 2x105- 1x106, 4x105- 3x106and 5x105- 2x106cells / ml, respectively. Cells were tested and confirmed to be mycoplasma free.
[0293] Table 3 - Cell culture conditions of cancer cell linesCell Line Cancer Type Culture Medium Trypsin Incubation PC3 Prostate cancer HAM’S F-12 + 10% FCS 4 minMDA-MB- Breast cancer RPMI + 10% FCS 4 min231BT549 Breast cancer RPMI + 10% FCS, 0.01mg / ml 3-4 mininsulinAsPC-1 Pancreatic RPMI + 10% FCS 4-5 mincancerC32 Melanoma RPMI + 10% FCS 2 minSK-MEL-5 Melanoma RPMI + 10% FCS 1 minSK-M EL- Melanoma RPMI + 10% FCS 1 min28PC9 Lung cancer RPMI + 10% FCS 5 minNCI-H460 Lung cancer RPMI + 10% FCS 3-4 min LIM1215 Colorectal RPMI + 10% FCS, 0.6pg / ml 4 mincancer insulin, lOpM 1-thioglycerol,1pg / ml hydrocortisoneOVCAR3 Ovarian cancer RPMI + 20% FCS, 0.01mg / ml 3-4mininsulinOVCAR5 Gastrointestinal DM EM + 10% FCS 3-4mincancerSKOV3 Ovarian cancer McCoy’s 5A or DM EM + 10% 4 minFCS UMSCC-1 Head / Neck DM EM + 10% FCS, 3-4 min squamous 1% non-essential amino acidsBE(2)-M17 Neuroblastoma 1:1 EMEM:HAM’s F-12 + 4 min15% FCS, 1% non-essentialamino acidsRD Rhabdomyosarc RPMI + 10% FCS 3-4 minomaSK-ND-Z Neuroblastoma DM EM + 10% FCS, 3-4 min1% non-essential amino acidsRPMI-8226 Multiple RPMI + 10% FCS - myelomaNamalwa B-cell lymphoma RPMI + 10% FCS - Raji B-cell lymphoma RPMI + 10% FCS - Ramos B-cell lymphoma RPMI + 10% FCS -
[0294] Generation of CAR constructs
[0295] The nfP2X7 -specific CAR lentiviral plasmid was generated by cloning a human nfP2X7 -specific binding domain into a second-generation CAR construct provided by the Jensen Laboratory (Dr Michael Jensen, Seattle Children’s Research Institute). The nfP2X7 -specific binding domain was developed by Biospectre (Cambridge, UK). To generate chemokine receptor-expressing constructs, the truncated EGFR reporter cDNA was removed from the nfP2X7 -specific CAR construct by restriction digest and replaced with CXCR2, CXCR6 or CCR10 cDNA via Gibson assembly. nfP2X7 CAR constructs were based on those disclosed in (Bandara & Foeng et al., 2023, supra, and WO2017 / 041143) the entire disclosures of which are incorporated herein by way of this reference.
[0296] CAR-T Cell Manufacture
[0297] CXCR2-modified nfP2X7 -targeting CAR-T cells were generated in parallel with untransduced (UT) and unmodified control CAR-T cells. Aside from the transduction step, these controls were treated in an identical manner and derived from the same healthy donor. CAR-T cell manufacturing was performed with an optimised protocol which improved expansion and favourable T cell phenotype frequencies relative to the method used for in vitro analysis in our previous study (Bandara & Foeng et al., 2023).
[0298] CD3+cells were isolated from human peripheral blood and stimulated with Human T-Activator a-CD3 / a-CD28 Dynabeads™ (Life Technologies™) for 7 days. On d1 post-isolation, cells were transduced with lentivirus encoding the CAR construct for 24 hours in the presence of 8pg / ml polybrene at a range of multiplicities of infection before dilution of the virus via partial media changes. The lowest MOI that gave a saturating level of transduction efficiency, as assessed by flow cytometric staining on d7 post-isolation, was selected for rapid expansion. On d7 post-isolation, a-CD3 and a-CD28 beads were removed. On d2 (AM and PM), d3, d5 and d7 post-isolation, T cells were fed with complete X-VIV015 T cell media (X-VIVO supplemented with 2% KnockOut™ Serum Replacement (Gibco™), 50U / ml rh IL-2, 5ng / ml rh IL-7 and 0.5ng / ml rh IL-15) by partial media change such that the added cytokines supplemented the entire volume. On d8 post-isolation, cells were rapidly expanded with 40 Gray-irradiated PBMCs and a 30ng / ml soluble a-CD3 monoclonal antibody (OKT3, Invitrogen). On d2 post-PBMC, CAR-T cells were fed with 30ng / ml a-CD3 (OKT3), 100U / ml rh IL-2 and 1ng / ml rh IL-15 using a partial media change. After this timepoint, OKT3 was not included in the rapid expansion medium. On d4 or d5, d7, d9, d11 and d14 post-PBMC, T cells were fed with 2x complete RPM1 1640 T cell media (10% FCS, 100U / ml IL-2 and 1ng / ml IL-15) using a partial media change. T cell phenotype and transduction efficiency was routinely assessed on dO, d7, d8, d15 (d7 post-PBMC) and d22 (d14 post-PBMC) post-isolation. In some experiments, T cell subset phenotype was assessed on d29 (d21 post-PBMC) in addition to these timepoints. Cells were frozen down at d23 post-isolation (d15 post-PBMC). CAR-T cells were assessed in vivo or in in vitro assays following thawing and recovery in culture for 3 days post-thaw.
[0299] Flow cytometric analysis
[0300] Cells were stained in 96-well round bottom plates (Corning™), with 1x104-1x105T cells or 1x106cells from single cell suspensions of tumours plated per well, using antibodies and other reagents detailed in Table 4. For intracellular cytokine and cytotoxic molecule staining, cells were first incubated for 4h at 37°C in 5% CO2 in restimulation medium (IMDM (Gibco) with 10% FCS (Sigma-Aldrich), 100U / ml penicillin / streptomycin (Gibco), 1x GlutaMAX (Gibco), 54pM [3-mercaptoethanol (Sigma-Aldrich), 50ng / ml phorbol 12-myristate 13-acetate (Life Technologies), 1nM ionomycin (Life Technologies), 1 / 1500 GolgiStop (BD Biosciences) and 1 / 1000 GolgiPlug (BD Sciences or Biolegend)). To stain CD107a, a directly conjugated antibody was added at the beginning of the PMA stimulation. All subsequent incubations were performed at room temperature unless stated otherwise. Cells were stained with Fixable Viability Stain 780 (BD Biosciences™) diluted 1 / 1000 and blocked with Human Fc Block (BD Biosciences™) or 10% human serum (Sigma-Aldrich™) for 10min. Cells were then washed and stained with directly conjugated antibodies in Brilliant Stain Buffer (BD Biosciences™) for 30min. For biotinylated peptide mimetics, cells were stained with the peptide mimetic along with directly conjugated antibodies, washed and stained with streptavidin for 20min. For intracellular staining, cells were incubated with Cytofix / CytoPerm ™ (BD Biosciences™) for 20min at 4°C, washed in Perm / Wash Buffer (BD Biosciences™) and stained with directly conjugated antibodies for 30min at 4°C. After staining, cells were washed twice and resuspended in PBS 1% paraformaldehyde and stored at 4°C in the dark. Stained cells from culture were acquired on the BD LSRFortessa X-20™ flow cytometer on the same day. Stained ex vivo cell suspensions were acquired within 5 days. Data analysis was performed using FlowJo™ Software V.10 (TreeStar, BD Biosciences™).
[0301] To measure transduction efficiency of the CAR, CXCR2 and peptide mimetic staining was utilized to report CAR transduction in CXCR2-modified CAR-T cells while staining of the truncated EGFR and peptide mimetic reported CAR transduction in control CAR-T cells.
[0302] Table 4 - Monoclonal antibodies and related reagents.Primary antibodies for flow cytometry and cell culture Specificity Conjugate Clone Final Dilution Manufacturer CD3 BUV737 UCHT1 1 / 8 BD Purified OKT3 30ng / ml Invitrogen CD4 BUV496 SK3 1 / 4 BD CD8 BUV395 RPA-T8 1 / 8 BD Granzyme B BV421 GB11 1 / 2 BD Perforin FITC B-D48 1 / 4 Biolegend CD 107a PE-Cy7 H4A3 1 / 6 BD IFNy PE B27 Recommended BD TNFa APC MAb11 1 / 2 BD IL-2 BV711 5344.111 1 / 4 BD CCR7 PE 150503 Recommended BD PE 2-L1-A Recommended BD CD45RA BB515 HI100 1 / 6 BD CD45RO PE-Cy7 UCHL1 Recommended BD CD62L BV421 DREG-56 1 / 2 BD CD27 APC M-T271 Recommended BD CD28 BUV737 CD28.2 Recommended BD CD95 PE-Cy7 DX2 1 / 8 BD CXCR3 BV421 1C6 / CXCR3 Recommended BD PD-1 PE-Cy7 EH12.1 Recommended BD CTLA-4 BV421 BNI3 Recommended BD TIM-3 BB515 7D3 Recommended BD LAG-3 APC T47-530 Recommended BD CD39 PE-CF594 TU66 Recommended BD BUV805 TU66 Recommended BD EGFR eF660 me1B3 Recommended ThermoFisher lgG2a isotype BV421 G155-178 1 / 10 BD Related flow cytometry reagentsFixable Viability Dye NIR780 - 1 / 1000 BD Streptavidin BV421 - 2.5pg / ml BD NfP2X7 peptide Biotin - 400nM GenScript mimeticMutant peptide Biotin - 400nM GenScript mimetic
[0303] In vitro cytotoxicity assay
[0304] T cells were rapidly thawed in a 37°C water bath and rested in complete RPMI 1640 T cell media (10% FCS, 50U / ml IL-2 and 0.5ng / ml IL-15) for 1-3 days at 37°C in 5% CO2. T cells were co-cultured with 1x104luciferase-expressing tumour cells at 30:1, 10:1, 3:1, 1:1 effector: target ratios in complete RPMI 1640 T cell medium (without phenol red) in 96-well round bottom plates. Tumour cells alone and tumour cells treated with 2% SDS in Milli-Q H2O were plated as maximum target cell luminescence and maximum target cell cytolysis controls, respectively. In some experiments, cells were treated with the CXCR2 small molecule antagonists, SB265610 (Sigma-Aldrich™) and SB225002 (Sigma-Aldrich™), at a final concentration of 100nM or 5pM, respectively. Cells were incubated for 16h at 37°C in 5% CO2. For analysis, cells were resuspended in BrightGlo™ substrate (Promega™) and incubated for 5 min at room temperature before transfer into an opaque flat-bottom 96-well plate (Grenier Bio-One™). Cell luminescence was measured on the PHERAstar™ or Promega GloMax™ Discover plate reader. Percentage cytolysis was calculated as 100% x ((maximum target cell luminescence - experimental cytolysis luminescence) / (maximum target cell luminescence - maximum target cell cytolysis luminescence)). Each condition was plated in triplicate.
[0305] In vitro proliferation assay
[0306] T cells were rapidly thawed in a 37°C water bath and rested in complete RPMI 1640 T cell media (10% FCS, 50U / ml IL-2 and 0.5ng / ml IL-15) for 3 days at 37°C in 5% CO2. T cells were labelled with CellTrace Violet dye (ThermoFisher™) according to manufacturer’s instructions, before co-culture with 1x104ffluc+GFP+Namalwa Burkitt’s lymphoma cells at 30:1, 10:1, 3:1, 1:1 effectortarget ratios in complete RPMI 1640 T cell media. For the effector only condition, T cells were plated with IL-2 and IL-15 and without tumour cells. For the unstimulated condition, T cells were plated without IL-2 and IL-15 or tumour cells. Cells were incubated for 24h, 48h or 72h post-labelling, before staining with Fixable Viability Stain 780 (BD Biosciences™) diluted 1 / 1000 and assessment by flow cytometry. The fluorescence intensity of unstimulated cells at 24hpost-labelling was used to set the appropriate gate to identify divided cells. Cell numbers were quantified by normalizing CD3+cells to counting beads acquired in the same sample. Each condition was plated in triplicate. Cells were acquired on a BD LSR Fortessa X-20™ flow cytometer. Data analysis was performed using FlowJo™ Software V10.8 (BD Biosciences™).
[0307] Chemotaxis assay
[0308] T cells were rapidly thawed in a 37°C water bath and rested in complete RPMI 1640 T cell media for 1-3 days at 37°C in 5% CO2. T cells were washed twice in Dulbecco’s PBS and rested for 4h in chemotaxis buffer (RPMI 1640 with 0.5% BSA (Bovogen™) and 20mM HEPES (Gibco™). Chemokine ligands (Peprotech™) were serially diluted in chemotaxis buffer and loaded into the lower chamber of 96-well transwell plates (Corning™), containing inserts with a 5pm pore size. 2x105T cells were loaded into the upper chambers and incubated for 1h for chemotaxis to CXCL8 (CXCR2) or 3h for chemotaxis to CXCL16 (CXCR6) or CCL27 (CCR10) at 37°C in 5% CO2. Following incubation, media from the lower chambers were transferred to a 96-well round bottom tray and stained for flow cytometry. Before acquisition, CountBright™ Beads (Invitrogen™) were vortexed and added to samples. Event counts for each sample were normalized to beads, and were then divided by normalized event counts from a no ligand control to determine the chemotaxis index. Each condition was plated in triplicate. Cells and beads were acquired on a BD LSR Fortessa X-20™ flow cytometer. Data analysis was performed using FlowJo™ Software V10.8 (BD Biosciences™).
[0309] Subcutaneous inoculation of cancer cell lines
[0310] Cancer cell lines were cultured according to the conditions detailed in Table 3 (above). On the day of injection, adherent cells were rinsed in PBS, incubated with trypsin-EDTA solution (Gibco™) at 37°C, washed once in culture medium and twice in PBS. Cells were kept on ice until injection. NSG mice were anaesthetised using isofluorane (Henry Schein™). For the MDA-MB-231 human breast cancer model, 7-9 week old female NSG mice were injected subcutaneously into the 4th left mammary fat pad (L4) with 2x106MDA-MB-231 cells resuspended in sterile PBS:Matrigel™ such that the final protein concentration was 4-6mg / ml. MDA-MB-231 cells were resuspended ina 45-50pl volume and injected using a 26 gauge needle attached to a 50pl glass syringe (Hamilton Company™, NV, USA). For the PC3 prostate cancer model, 7-9 week old male NSG mice were injected subcutaneously into the lower abdomen. 1x106PC3 cells were resuspended in a 200pl volume and injected using a 26 gauge needle attached to a 1ml Luer Lock syringe (BD Biosciences™). Tumours were measured every 2 days beginning on d7 post-tumour injection using digital callipers (Mitutoyo™, Japan), by measuring the longest distance as length and the perpendicular distance as width. Tumour size was calculated as the multiple of length and width measurements and was represented in mm2. Mice were euthanized when tumour area was equal to or greater than 100m2or upon display of clinical disease symptoms. Tumours were measured with groups blinded.
[0311] Intravenous transfer of CAR-T cells
[0312] T cells were rapidly thawed in a 37°C water bath and rested in complete RPM1 1640 T cell media for 1-3 days at 37°C in 5% CO2. On the day of injection, T cells were washed twice in dPBS, and resuspended in dPBS for injection in a 200pl volume per dose. Cells were kept on ice until injection. Mice were restrained and injected with a cell suspension containing 0.25-2x107cells via the tail vein at day 7 post-tumour injection, without requiring vein dilation using a heat lamp. For trafficking and proliferation experiments, T cells were rapidly thawed in a 37°C water bath and rested in complete RPM1 1640 T cell mediators days at 37°C in 5% CO2. T cells were labelled with eFluor670 proliferation dye (ThermoFisher™) according to the manufacturer’s instructions and mice were injected with a cell suspension containing 1x107cells. In all experiments, T cells were administered with groups blinded.
[0313] Human lymphocyte isolation from tumours and spleens
[0314] Tumours were excised, manually minced into small pieces and incubated in warm digestion media (DMEM (Gibco™) with 5% heat-inactivated FCS (Sigma-Aldrich™), 2.5mM CaCl2, 10mM HEPES (Gibco™), 100U / ml penicillin / streptomycin (Life Technologies™), 30U / ml DNase I (Sigma-Aldrich™) and 1mg / ml collagenase IA (Sigma-Aldrich™) for 1-1.5 hours at 37°C with continuous gentle agitation. Tumours were mixed every 15-20 min by resuspension. Tumour homogenates were passed through a 70pm filter (BD Biosciences™) with mechanical dissociation using the backof a 3ml Luer Lock syringe (BD Biosciences™). Where applicable, spleens were excised and passed through a 70pm filter (BD Biosciences™) with mechanical dissociation using the back of a 3ml Luer Lock syringe (BD Biosciences™). All cells were then washed in PBS, incubated in mouse red cell lysis buffer for 5min at 37°C and washed a second time with PBS before staining for flow cytometry.
[0315] Flow cytometric division analysis
[0316] Cells were stained in 96-well round bottom plates (Corning™), with 1x106cells from single cell suspensions of tumours or spleens plated per well, using antibodies and other reagents detailed in Table 4 (above). All incubations were performed at room temperature. Cells were stained with Fixable Viability Stain 780 (BD Biosciences™) diluted 1 / 1000 and blocked with Human Fc Block (BD Biosciences™) or 10% human serum (Sigma-Aldrich™) for 10min. Cells were then washed and stained with directly conjugated antibodies for CD3, CD4 and CD8 in Brilliant Stain Buffer (BD Biosciences™) for 30min. After staining, cells were washed twice and resuspended in PBS 1% paraformaldehyde and stored at 4°C in the dark. Stained ex vivo cell suspensions from culture were acquired on the BD LSRFortessa X-20™ flow cytometer within 5 days. Data analysis was performed using FlowJo™ Software V.10 (TreeStar, BD Biosciences™) and division index was calculated using the formula: total number of divisions / (total number of divided cells + undivided cells) (Roederer M, Noz M, Anderson M, et al. Interpretation of Cellular Proliferation Data: Avoid the Panglossian. Cytometry Part A. 2011 ;79A(3):95-101.), with divided cells tracked via eFluor670 fluorescence.
[0317] mRNA isolation and qPCR
[0318] Whole snap-frozen tumours and lungs were ground into a fine powder. All following procedures followed manufacturer’s instructions. Ground tissue was homogenized in TRIzol™ reagent (Life Technologies™), before RNA extraction in chloroform, precipitation in isopropanol, washes in ethanol and resuspension in RNAse-free water. DNAses were removed using the Turbo DNA-free™ kit (Life Technologies™). DNAse-treated RNA was used as starting template for cDNA synthesis using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems™). Quantitative polymerase chain reaction (qPCR) was performed usingPowerllp™ SYBR™ Green Master Mix (Applied Biosystems™) on a LifeCycler-480™ instrument (Roche™). Relative gene expression was calculated as 2-<CTtar9et-CTreference> where the reference gene was RPLPO. All procedures involving RNA were conducted with equipment and workspaces treated with RNaseZap™ (ThermoFisher™) to remove contaminating RNases. Primer sequences used for qPCR are listed in Table 5.
[0319] Table 5 - qPCR primersGene Forward Primer 5’ -> 3’ Reverse Primer 5’ -> 3’ CCL1 GGCACTGCCCGTCAAAAA TCCAGAGCCCACAATGGAA CCL2 CAAGCAGAAGTGGGTTCAGGAT TCTTCGGAGTTTGGGTTTGC CCL3 CCATGGCTCTCTGCAACCA GCGGTCGGCGTGTCACCL4 CCTGAGCCCGGATGCTT GCGGAGAGGAGTCCTGAGTATG CCL5 TCGCTGTCATCCTCATTGCTA GAATATGGGAAGGCAGATGCA CCL7 AAACCAGAAACCTCCAATTCTCAT GCTGCAGAGGCTTTCATGTTG CCL8 ACCTCTCATGCTGAAGCTCACA CAGAAGCGCTGCAGAAACCT CCL11 GCGACTAGAGAGCTACAGGAGAATC GGTCTTGAAGATCACAGCTTTCTG CCL13 GTGCCTGCTGCTCATGACA TGCATCTGGCTGAGCAAGTC CCL14 CCAACAGCCAGTGCTCCAA GACGGAATGGCCCC I l l i CCL16 CCGAGGCTGCCCTGTCT GCTGCGAGAAGCCGAAGTAA CCL17 GAAGACGTGGTACCAGACATCTGA CCCTGCACAGTTACAAAAACGA CCL18 GGAGGCCAGGAGTTGTGAGTT GCAGGCAGAGAAGTGGTCAGA CCL19 TTCCCCAGCCCCAACTCT TCACAGACAGGCAGCAGTCTTC CCL20 AAAAACCATGTGCTGTACCAAGAG TGGAGTAGCAGCACTGACATCA CCL21 AGATTCCCGCCAAGGTTGT TGGAGCAGCCTAAGCTTGGT CCL22 CGGCGCCAACATGGAA CAGACGGTAACGGACGTAATCA CCL23 TGTGCCAACCCCAGTGATAA CGTGTGTCCAGCTTCAGCAT CCL24 TCCCTGCTGCATGTTCTTTG GGTAGCTGACCACTCGGTTCTC CCL25 TGCCCGTCTGGCAACTG AGCGGCAAAAGGCTTAAAATC CCL26 GGAATTGAGGCTGAGCCAAA GCCTGATCCCC I l l i ATGAGACT CCL27 ACGCAGCATCTGCATCCA GGTGCTCAAACCACTGTGACA CCL28 TTGGCTGCTGTCATCCTTCAT GTTGTGCGGGCTGACACA CXCL1 CCACTGCGCCCAAACC GCAAGCTTTCCGCCCATT CXCL2 AAGGAGGCCCTGCCCTTA GTGGCCTCTGCAGCTGTGTCXCL3 GCATCCCCCATGGTTCAG TCAGTTGGTGCTCCCCTTGT CXCL4 CAGAGACCCAGCCCGAGTT GCAGAGCTTCCAGCAGGATCT CXCL5 GAGAGCTGCGTTGCGTTTG CAGATTACTGATCA I l l i GGGATGA CXCL6 ACACTGCCCCCTGAGTTCAG ACTGGCAGGAAACTCAAGCTTT CXCL7 GCTGACTGCTCTGGCTTCCT TGCCTTTCGCCAAGTTTCTC CXCL8 CACCGGAAGGAACCATCTCA AGAGCCACGGCCAGCTT CXCL9 GCAAGGAACCCCAGTAGTGAGA TAGTCCCTTGGTTGGTGCTGAT CXCL10 TTCCTGCAAGCCAA I I I I G I C TCTTCTCACCCTTC I I I I I CA I TGT CXCL11 CACTTCTTTCCCCAAACATCATG ACAAACCAAATGATGCATAAGAATG CXCL12 TCAATTGCATCTCCCAGATAATGT TGCCAGAGCCAACGTCAA CXCL13 ATTTGCCTTGACAAACTTCTTTCA CCCGCCCCCCACAACXCL16 CAGAAGCAGCCGGAAAAAAA CGGCACTGTGGCTGATGTC
[0320] Statistical Analysis
[0321] All statistical analyses were performed using GraphPad Prism™ version 7, 8 and 9 for Windows. An unpaired f-test was used when comparing two sets of unpaired, continuous data with a normal distribution and similar standard deviations. A paired f-test was used when comparing two sets of paired, continuous data with a normal distribution. A one-way ANOVA was used when comparing three or more groups of continuous data with approximately normal distribution, which were represented by one independent and one dependent variable. A two-way ANOVA was used when comparing two or more groups of continuous data with approximately normal distribution, which were represented by two independent variables and one dependent variable.
[0322] Example 2 - CXCR2 expression improves performance of suboptimal LGR5-targeting CAR-T cells and the killing of cancers expressing low levels of antigen
[0323] Having determined that exogenous CXCR2 expression can improve the proliferation and cytotoxicity of CAR-T cells directed against non-functional P2X7, the inventors evaluated if this could be replicated in other CAR-T cells.
[0324] The inventors have previously developed CAR constructs and CAR-T cells that target the receptor Leucine-rich repeat-containing G-protein coupled receptor 5(LGR5) (see WO2022 / 104424). These CAR constructs are identical to that in Figures 1A and 1B with the exception of the antigen-binding domain 3 directed against LGR5 rather than nfP2X7. The binding domain of the anti-LGR5 CAR (denoted CNA3103 SEQ ID NO: 14 of the present application - and as described in WO2022 / 104424) comprised an scFv including a variable heavy (VH) chain of the antibody 18G7H6A1 linked at its C-terminus to the N-terminus of a variable light (VL) chain of the same antibody. This scFv antigen-binding domain 3 (SEQ ID NO: 13) was linked to the CD28 transmembrane and intracellular domain 6 (SEQ ID NO: 59) by an lgG4 hinge and CH3 region (termed medium hinge in WQ2022 / 104424) comprising the 119 amino acids (SEQ ID NO: 57).
[0325] Accordingly, the two anti-LGR5 CAR constructs used in these experiments were termed CNA3102 (anti-LGR5 CAR having the amino acid sequence set forth in SEQ ID NO: 14, and is encoded by the DNA sequence set forth in SEQ ID NO: 73) and CNA310201 (anti-LGR5-CAR-CXCR2 having the amino acid sequence set forth in SEQ ID NO: 21 , and is encoded by the DNA sequence set forth in SEQ ID NO: 74.
[0326] CXCR2 expression improves CNA3102 CAR-T cell efficacy when targeting cancers expressing low levels of LGR5
[0327] As shown in Figure 15, LGR5 is expressed at variable levels on different cancer cell lines. Accordingly, testing was performed on the cell lines LIM1215, LoVo and HCT 116 which expressed relatively high, moderate and low levels of LGR5 (Figure 15B).
[0328] In low serum conditions (1% fetal calf serum) CNA310201 cells displayed improved target cell lysis compared to CNA3102 cells against LoVo cells and HCT 116 cells, which express moderate and low levels of LGR5. By comparison, CNA310201 (CXCR2 expressing) CAR-T cells displayed comparable lysis to CNA3102 (non CXCR2) CAR-T cells against LIM1215 cells, which express a high level of LGR5 (Figure 16).
[0329] These results are notable as they demonstrate that for at least some CAR-T cells, the role of CXCR2 in improving cell lysis is conditional on factors such as antigen expression of the target and the relationship with the chimeric antigen receptor.
[0330] CXCR2 expression may improve the in vivo efficacy of suboptimal LGR5-targeting CAR-T cells.
[0331] Having demonstrated variable cell lysis in vitro for anti-LGR5 CAR-T cells, the role of CXCR2 expression in modifying the efficacy of anti-LGR5 CAR-T cells in vivo was assessed.
[0332] To assess the role of CXCR2 in promoting cancer survival, a xenograft mouse model was employed.
[0333] Five million CAR-T cells (CNA3102 or CNA310201) or untransduced cells from two separate donors were administered to male NSG mice 14 days after subcutaneous injection of 2x106LoVo colorectal cancer cells. This model was chosen to evaluate later-stage administration of the anti-LGR5 CAR-T cells. From day 14-post cancer cell injection tumour size was measured every 2 days until death (or euthanised on day 100, whichever was earlier) at which time the spleens and tumours were harvested from the mice for assessment.
[0334] CAR-T cells prepared from one donor (Figure 17) showed high efficacy at controlling tumours with significant regression of disease following administration of both CNA3102 and CNA310201 cells with 3 out of 4 (75%) mice surviving to 100 days in the CNA310201 treatment group and 5 out of 7 (72%) mice surviving to 100 days in the CNA3102 treatment group. By comparison all mice in the untransduced cell group succumbed to cancer by day 43, as based on the euthanasia criteria of having a tumour greater or equal to 100m2. Notably, anti-LGR5 CAR-T cell efficiency was not improved further by the addition of CXCR2 when CAR-T cells were already highly effective at killing target cancer cells.
[0335] Unlike the first donor, CAR-T cells prepared from a second donor (Figure 18) showed significantly reduced efficacy against tumour growth in all treatment groups, with mice succumbing to disease by day 55 as based on euthanasia criteria. Notably, there was no statistically significant difference in the survival time of mice treated with CNA3102 CAR-T cells or UT cells. Under these conditions, where the prepared CAR-T cells were suboptimal, exogenous expression of CXCR2 appeared to improve the efficacy of the anti-LGR5 CAR-T cells with mice receiving CNA310201CAR-T cells having a statistically significant improvement in survival compared to mice treated with UT cells.
[0336] These data show that exogenous expression of CXCR2 may improve the function of suboptimal LGR5-targeting CAR-T cells, with no discernible effect in highly functioning CAR-T cells.
[0337] To assess if earlier treatment with CAR-T cells would alter the progression of disease, a protocol similar to the above was performed with the exception of CAR-T cells (or control cells) being administered at day 7 post-tumour cell injection, with mice euthanised 21 days later. Specifically, 5 million CAR-T cells (CNA3102 orCNA310201) or untransduced cells derived from a third unique donor were administered to male NSG mice 7 days after subcutaneous injection of 2 million LoVo colorectal cancer cells. From day 7 post-tumour cell injection tumour size was measured every 2 days until euthanasia of the mice on day 28 (21 days post CAR-T cell injection) at which time the spleens and tumours were harvested from the mice for assessment.
[0338] CAR-T cells generated from this donor showed moderate efficacy at reducing tumour progression in mice with a statistically significant reduction in tumour weight at day 28 post-tumour injection and a trend toward reduced tumour size (Figure 19). Chimeric antigen receptor T cells expressing exogenous CXCR2 (CNA310201) showed comparable or slightly improved efficacy with a trend toward lower tumour size and a moderate reduction in tumour weight at day 28.
[0339] These data support the finding that exogenous CXCR2 expression may improve the function of suboptimal CAR-T cells directed against LGR5.
[0340] Further assessment was performed with a higher number of CAR-T cells administered at either day 14 post-tumour cell injection or day 21 post-tumour cell injection. Specifically, 106million CAR-T cells (CNA3102 or CNA310201) or untransduced cells derived from the first donor (i.e. , the same donor as Figure 17) were administered to male NSG mice 14 days or 21 days after subcutaneous injection of 2 million LoVo colorectal cancer cells. From day 7 post-tumour injection, tumour size was measured every 2 days until euthanasia criteria was reached (tumours equal to greater than 100mm2).
[0341] Figure 20A and Figure 20B show the result for mice administered CAR-T cells on day 14 post-tumour injection. Figure 20A depicts a truncated extract of the first 33 days from administration of tumour cells (day 33 being the time point of first death due to euthanasia criteria). While all mice in the untransduced and control CAR-T groups were euthanized by day 53 and day 49 post-tumour injection, respectively, mice which received CXCR2-modified CAR-T cells survived up to day 76 post-tumour injection before euthanasia.
[0342] Figure 21 A and Figure 21 B show the result for mice administered CAR-T cells on day 21 post-tumour injection. Figure 21 A depicts a truncated extract of the first 37 days (time of first death) from administration of tumour cells. While there were varying numbers of mice per group, the average time point for euthanasia was day 43, day 50 and day 59 post-injection of tumour cells for mice which received untransduced, control CAR-T cells or CXCR2-modified CAR-T cells, respectively.
[0343] As can be seen in these two examples utilising CAR-T cells demonstrating minimal to moderate efficacies in treating cancer, exogenous expression of CXCR2 improved anti-LGR5 CAR-T cell function with a statistically significant increase in survival in mice administered CNA310201 transduced cells (CXCR2 -expressing LGR5 CAR-T cells) compared to CNA3102 transduced cells (LGR5 CAR-T cells). This was reflected in a statistically significant reduction in tumour sizes in mice receiving CNA310201 cells compared to those receiving CNA3102 cells (Figure 20A and Figure 21 A) at time of first death. This further supports a role for CXCR2 expression in enhancing the efficacy of suboptimal anti-LGR5 CAR-T cells.
[0344] The ability of CXCR2 expression in enhancing the function of anti-LGR5 CAR-T cells is further illustrated in Figure 22A and Figure 22B. These figures, depict pooled and individual tumour growth curves (respectively) following administration of CAR-T cells on day 7 post-tumour injection. As can be seen, CXCR2-expressing CAR-T cells (CNA310201) elicited enhanced efficacy of CAR-T cells and regression of tumour size compared to control anti-LGR5 CAR-T cells (CNA3102) that did not express CXCR2. Eight out of ten mice in the CXCR2-expressing CAR-T cell group had no palpable tumours at the last time point measured, compared to three out of eleven mice in the control CNA3102 group. These results demonstrate that CXCR2 modification of moderately effective CAR-T cells can further improve the efficacy ofCAR-T cells in treating cancer, driving CAR-mediated tumour regression and inhibition of further tumour growth, and resulting in the complete rejection of tumour cells in a subset of treated mice.
[0345] Methods
[0346] Generation of CAR constructs
[0347] The LGR5-specific CAR lentiviral plasmid was generated as per WO by cloning a human LGR5-specific binding domain (sequence based on BNC101 developed by Bionomics; patent: US20160031984 A1) into a second-generation CAR construct provided by the Jensen Laboratory (Dr Michael Jensen, Seattle Children’s Research Institute). To generate CXCR2-encoding constructs, the truncated EGFR reporter cDNA was removed from the CAR construct by restriction digest and replaced with a CXCR2 cDNA via Gibson assembly.
[0348] CD3+cell isolation from whole peripheral blood for CAR-T cell manufacture
[0349] Peripheral blood was drawn from healthy volunteers. All cell isolation procedures followed the manufacturer’s protocol. CD3+cells were enriched from whole peripheral blood using the RosetteSEP HLA enrichment cocktail (StemCell) and isolated via density gradient separation using Ficoll Paque Plus medium (GE Healthcare Life Sciences). Following enrichment, cells were treated with human red cell lysis buffer (HRCLB, StemCell) to remove red blood cells, washed in Dulbecco’s PBS (dPBS, Sigma-Aldrich) supplemented with 2% KnockOut Serum Replacement (ThermoFisher), and assessed via flow cytometry to confirm purity of isolated cells as > 95% CD3+.
[0350] Manufacture of CAR-T Cells
[0351] Human CD3+cells were stimulated with Human T-Activator a-CD3 / a-CD28 Dynabeads (Life Technologies) for 2 days at a 3:1 bead:cell ratio. On d1 post-isolation, cells were transduced with lentivirus encoding the CAR construct in the presence of 8pg / ml polybrene for 24h. On d2 post-isolation, a-CD3 / a-CD28 beads were removed and CD3+cells were further stimulated with irradiated peripheral blood mononuclear cells. On d4 and d6 post-isolation, CD3+cells were fed with fresh T cell media using a partial media change. On d9 post-isolation, CD3+cells were frozen down in CryoStorCS5 (StemCell). CAR-T cells were thawed and recovered for 3 days in culture in X-VIVO (Lonza Biosciences) supplemented with 2% KnockOut Serum Replacement (Gibco), 50U / ml rh IL-2 and 0.5ng / ml rh IL-15 before in vivo or in vitro analysis.
[0352] Media - On dO post-isolation, cells were incubated with TheraPEAK X-VIVO15 (Lonza Biosciences) supplemented with 2% KnockOut Serum Replacement (Gibco), 50U / ml rh IL-2, 5ng / ml rh IL-7 and 0.5ng / ml rh IL-15. On d2 post-isolation, cells were incubated with TheraPEAK X-VIVO15 (Lonza Biosciences) supplemented with 2% KnockOut Serum Replacement (Gibco), 50U / ml rh IL-2, 0.5ng / ml rh IL-15 and 30ng / ml a-CD3 (OKT3). On d4 post-isolation, cells were fed with TheraPEAKX-VIVO15 (Lonza Biosciences) supplemented with 2% KnockOut Serum Replacement (Gibco), 100U / ml rh IL-2, 1ng / ml rh IL-15 and 30ng / ml a-CD3 in a partial media change (half volume removed). On d6 post-isolation, cells were fed with the d4 formulation with OKT3 excluded.
[0353] Tissue culture of cancer cell lines
[0354] All cell lines were maintained in culture medium supplemented with 10% FCS (Sigma-Aldrich, Bovogen Biologicals) and were cultured at 37°C in 5% CO2. Cell lines were passaged every 2-3 days by rinsing the flasks with sterile PBS and dissociating cells with trypsin-EDTA solution (Gibco) at 37°C. Cells were confirmed to be mycoplasma free by PCR.
[0355] Flow cytometric analysis
[0356] T cell transduction was assessed using flow cytometry as described above for nfP2X7 CAR-T cells and as described in Bandara and Foeng et al., 2023, supra. Antibodies and related reagents are detailed in Table 4 with the exception that for staining of LGR5, a commercially available antibody was used (Alexa Fluor® 647-conjugated rat anti-human LGR5 (N-terminal); 8F2; BD Biosciences™).
[0357] In vitro cytotoxicity assay by luciferase
[0358] T cells were rapidly thawed in a 37°C water bath and rested in complete X-VIVO T cell media (TheraPEAK X-VIVO, Lonza Biosciences, supplemented with 2% KnockOut Serum Replacement, ThermoFisher; 50U / ml rh IL-2 and 0.5ng / ml rh IL-15; all cytokines purchased from Miltenyi Biotec) for 3 days at 37°C in 5% CO2. T cells wereco-cultured with 1x104luciferase-expressing tumour cells at 3:1, 1:1, 1:3, 1:100 effector: target ratios in complete RPMI 1640 T cell medium (Gibco formulation without phenol red and supplemented as described above) in 96-well round bottom plates. Tumour cells alone and tumour cells treated with 2% SDS in Milli-Q H2O were plated as maximum target cell luminescence and maximum target cell cytolysis controls, respectively. Cells were incubated for 16h at 37°C in 5% CO2. For analysis, cells were mixed with BrightGlo substrate (Promega) and incubated for 5 min at room temperature in the dark, before transfer into an opaque flat-bottom 96-well plate (Grenier Bio-One). Cell luminescence was measured on the Promega GloMax® Discover plate reader. Percentage cytolysis was calculated as 100% x ((maximum target cell luminescence -experimental cytolysis luminescence) / (maximum target cell luminescence - maximum target cell cytolysis luminescence)). Each condition was plated in triplicate.
[0359] Thawing CAR-T cells for injection
[0360] T cells were rapidly thawed in a 37°C water bath and transferred into prewarmed X-VIVO media supplemented with 2% KnockOut Serum Replacement. T cells were centrifuged and resuspended in complete X-VIVO T cell media and rested for 3 days post-thaw. T cells were washed twice in Dulbecco’s PBS (dPBS) and resuspended in dPBS such the appropriate dose was injected in a 200pl volume.
[0361] Mice
[0362] NOD-scid IL2Rynul1(NSG) were purchased from the Animal Resource Centre / Ozgene (Perth, WA) or Australian Bio Resources (Moss Vale, New South Wales) and were housed at the Helen Mayo Animal House (HMAH) facility at the University of Adelaide (Adelaide, SA) in specific pathogen-free conditions. Experiments used male age-matched mice between 6-9 weeks of age. Mice were acclimatised for one week before experimental procedures were performed. All procedures were conducted under the approval of the University of Adelaide Animal Ethics Committee (S / 2018 / 007, S / 2022 / 006).
[0363] Subcutaneous inoculation of colorectal tumour xenografts
[0364] L0V0 cells were cultured for 1-2 weeks before injection. To prepare for injections, cells were rinsed in PBS, incubated with trypsin-EDTA solution (Gibco) at37°C, washed once in culture medium and twice in PBS. Mice were anaesthetised using isofluorane (Henry Schein™) and 2x106LoVo cells were injected subcutaneously into the lower abdomen using a 1ml Luer-Lok™ syringe (BD Biosciences) fitted with a 26 >2 gauge needle. Tumours were measured every 2 days beginning on day 7 posttumour injection using digital callipers (Mitutoyo, Japan), by measuring the longest distance as length and the perpendicular distance as width. Tumour size (mm2) was calculated as length x width. Mice were euthanized when tumour area was greater than 100m2or upon display of clinical disease symptoms. Tumours were measured with groups blinded.
[0365] Intravenous administration of CAR-T cells
[0366] T cells were rapidly thawed in a 37°C water bath and rested in complete X-VIVO15 (Lonza) T cell media for 3 days at 37°C in 5% CO2. On the day of injection, T cells were washed twice in dPBS, and resuspended in dPBS for injection in a 200pl volume per dose. Cells were kept on ice until injection. Mice were restrained and injected with a cell suspension containing 5-10x106cells via the tail vein at various timepoints post-tumour injection. T cells were injected with groups blinded.
[0367] Definitions and Qualifications
[0368] The nucleotide and polypeptide sequences referred to herein are represented by a sequence identifier number (SEQ ID NO:). A summary of the sequence identifiers is provided in Table 6. A sequence listing is also provided as part of the specification.
[0369] Table 6 - Sequence identifiers used in this applicationSEQ ID Sequence Sequence descriptionNO: type* C-X-C motif chemokine receptor 2 (CXCR2) - UniProt number AA1 P25025Leucine-rich repeat-containing G-protein coupled receptor 5 AA2 (LGR5)3 Heavy chain CDR1 of anti-LGR5 CAR AA4 Heavy chain CDR2 of anti-LGR5 CAR AASEQ ID Sequence Sequence descriptionNO: type* 5 Heavy chain CDR3 of anti-LGR5 CAR AA Light chain CDR1 of anti-LGR5 CAR AA 7 Light chain CDR2 of anti-LGR5 CAR (sequence “LTS”) AA 8 Light chain CDR3 of anti-LGR5 CAR AA 9 Anti-LGR5 CAR heavy chain AA 10 Anti-LGR5 CAR light chain AA 11 CAR scFv fusion protein domain (linker) AA 12 CNA30XX antigen-binding domain (VL-VH) AA 13 CNA31XX antigen-binding domain (VH-VL) AA 14 CNA3103 - VH-VL-lgG4hinge-CH3 (medium hinge) AA 15 CNA3002 - VL-VH-lgG4 hinge (short hinge) AA 16 CNA3003 - VL-VH-lgG4hinge-CH3 (medium hinge). AA 17 CNA3004 - VH-VL-lgG4hinge-CH2-CH3 (long hinge). AA 18 CNA3102 - VH-VL-lgG4hinge-CH3 (short hinge) AA 19 CNA3104 - VH-VL-lgG4hinge-CH2-CH3 (long hinge). AA 0 CAR CXCR2 portion AA 1 Anti-LGR5-CAR-CXCR2 (CNA310301) AA P2rx7 receptor Purinergic receptor P2X, ligand-gated ion2 channel, 7 (Uniprot Q99572) AA 3 PEP2-2-3 binding (SEQ ID NO: 10) AA 4 PEP2-2-1-1 binding peptide (SEQ ID NO: 32) AA 5 PEP2-472-2 binding peptide (SEQ ID NO: 33) AA 6 PEP2-2-12 binding peptide (SEQ ID NO: 34) AA 7 Heavy chain CDR1 of anti-nfP2X7 CAR AA 8 Heavy chain CDR2 of anti-nfP2X7 CAR AA 9 Heavy chain CDR3 of anti-nfP2X7 CAR AA 30 Variable heavy chain of anti-nfP2X7 CAR AA 31 PEP2-2-3 CAR (short hinge) AA 32 PEP2-2-3 CAR (long hinge) AA 33 PEP2-2-1-1 CAR AASEQ ID Sequence Sequence descriptionNO: type* 34 PEP2-472-2 CAR AA 35 PEP2-2-12 CAR AA 36 Anti-nfP2X7-CAR (CNA1003) AA 37 Anti-nfP2X7-CAR-CXCR2 (CNA100301 ) AA 38 lgG4 CH3 AA 39 lgG1 hinge AA 0 lgG2 hinge AA 1 lgG3 hinge AA 2 lgG4 hinge AA 3 lgG4 hinge (modified) AA 4 lgA1 hinge AA 5 IgD hinge AA 6 IgM common heavy (CH) 2 AA 7 IgE CH2 AA 8 CD28 Hinge AA 9 CD8a Hinge (1) AA 50 CD8a Hinge (2) AA 51 CD8b Hinge (1) AA 52 CD8b Hinge (2) AA 53 CD7 AA 54 CD4 Hinge AA 55 PolyG / S AA 56 Short CAR linker (12 a. a.) AA 57 Medium CAR linker (119 a.a.) AA 58 Long CAR linker (229 a.a.) AA 59 CD28 portion of CAR transmembrane domain AA 0 CD3 zeta amino acid sequence AA 1 CD3 epsilon amino acid sequence AA 2 CD3 gamma amino acid sequence AA 3 CD3 delta amino acid sequence AASEQ ID Sequence Sequence descriptionNO: type* 64 Portion of CD3 zeta in CAR constructs AA65 FCsR1 amino acid sequence AA66 FCyR1 amino acid sequence AA67 4-1 BB portion of CARs AA68 Intracellular activation and co-stimulation portion of CARs AA69 Truncated EGFR (tEGFR) AA70 T2A Protein (T2A) AA71 Encoding sequence for anti-nfP2X7 CAR (CNA1003) DNA Encoding sequence for anti-nfP2X7-CAR-CXCR272 (CNA100301) DNA 73 Encoding sequence for LRG5-CAR (CNA3103) DNA 74 Encoding sequence for LRG5-CAR-CXCR2 (CNA310301) DNA 75 CSF2Ra leader AA
[0370] *AA = amino acid sequence; DNA = deoxyribonucleic acids sequence
[0371] The discussion of documents, acts, materials, devices, articles and the like is included in this specification solely for the purpose of providing a context for the present invention. It is not suggested or represented that any or all of these matters formed part of the prior art base or were common general knowledge in the field relevant to the present invention as it existed before the priority date of each claim of this application.
[0372] Throughout this specification, unless the context requires otherwise, the word “comprise”, or variations such as “comprises” or “comprising”, will be understood to imply the inclusion of a stated element or integer or group of elements or integers but not the exclusion of any other element or integer or group of elements or integers.
[0373] It is to be further understood that terminology such as “comprise”, or variations such as “comprises” or “comprising” inherently include within their scope (without being limited to) versions of the invention that excludes other elements directly related to the invention. Accordingly, terminology such as “consisting of” or “consisting essentially of” can be substituted for terminology such as “comprise”, “comprises” or“comprising” with the effect of limiting the scope of the invention to the specifically recited elements. Notably, where it is explicitly intended for the invention to be considered in an exhaustive manner, such limitations should be considered to relate only to the inventive concept disclosed herein and other features can be added which fall outside of the scope of the inventive concept. Such features or elements may include, but are not limited to, excipients, formulations, additives, diluents, packaging, adjuvants, and collocated features which are not to be excluded by terminology such as “consisting of” or “consisting essentially of’.
[0374] As used herein a “functional variant” of a specified peptide or nucleic acid may have modifications and mutations in the sequence. As would be understood to those skilled in the art a “functional variant” still maintains a portion of, or all, of the function of the original peptide or nucleic acid. As such, the functional variant may, for example, have one or more amino acid insertions, deletions or substitutions relative to one of SEQ ID NOs. provided above. Or, in the case of a nucleic acid, a function variant may include one or more synonymous mutation(s) thereby still encoding the same amino acid sequence or may include one or more non-synonymous mutation(s), so long as the encoded peptide is a functional variant of the originally encoded peptide. Unless otherwise specified a functional variant may have at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity to a specified sequence, while maintain a portion of, or all of, the function of the original sequence.
[0375] Referenced documents, publications and patents are to be included in their entirety by way of reference. The teachings and disclosures in such documents, publications and patents are therefore considered to form part of the disclosure of this specification.
[0376] All methods described herein can be performed in any suitable order unless indicated otherwise herein or clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., "such as", “i.e.”) provided herein, is intended merely to better illuminate the example embodiments and does not pose a limitation on the scope of the claimed invention unless otherwise claimed. No language in the specification should be construed as indicating any non-claimed element as essential.
[0377] The description provided herein is in relation to several embodiments which may share common characteristics and features. It is to be understood that one or more features of one embodiment may be combinable with one or more features of the other embodiments. In addition, a single feature or combination of features of the embodiments may constitute additional embodiments.
[0378] The subject headings used herein are included only for the ease of reference of the reader and should not be used to limit the subject matter found throughout the disclosure or the claims. The subject headings should not be used in construing the scope of the claims or the claim limitations.
[0379] Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described. It is to be understood that the invention includes all such variations and modifications. The invention also includes all of the steps, features, compositions and compounds referred to, or indicated in this specification, individually or collectively, and any and all combinations of any two or more of the steps or features.
[0380] Also, it is to be noted that, as used herein, the singular forms “a”, “an” and “the” include plural aspects unless the context already dictates otherwise.
[0381] Future patent applications may be filed on the basis of claiming priority from the present application, or being continuations of, or having divisional status from, the present application. It is to be understood that the following claims are not intended to limit the scope of what may be claimed in any such future application. Features may be added to or omitted from the claims at a later date so as to further define or re-define the invention or inventions claimed.
[0382] It will be apparent to the person skilled in the art that while the invention is described herein in detail for the purposes of clarity and understanding, various modifications and alterations to the embodiments and methods described herein may be made without departing from the scope of the inventive concept disclosed in this specification.
Claims
Claims:
1. A method of increasing the proliferation or cytotoxicity of chimeric antigen receptor (CAR) expressing immune effector cells, the method comprising engineering the expression or overexpression of C-X-C motif chemokine receptor 2 (CXCR2) in the CAR expressing cells and stimulating the cells.
2. A method of producing a chimeric antigen receptor (CAR) immune effector cells, the method comprising engineering isolated immune effector cells to express a CAR and express or overexpress CXCR2 and stimulating the cells.
3. The method according to claim 1 or claim 2, wherein the method further includes exposing the immune effector cells comprising the CAR to one or more of interleukin 2, interleukin 15, interleukin 7, or interleukin 21.
4. The method according to any one of claims 1 to 3, wherein the cells comprising the CAR are NK cells.
5. The method according to any one of claims 1 to 3, wherein the immune effector cells comprising the CAR are T cells.
6. The method according to claim 5, wherein the CAR-T cells are stimulated with at least one T cell mitogen or T cell antigen.
7. The method according to claim 5 or claim 6, wherein the CAR-T cells are stimulated with a CD3 agonist.
8. The method according to claim 7, wherein the CAR-T cells are also stimulated with a CD28 agonist.
9. The method according to any one of claims 5 to 8, wherein the T cells are assessed for characteristics of T cell exhaustion or T cell differentiation prior to engineering expression or overexpression of CXCR2.
10. The method according to claim 9, wherein the characteristics of T cell exhaustion or T cell differentiation comprise an increased frequency of T cells in a population expressing one or more of: PD-1 , CTLA-4, LAG-3, TIGIT, CD160 (BY55), CD38, CD39, CD272 (BTLA), CD244 (2B4) and VISTA, or an increased expression onT cells of one or more of: PD-1, CTLA-4, LAG-3, TIGIT, CD160 (BY55), CD38, CD39, CD272 (BTLA), CD244 (2B4) and VISTA.
11. The method according to any one of claims 5 to 10, wherein the method includes determining the expression of one or more of CD45RO or CD62L.
12. The method according to any one of claims 5 to 11 , wherein the method includes determining the frequency of T cells in a population having one or more of the following profiles:a. CD45RO+CD62L-; orb. CD45RO-CD62L-.
13. The method according to any one of claims 5 to 12, wherein the method is performed on a CAR-T cell population comprising an increased frequency of T cells with one or more of the following profiles:a. CD45RO+CD62L-; orb. CD45RO-CD62L-.
14. The method according to claim 13, wherein the method is performed on a CAR- T cell population comprising 26% or more T cells with the profile CD45RO+CD62L-.
15. The method according to claim 13 or claim 14, wherein the method is performed on a CAR-T cell population comprising 13% or more T cells with the profile CD45RO-CD62L-.
16. The method according to any one of claims 1 to 15, wherein the method is performed in vitro.
17. The method according to any one of claims 1 to 16, wherein the CAR-expressing immune effector cells are stimulated with the CAR’s cognate antigen.
18. The method according to any one of claims 1 to 16, wherein the method is performed without stimulation with the cognate antigen of the CAR.
19. The method according to any one of claims 1 to 18, wherein the immune effector cells comprising the CARs are CD8+ T cells.
20. The method according to any one of claims 1 to 18, wherein the immune effector cells comprising the CARs are iNKT cells.
21. The method according to any one of claims 1 to 20, wherein the immune effector cells were isolated from a patient that has undergone cancer treatment comprising one or more of radiotherapy or chemotherapy prior to isolation of the cells.
22. The method according to any one of claims 1 to 21, wherein the CAR includes an antigen-binding domain which binds to LGR5.
23. The method according to any one of claims 1 to 21, wherein the CAR includes an antigen-binding domain which binds to non-functional P2X7 (nfP2X7).
24. A method of treating cancer, the method comprising administering to a subject having cancer immune effector cells comprising a CAR and engineered to express, or overexpress, CXCR2.
25. The method according to claim 24, wherein the cells are prepared by the method of any one of claims 1 to 23.
26. The method according to claim 24 or claim 25, wherein the cancer is selected from the group consisting of: ovarian cancer, melanoma, non-small cell lung cancer, head and neck carcinoma, B-cell lymphoma, prostate cancer, breast cancer, neuroblastoma, pancreatic cancer, liver cancer, gastric cancer and colorectal cancer.
27. The method according to claim 24 or claim 25, wherein the cancer is a solid tumour.
28. The method according to any one of claims 24 to 27, wherein the cancer is a primary cancer.
29. The method according to any one of claims 24 to 27, wherein the cancer is a secondary cancer.
30. The method according to any one of claims 24 to 29, wherein the cancer expresses a moderate or low level of the cognate antigen for the CAR.
31. The method according to claim 30, wherein a cancer expressing a moderate or low level of the cognate antigen comprises approximately 60% or less, approximately 50% or less, approximately 40% or less, approximately 30% or less, approximately 20% or less, approximately 15% or less, approximately 10% or less, or approximately 5% or less of the cancer cells expressing the cognate antigen of the CAR.
32. The method according to any one of claims 24 to 31, wherein the method includes a step of identifying the expression of the cognate antigen of the CAR on the cancer.
33. The method according to any one of claims 24 to 32, wherein the subject had a low response to previous treatment with immune effector cells comprising a CAR.
34. The method according to claim 33, wherein the immune effector cells used in the previous treatment are T cells and these cells express markers of T cell exhaustion and / or T cell differentiation.
35. The method according to any one of claims 24 to 34, wherein the immune effector cells comprising a CAR target LGR5.
36. The method according to any one of claims 24 to 34, wherein the immune effector cells comprising a CAR target non-functional P2X7 (nfP2X7).
37. The method according to any one of claims 24 to 36, wherein the method of treatment comprises a combination therapy including the administration of an immune checkpoint inhibitor.
38. The method according to claim 37, wherein the immune checkpoint inhibitor inhibits signalling of one or more of: PD-1 , CTLA-4 or LAG-3.
39. A method of treating a subject having cancer according to any one of claims 24 to 38, wherein the subject is administered a reduced dose of immune effector cells comprising a CAR.
40. The method according to claim 39, wherein a reduced dose of immune effector cells comprising a CAR comprises approximately 90% or less, approximately 80% or less, approximately 70% or less, approximately 60% or less, approximately 50% or less, approximately 40% or less, approximately 30% or less, approximately 20 % or less, approximately 15% or less, or approximately 10% or less of the standard dose of immune effector cells comprising a CAR normally administered to the subject.
41. An immune effector cell comprising a chimeric antigen receptor (CAR), wherein the immune effector cell comprising the CAR is engineered to express or overexpress CXCR2.
42. The cell according to claim 41 , wherein the cell is engineered to express one or more of interleukin 2 (IL-2) or interleukin 15 (IL-15).
43. The cell according to claim 41 or claim 42, wherein the cell is engineered with a construct encoding both the CAR and CXCR2.
44. The cell according to any one of claims 41 to 43, wherein the CAR includes an antigen-binding domain which binds to LGR5.
45. The cell according to any one of claims 41 to 43, wherein the CAR includes an antigen-binding domain which binds to non-functional P2X7 (nfP2X7).
46. The cell according to claim 44, wherein the antigen-binding domain includes:a heavy chain CDR1 having an amino acid sequence as set forth in SEQ ID NO: 3, or having an amino acid sequence as set forth in SEQ ID NO: 3 with up to 2 amino acid modifications,a heavy chain CDR2 having an amino acid sequence as set forth in SEQ ID NO: 4, or having an amino acid sequence as set forth in SEQ ID NO: 4 with up to 2 amino acid modifications, anda heavy chain CDR3 having an amino acid sequence as set forth in SEQ ID NO: 5, or having an amino acid sequence as set forth in SEQ ID NO: 5 with up to 2 amino acid modifications.
47. The T cell according to claim 44 or claim 46, wherein the antigen-binding domain includes:a light chain CDR1 having an amino acid sequence set forth in SEQ ID NO: 6, or having an amino acid sequence as set forth in SEQ ID NO: 6 with up to 2 amino acid modifications,a light chain CDR2 having an amino acid sequence of LTS, or having an amino acid sequence of LTS with 1 amino acid modifications, anda light chain CDR3 having an amino acid sequence set forth in SEQ ID NO: 8, or having an amino acid sequence as set forth in SEQ ID NO: 8 with up to 2 amino acid modifications.
48. The T cell according to claim 45, wherein the antigen-binding domain includes:a heavy chain CDR1 having an amino acid sequence as set forth in SEQ ID NO: 27, or having an amino acid sequence as set forth in SEQ ID NO: 27 with up to 2 amino acid modifications,a heavy chain CDR2 having an amino acid sequence as set forth in SEQ ID NO: 28, or having an amino acid sequence as set forth in SEQ ID NO: 28 with up to 2 amino acid modifications, anda heavy chain CDR3 having an amino acid sequence as set forth in SEQ ID NO: 29, or having an amino acid sequence as set forth in SEQ ID NO: 29 with up to 2 amino acid modifications.
49. The T cell according to any one of claims 44 to 47, wherein the antigen-binding domain comprises a single variable antibody domain.
50. The cell according to claim 49, wherein the binding domain comprises a singlechain variable fragment comprising the C-terminus of a variable heavy (VH) chain linked to the N-terminus of a variable light (VL) chain.
51. The cell according to claim 49, wherein the binding domain comprises a singlechain variable fragment comprising the C-terminus of the variable light (VL) chain linked to the N-terminus of the variable light (VH) chain.
52. The cell according to any one of claims 41 to 51 , wherein the CAR comprises an extracellular domain which includes a linker domain that links an antigen-binding domain to a transmembrane domain.
53. The cell according to claim 52, wherein the linker domain is at least 12 amino acids in length, or is at least about 12 amino acids in length.
54. The cell according to claim 52, wherein the linker domain is at least 119 amino acids in length, or is at least about 119 amino acids in length.
55. The cell according to claim 52, wherein the linker domain is at least 229 amino acids in length, or is at least about 229 amino acids in length.
56. The cell according to claim 52 or claim 53, wherein the linker domain is up to 119 amino acids in length, or up to about 119 amino acids in length.
57. The cell according to any one of claims 52 to 54, wherein the linker domain is up to 229 amino acids in length, or up to about 229 amino acids in length.
58. The cell according to any one of claims 52 to 57, wherein the linker domain includes an amino acid sequence identical to the sequence of the lgG4 hinge or includes a sequence identical to a modified version of the lgG4 hinge, having up to 2 amino acid modifications.
59. The cell according to any one of claims 52 to 58, wherein the linker domain includes an amino acid sequence identical to the CH3 sequence of lgG4.
60. The cell according to any one of claims 52 to 59, wherein the linker domain includes an amino acid sequence identical to the CH2 sequence of lgG4.
61. The cell according to claim 52, wherein the linker domain includes, or consists of, a sequence selected from SEQ ID NO: 56, 57 or 58, or functional variants thereof.
62. The cell according to any one of claims 41 to 61, wherein the immune effector cell comprising the CAR is an NK cell.
63. The cell according to any one of claims 41 to 61, wherein the immune effector cell comprising the CAR is a T cell.
64. The method of any one of claims 1 to 40, or the cell according to any one of claims 41 to 63, wherein the cell is engineered to express an exogenous nucleic acid encoding CXCR2, or a genomically integrated form thereof.
65. The method or cell of claim 64, wherein the nucleic acid is a DNA vector.
66. The method or cell of claim 64 or claim 65, wherein the nucleic acid encodes for the CXCR2 and the CAR.
67. The method according to any one of claims 1 to 40, wherein the immune effector cell is an immune effector cell according to any one of claims 41 to 66.
